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Abstract
The prevalence of chronic Lyme disease (CLD) remains relatively unknown in
Connecticut because there is not an agreement on what CLD is and how it should be
diagnosed in addition to which pathological agent causes CLD. The aim of this
quantitative study was to assess whether there were significant differences between two
groups of primary care physicians (PCP) working in Connecticut from two different
points in time regarding their knowledge in the diagnosis, treatment, and management of
CLD. A knowledge, attitude, and practice model was used as the underlying theoretical
framework for this study. A random cross-sectional survey was mailed out to the 1,726
PCPs found in the list of certified medical doctors in Connecticut of 2015. One hundred
and forty-five PCPs responses (11.9% response rate) were received and compared to
responses from previous data (a 2010 study) of 285 PCPs (39.1% response rate) from the
list of certified medical doctors in 2006. The PCP estimated mean number of patients
diagnosed and treated for CLD was not significantly different between 2006 and 2015.
However, a significantly higher number of PCPs in 2015 reported knowing Lyme disease
(LD) symptoms but not feeling comfortable diagnosing LD (χ² = 536.83, p < 0.001), and
significantly more PCPs in 2015 reported knowing LD symptoms and feeling
comfortable diagnosing CLD (χ² = 265.41, p < 0.001). This study can promote social
change by encouraging Connecticut PCPs to recognize CLD as a diagnosis to enable the
development of registries and case-control assessments. The findings of this study may
also inspire future studies.
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Chapter 1: Introduction to the Study
Introduction
In this study, I used knowledge from epidemiology, microbiology, and public
health to investigate chronic Lyme disease (CLD) also known as post treatment Lyme
disease syndrome (PTLDS), a probable but unreported new health condition that affects
humans (Centers for Disease Control and Prevention [CDC], 2019a; Johnson, Shapiro, &
Mankoff, 2018). I describe how frequently primary care physicians (PCPs) diagnosed and
treated Lyme disease (LD) and CLD/PTLDS in Connecticut; however, there has been no
agreement on what CLD/PTLDS is, how it should be diagnosed, and certainty regarding
the pathological agent that causes CLD. There is speculation that CLD/PTLDS may be a
health condition disseminated through the bites of vector-borne pathogens, and many
researchers associate CLD/PTLDS with LD (Van Hout, 2018).
Therefore, this study was conducted as a validation of the previous research done
on the same topic by Johnson and Feder (2010), who were pioneers investigating
CLD/PTLDS in Connecticut among PCPs. Johnson and Feder found the differences in
the knowledge, attitudes, and practices (KAP) of physicians who diagnosed and treated
CLD/PTLDS, who were undecided on CLD, and who did not believe that CLD/PTLDS
existed in the last 3 years. Johnson and Feder found that a few physicians (less than 3%)
diagnosed patients with CLD/PTLDS, and 49% of physicians did not treat their patients
with CLD/PTLDS because they believed that it did not exist. Data from Johnson and
Feder’s study (PCP survey responses from 2006) were compared to data in this current
study (PCP survey responses in 2015).
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I aimed to collect data and use descriptive and analytical epidemiological
knowledge to examine CLD/PTLDS, a potential new health challenge, as well as study
how PCPs diagnose and treat patients for CLD/PTLDS. This research is a quantitative
cross-sectional study on how frequently Connecticut PCPs have diagnosed and treated
patients for LD and CLD/PTLDS in the last 3 years. Results were compared to the 2006
distributions of PCP found in the historical population published in 2010 from a study on
the same topic. Chapter 1 continues with presenting the problem, background, purpose,
research question, theory, and rationale for the selection of the theory frame design,
concise definitions, assumptions, limitations, potential contributions, and a study
summary.
Background
CLD/PTLDS is a health challenge (Ali, Vitulano, Lee, Weiss, & Colson, 2014;
Cameron, 2010; Johnson & Feder, 2010, Johnson, Wilcox, Mankoff, & Stricker, 2014).
However, physicians and other health professionals have not developed a protocol to
diagnose and treat CLD/PTLDS. Numerous physicians do not believe that CLD/PTLDS
is a real illness affecting humans because no one has found valid evidence-based medical
knowledge about the causal agent and databases collected to confirm or corroborate
CLD/PTLDS as a new disease (Baker, 2008; Cameron, 2010; Feder et al., 2007; Johnson
& Feder, 2010; Lantos, 2011; Lantos, 2015a; Wormser & Shapiro, 2009). Despite the
lack of primary evidence (e.g., origin, mode of transmission, prevalence, incidence rates,
and risk factors) to identify a possible new or emergent infectious illness, epidemiology
can be used as a deductive science to gather new insights when the pathogen is unknown
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to the medical community. It is also advantageous to compare past and present cases
when investigating a disease that affects the members of a community, which is further
supported by PCPs’ knowledge that can provide insights for epidemiological and
evidence-based medical investigations.
Various scientists have contributed to the origin of evidence-based medicine
without being aware they used the field principles of epidemiology. With such
epidemiological applications as data collection and the use of statistical analysis, they
were able to contribute to the cure for many infectious diseases in the past. For example,
Hippocrates (the prescription of a form of aspirin and the introduction of how the
environment may be a risk factor for diseases), Edward Jenner (the vaccination of
Smallpox), Ignaz Semmelweis (prevention of the transmission of puerperal fever), Joseph
Lister (the use of antiseptic), Robert Koch (germ theory), and Alexander Fleming (the
discovery of penicillin) made profound contributions in the field of medicine (Gaynes,
2017; Hajar 2015).
Some new advances in epidemiology include clinical epidemiology (Mullan,
1984; Young, Naude, Brodovcky, & Esterhuizen, 2017), foundations for microbiomics
(Foxman & Martin, 2015), molecular epidemiology (Carroll et al., 2015), primary care
epidemiology (Hannaford, Smith, & Elliott 2006), and public health informatics (Friede,
Blum, & Mc Donald, 1995). Because of these epidemiological advances and the use of
electronic primary care records, surveillance, and public health informatics, medical
doctors and other health practitioners (e.g., epidemiologists) can help prevent, eliminate,
and control diseases. For example, Koch had applied data collection and surveillance
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practices with his discovery of Mycobacterium tuberculosis in 1882, which has the major
symptoms of a fever, severe coughing, and chest pain (Fogel, 2015). Koch observed how
patients with tuberculosis had similar symptoms, and with microscopic laboratory
techniques was able to recognize the bacteria that caused their symptoms. Koch’s
discovery established the importance of case definitions in preventing diseases (Cambau
& Drancourt, 2014). Additionally, Koch’s work set the precedent for evaluating diseases
with epidemiological applications, creating follow-up for effective treatment techniques,
and using laboratory techniques as support for clinical diagnoses (Cambau & Drancourt,
2014). However, there are not always methods for data collection and surveillance
because there are no accepted case definitions, international classification of disease
(ICD) codes, or clear guidelines for diagnosis and treatment, which is the case for
CLD/PTLDS.
Though not all health conditions are recognized, the CDC has a surveillance
system—the standardization of the list of reportable diseases across the United States and
territories (CDC, 1990a). Additionally, after the 1990s, the developed guidelines for
surveillance by telecommunications systems required public health agencies to relay
reportable diseases to the CDC. Consequently, standardized case definitions for
reportable diseases were needed (CDC, 1990a, 1990b). Once a disease’s case definition is
established and reported, term standardization enables epidemiologists to calculate
incidence, prevalence, and risk factors affecting humans and animals. The case definition
process begins after a new disease is found and aids in the collection of epidemiological
information. Therefore, epidemiologists focus on determining and monitoring the
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distribution and determinants of diseases within susceptible populations via public health
surveillance (Choi, 2012; Kuller, 2016). Moreover, after case definition usage is
established, researchers can track incidence rates and monitor temporal or long-term
trends in disease occurrence. Epidemiologists also examine factors such as whether the
disease is seasonal, acute or chronic, and infectious or noninfectious. The Council of
State and Territorial Epidemiologists in the United States (CDC, 1990a, 1997) started to
use case definitions to classify and survey diseases in 1990:
•

Confirmed case: a case that is classified as confirmed for reporting purposes.

•

Probable case: a case that is classified as probable for reporting purposes.

•

Laboratory-confirmed case: a case that is confirmed by one or more of the
laboratory methods listed in the case definition under “Laboratory criteria for
diagnosis.” Although other laboratory methods may be used in clinical
diagnosis, only those listed are accepted for laboratory confirmation for
reporting purposes.

•

Clinically compatible case: a clinical syndrome generally compatible with the
disease, but no specific clinical criteria need to be met unless they are noted in
the case classification.

•

Supportive laboratory results: specified laboratory results consistent with the
diagnosis but not meeting the criteria for laboratory confirmation.

•

Epidemiologically linked case: a case in which the patient has/has had contact
with one or more persons who have/had the disease, and transmission of the
agent by the usual modes of transmission is plausible. A case may be
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considered epidemiologically linked to a laboratory-confirmed case if at least
one case in the chain of transmission is laboratory confirmed.
•

Meets the clinical case definition: meets precisely the clinical case definition.
Although in clinical practice the diagnosis may be made with the use of other
criteria, for reporting purposes the stated criteria must be met. (Wharton,
Vogt, & Buehler, 1990).

In the field of public health (i.e., epidemiology) the number of individual illness
cases is significant, and the data enable epidemiologists to calculate incidence rates. This
information is vital for health practitioners, such as PCPs and local health directors, to
monitor diseases in their communities. Most disease investigations are initiated once the
incidence exceeds expected occurrence levels for the specific condition and time. In some
cases, there is a well-organized system for collecting data from ill community members,
which is the case for CLD/PTLDS. It is frequently not reported by local health
departments because it is a health condition without a standardized case definition and
unknown etiological origin. Therefore, PCPs may have no easy way to share
CLD/PTLDS patient information with health agencies such as the Connecticut
Department of Health (CT DPH). Further, access to data from epidemiological research is
limited to public health officers, which results in a lack of disease prevention and control
efforts (Bach et al., 2017; Choi, 2012; Kuller, 2016). Thus, understanding the importance
of public health data collection and surveillance will help analyze quantitative
information, which may lead to health policies to reduce mortality and morbidity
(Wetterhall, Pappaioanou, Thacker, Eaker, & Churchill, 1992).
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Defining and Diagnosing Chronic Lyme Disease
In the United States, LD is a major disease caused by B. burgdorferi and B.
mayonii (Dolan et al., 2017). LD is transmitted to humans through the bites of infected
blacklegged ticks (Citera, Freeman, & Horowitz, 2017; Moore et al., 2016). The CDC
estimates that there are more than 300,000 LD cases in the United States annually
(Rebman et al., 2017). The most common symptom is the erythema migrans (EM) rash
(Nadelman et al., 2012). However, not all patients who contract LD develop this red rash
(Citera et al., 2017). Table 1 presents the basis for different diagnoses, and Table 2
presents the ICD codes for Lyme Disease.
Table 1
Categories for Diagnosis
Patient Category
Basis for Diagnosis
Undisputed Lyme disease Diagnosed on appropriate clinical grounds in early disease or
by reference laboratory testing in disseminated Lyme disease.
Post-Treatment Chronic
Lyme syndrome

Diagnosed as above but failing to experience complete
symptom resolution after standard antibiotic therapy.

Alternatively, diagnosed
chronic Lyme syndrome

Diagnosed on clinical grounds supported only by alternative
tests, the validity of which is questioned by major reference
laboratories and the CDC.

Seronegative Lyme
disease

Diagnosed on purely clinical grounds (a controversial
category outside of early disease).

Note. Information from Patrick et al. (2016).
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Table 2
ICD-10 Codes for Lyme Disease
Diagnosis Code
A69.2
A69.20
A69.21

Description
LD
LD, unspecified
Meningitis due to
LD

Category
Other spirochetal (A69)
Other spirochetal (A69)
Other spirochetal (A69). Meningitis in LD ·
Meningitis (basal) (basic) (brain) (cerebral) (cervical)
(congestive) (diffuse) (hemorrhagic) (infantile)
(membranous) (metastatic) (nonspecific) (pontine)
(progressive) (simple) (spinal) (subacute)
(sympathetic) (toxic)

A69.22

Other neurologic
disorders in LD

Other spirochetal (A69).
Cranial neuritis · Meningoencephalitis ·
Polyneuropathy · Cranial neuritis due to LD · Lyme
cranial neuritis · Lyme meningoencephalitis · Lyme
polyneuropathy · Meningoencephalitis due to LD

A69.23

Arthritis due to
LD

Other spirochetal (A69). Lyme arthritis · Arthritis,
arthritic (acute) (chronic) (nonpyogenic) (subacute)
M19.90 due to or associated with LD

A69.29

Other condition
associated with
LD

Other spirochetal (A69). Lyme myopericarditis ·
Myocarditis (with arteriosclerosis) (chronic) (fibroid)
(interstitial) (old) (progressive)

Note. Information from http://www.icd10data.com/ICD10CM/Codes/A00-B99/A65A69/A69-/A69.20. CLD/PTLDS does not have an ICD code so patients can be diagnosed
and have their health insurance paying such medical process like in the case here with
LD.
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In 2019, the International Lyme and Associated Diseases Society (ILADS)
defined CLD (also known as PTLDS) as “an ongoing infection with any of the
pathogenic bacteria in the Borrelia burgdorferi sensu lato group that is poorly understood
and often mischaracterized.” Associated with this definition in 2018, the International
Lyme and Associated Diseases Society recognized that symptoms of fibromyalgia,
chronic fatigue syndrome, and depression were often misdiagnosed in patients with
CLD/PTLDS (ILADS, 2018, p. 8). Other symptoms for CLD/PTLDS include peripheral
neuropathy, motor neuron disease, neuropsychiatric presentations, cardiac presentations
with electrical conduction delays and dilated cardiomyopathy, and musculoskeletal
problems (ILADS, 2004).
Many health organizations, including the CDC (2019) and the National Institute
of Allergy and Infectious Diseases (2019), do not accept the term CLD/PTLDS as a
standard medical diagnosis. These health organizations prefer the term PTLDS. PTLDS is
a known disease related to LD in patients who previously had EM or recurring symptoms
(CDC, 2019a; Horowitz & Freeman, 2018). The CDC defines PTLDS (also known as
CLD) as a health condition in which patients treated for LD continue to have symptoms
of fatigue, pain, or joint and muscle aches after two to four weeks (CDC, 2017c).
However, the cause of PTLDS remains unknown (Marques, 2008). Consequently, an
ICD-10 diagnosis code is designated for PTLDS and not for the term CLD alone because
the International Lyme and Associated Diseases Society definition does not fit a
diagnosis among PCPs. Therefore, the controversial health condition of CLD/PTLDS
may never be reported or will be under- or mis-reported by the CDC, National Institute of
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Health, Infectious Diseases Society of America, and International Lyme and Associated
Diseases Society. Additionally, these health organizations do not agree on billing and
legislation guidelines for appropriately treating LD patients (Naktin, 2017). Therefore,
there are many gaps in the medical field regarding CLD/PTLDS.
There is also controversy surrounding the diagnosis of CLD/PTLDS (Lantos,
2015a; Maloney, 2016). The Infectious Diseases Society of America, ILADS, and the
CDC have differing perspectives on the existence of CLD/PTLDS. Many medical doctors
do not believe that CLD/PTLDS is a chronic form of LD, and epidemiologists are not
sure of its origins. Researchers have not identified a biological agent that causes
CLD/PTLDS, and there is no reliable laboratory test to detect it, which have impeded the
empirical study of CLD/PTLDS (Lantos et al., 2015c; Maloney, 2016).
To address the lack of knowledge on CLD/PTLDS, Johnson and Feder (2010)
conducted a study on physicians’ KAP regarding CLD/PTLDS. They collected KAP data
from a sample of 285 PCPs practicing in the state of Connecticut. Johnson and Feder
found that less than 3% of the 285 PCPs in their study had diagnosed patients with
CLD/PTLDS, 49.8% of the PCPs did not treat their patients for CLD/PTLDS because
they did not believe the condition existed, and 48.1% of the PCPs reported being
undecided as to whether CLD/PTLDS existed. However, little KAP knowledge of
CLD/PTLDS has been obtained in the 10 years since Johnson and Feder’s study, the only
exception being a study by Ferrouillet, Milord, Lambert, Vibien, and Ravel (2015).
Ferrouillet et al.’s (2015) study was similar in nature and scope to that of Johnson and
Feder but was focused on both LD and CLD/PTLDS. Ferrouillet et al. found that there
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were significant differences in the knowledge and practices of physicians regarding LD
diagnosis and treatment. Additionally, Ferrouillet et al. discovered that physicians had
diverse responses to the diagnosis, treatment, and management of LD and CLD/PTLDS.
Ferrouillet et al.’s findings demonstrate the necessity of this research because they may
be relevant in improving physician’s knowledge toward the latest trends of CLD/PTLDS
in Connecticut.
Another survey implemented in this study could address the informational gaps
related to CLD/PTLDS to build on the data collected by previous researchers. A new
study may help broaden the understanding of CLD/PTLDS in Connecticut. This study
expands the fields of medicine and epidemiology by applying both nonparametric and
parametric statistical analyses to gather evidence-based medical research when
encountering a health challenge (Levman & Takahashi, 2016; Roy et al., 2009).
Therefore, I conducted the same survey used by Johnson and Feder (2010) with a
statistical application to allow for the assessment, measurement, and evaluation of
whether awareness and treatment by PCPs have changed in Connecticut. All independent
variables pertain to the two study groups of Connecticut PCPs (2006 vs. 2015). I
employed Chi-square (χ²) goodness-of-fit tests when the dependent variables were
categorically coded and one-sample t tests when the dependent variables were ratio
coded.
This study filled the gap by investigating the KAP of PCPs’ positions on
CLD/PTLDS in Connecticut. The CT DPH currently does not collect epidemiological
information about CLD or PTLDS as distinctive from LD reporting, which is expected
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from the Council of State and Territorial Epidemiologist’s surveillance across the U.S.
States and Territories. This study is therefore limited because I was unable to ask PCPs in
Connecticut to utilize any of the ICD A69 subcodes to characterize the cases into specific
CLD/PTLDS categories epidemiologically. Therefore, the ability to collect
epidemiological data on CLD cases is limited in this study.
This study also contributes new knowledge to address gaps in communication
among PCPS in Connecticut regarding the status of CLD in Connecticut by comparing
two different PCP profiles (2006 vs. 2015). Lapses in communication between health
professionals about a critical issue of concern can create poor awareness of the magnitude
of the health problem, inefficiency in financing, and lack of adequate health policies to
benefit the members of a community (Mallonee, Fowler, & Istre, 2006). Therefore, I
aimed to assess, evaluate, and compare the differences in the KAP among PCPs who (a)
diagnose and treat CLD/PTLDS, (b) are undecided about it, and (c) do not believe that it
exists. These correlations were used to validate (yes or no) the outcomes found in
Johnson and Feder’s (2010) study.
After the position of PCPs is known regarding CLD/PTLDS, this study may have
scientific merit if the data obtained can enhance the necessity for the creation of a
baseline electronic system that will collect and document data from cases of
CLD/PTLDS. The study may also lead to equal guidelines across medical doctors to use
same standard care practices for diagnosing and treating CLD/PTLDS. As Moffett and
Moore (2011) stated, a competent physician treats patient equally under similar
circumstances. However, it is difficult to expect the same care from PCPs when they
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diagnose and treat patients without standardized care and guidelines (Cameron et al.,
2014, Infectious Diseases Society of America, 2006). When comparing the PCPs’
responses from the previous study (Johnson & Feder, 2010) and this study, it was
expected that the outcomes of the Chi-square (χ²) goodness-of-fit and the one-sample t
test will help PCPs to find new and constructive data that can be utilized to infer solutions
to improve their medical practices and approaches to better serve LD and CLD/PTLDS
patients. As Skela-Savič, Macrae, Lillo-Crespo, and Rooney (2017) stated in their study,
“Healthcare improvement science is the generation of knowledge to cultivate change and
deliver person-centered care that is safe, effective, efficient, equitable and timely. It
improves patient outcomes, health system performance, and population health” (p. 1)
The results of the study have the potential to contribute to social change by
presenting the position of PCPs regarding CLD/PTLDS in Connecticut as a new disease,
which may encourage future research and validation of CLD/PTLDS as a diagnosis. This
conflict around CLD/PTLDS may affect numerous patients who are or were severely sick
with CLD in Connecticut. Patients with CLD have found no much medical support for
their illness status (Ali et al., 2014; Johnson et al., 2014). Patients with CLD/PTLDS have
felt neglected without any medical help and paid more money out of their pocket when
they visited physicians in the state of Connecticut (Johnson et al., 2014). Patients with
CLD/PTLDS also lost their jobs and are or were experiencing a higher degree of
disability (Johnson et al., 2014).
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Problem Statement
There was a need to conduct a validation study to assess, evaluate, and determine
whether there are changes in Connecticut PCPs’ knowledge about the diagnosis,
treatment, and management approaches for CLD/PTLDS. LD could be associated with
the pathology of CLD/PTLDS; however, that association is currently unproven. Although
the pathological agent, transmission, and treatment of LD are well known, questions
remain regarding the best medical treatment practices for CLD/PTLDS (Bernard et al.,
2016; Delong, Blossom, Maloney, & Phillips, 2012). LD mimics other conditions, and
patients are not always aware that they have contracted the disease (Marzec et al., 2017).
There are few guidelines for the diagnosis, treatment, documentation, and management of
CLD patients.
There is also gap in the knowledge regarding significant differences in the KAP
of physicians on the diagnosis, treatment, and management of LD and CLD/PTLDS
among physicians who diagnose and treat CLD/PTLDS, physicians who are undecided
on CLD/PTLDS, and physicians who do not believe that CLD/PTLDS exits. Thus, I
surveyed these physicians by using Chi-square test (χ²) and t tests. The problem is current
and significant to the discipline because new knowledge on this topic may contribute to
social changes that will improve strategies in protocols needed for PCPs to deal with
CLD/PTLDS patients.
Purpose of the Study
The purpose of this quantitative study with a nonexperimental cross-sectional
comparative research design was to assess, exanimate, and determinate (for validity
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purposes) whether there were significant differences between two groups of PCPs
working in Connecticut regarding their KAP in the diagnosis, treatment, and management
of LD and CLD/PTLDS. In this study, the CT DPH medical doctors/Doctor of
Osteopathic Medicine (MD/DO) of 2015 was the independent variable for all study
questions. The complete data set for the Connecticut PCPs group from the list of certified
medical doctors in 2006 or CT DPH MD/DO of 2006 could not be obtained from
Johnson and Feder (2010). Therefore, I used the data presented in their study, and this
group of physicians is treated as a population with frequency and mean level data that
was compared to the data obtained from the sample of physicians in this study.
The first research question acted as a validation check, and it was expected that
the two groups would have similar frequencies of PCPs with general or family practice,
internal medicine, pediatric, and other primary care specialties since the two cluster
groups were withdrawn from the original lists of CT DPH MD/DO of 2006 and 2015.
The dependent variable for the second research question is the knowledge of LD,
measured categorically, and the dependent variable for the third research question was
the knowledge of CLD/PTLDS, the categorical variable. For the fourth and fifth research
questions, one-sample t tests were conducted to determine whether the two groups of
PCPs significantly differ concerning the number of patients diagnosed with and treated
for CLD/PTLDS, as well as the average course of antibiotic treatment for patients
diagnosed with CLD/PTLDS, the respective dependent variables. This study allowed for
a priori assumption and/or premise for the existence of CLD/PTLDS as defined by
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International Lyme and Associated Diseases Society(Cameron et al., 2014; ILADS,
2004).
Research Questions and Hypotheses
Research Question 1: Are the frequency distributions of the 2015 sample of
Connecticut PCPs across the four primary practice specialty areas (i.e., family medicine,
internal medicine, pediatrics, other) significantly different from the distributions of the
2006 (Johnson & Feder, 2010) sample of Connecticut PCPs?
H01: The frequency distributions of the 2015 sample of Connecticut PCPs across
the four primary practice specialty areas (i.e., family medicine, internal medicine,
pediatrics, other) are not significantly different from the distributions of the 2006
(Johnson & Feder, 2010) sample of Connecticut PCPs.
Ha1: The frequency distributions of the 2015 sample of Connecticut PCPs across
the four primary practice specialty areas (i.e., family medicine, internal medicine,
pediatrics, other) are significantly different from the distributions of the 2006 (Johnson &
Feder, 2010) sample of Connecticut PCPs.
Research Question 2: Are the frequency distributions of the 2015 sample of
Connecticut PCPs across the two knowledge of LD categories (i.e., know symptoms of
LD and feel comfortable diagnosing and treating LD vs. know LD but do not feel
comfortable diagnosing and treating LD) significantly different from the distributions of
the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs?
H02: The frequency distributions of the 2015 sample of Connecticut PCPs across
the two knowledge of LD categories (know symptoms of LD and feel comfortable
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diagnosing and treating LD versus know LD but do not feel comfortable diagnosing and
treating LD) are not significantly different from the distributions of the 2006 (Johnson &
Feder, 2010) sample of Connecticut PCPs.
Ha2: The frequency distributions of the 2015 sample of Connecticut PCPs across
the two knowledge of LD categories (know symptoms of LD and feel comfortable
diagnosing and treating LD versus know LD but do not feel comfortable diagnosing and
treating LD) are significantly different from the distributions of the 2006 (Johnson &
Feder, 2010) sample of Connecticut PCPs.
Research Question 3: Are the frequency distributions of the 2015 sample of
Connecticut PCPs across the three knowledge of CLD/PTLDS categories (do not believe
CLD exists, do not feel comfortable diagnosing and treating CLD/PTLDS, and feel
comfortable diagnosing and treating CLD/PTLDS) significantly different from the
distributions of the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs?
H03: The frequency distributions of the 2015 sample of Connecticut PCPs across
the three knowledge of CLD/PTLDS categories (do not believe CLD exists, do not feel
comfortable diagnosing and treating CLD/PTLDS, and feel comfortable diagnosing and
treating CLD/PTLDS) are not significantly different from the distributions of the 2006
(Johnson & Feder, 2010) sample of Connecticut PCPs.
Ha3: The frequency distributions of the 2015 sample of Connecticut PCPs across
the three knowledge of CLD/PTLDS categories (do not believe CLD/PTLDS exists, do
not feel comfortable diagnosing and treating CLD/PTLDS, and feel comfortable
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diagnosing and treating CLD/PTLDS) are significantly different from the distributions of
the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs.
Research Question 4: Is the estimated average number of patients diagnosed as
having CLD/PTLDS within a 3-year period by the 2015 sample of Connecticut PCPs
significantly different from the average number of patients diagnosed as having
CLD/PTLDS within a 3-year period by the 2006 (Johnson & Feder, 2010) sample of
Connecticut PCPs?
H04: The estimated average number of patients diagnosed as having CLD/PTLDS
within a 3-year period by the 2015 sample of Connecticut PCPs is not significantly
different from the average number of patients diagnosed as having CLD/PTLDS within a
3-year period by the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs.
Ha4: The estimated average number of patients diagnosed as having CLD/PTLDS
within a 3-year period by the 2015 sample of Connecticut PCPs is significantly different
from the average number of patients diagnosed as having CLD/PTLDS within a 3-year
period by the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs.
Research Question 5: Is the estimated average course of antibiotic treatment (in
weeks) for patients diagnosed as having CLD/PTLDS by the 2015 sample of Connecticut
PCPs significantly different from the average course of antibiotic treatment (in weeks) for
patients diagnosed as having CLD/PTLDS by the 2006 (Johnson & Feder, 2010) sample
of Connecticut PCPs?
H05: The estimated average course of antibiotic treatment (in weeks) for patients
diagnosed as having CLD/PTLDS by the 2015 sample of Connecticut PCPs is not
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significantly different from the average course of antibiotic treatment (in weeks) for
patients diagnosed as having CLD/PTLDS by the 2006 (Johnson & Feder, 2010) sample
of Connecticut PCP
Ha5: The estimated average course of antibiotic treatment (in weeks) for patients
diagnosed as having CLD/PTLDS by the 2015 sample of Connecticut PCPs is
significantly different from the average course of antibiotic treatment (in weeks) for
patients diagnosed as having CLD/PTLDS by the 2006 (Johnson & Feder, 2010) sample
of Connecticut PCP.
The KAP survey used in this study was relevant to measure how many PCPs
diagnose and treat CLD/PTLDS, are undecided on CLD/PTLDS, or do not believe that
CLD/PTLDS exists. Abdullah et al. (2013) have established the reliability and validity
for the KAP questionnaire. The Cronbach’s alpha coefficients were 0.96 (knowledge),
0.63 (attitude), and 0.79 (practice). The alpha coefficients were acceptable (Nyunnally,
1978).
Theoretical Framework
In 1962, Rogers developed the diffusion of innovations theory (Chien-Yun, WanFei, Yu- His, & Chia-Hung, 2012; Rogers, 2004). This innovations theory is a systematic
research investigation tool that can be applied to support how new concepts or ideas are
distributed and adopted by groups within society over time. Researchers in the modern
medical field have utilized diffusion of innovation theory to promote an understanding of
health challenges and to incorporate innovation adoptions into KAP for societal benefit
(Agyeman et al., 2009; Chien-Yun et al., 2012; Launiala, 2009).
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Examples of researchers who use the KAP theory to change physician behavior
include AI-Dharrab, Mangoud, and Mohsen (1996) and Magri, Johnson, Herring, and
Greenblatt (2002). Al-Dharrad et al. administered a KAP study to physicians and nurses
to collect data on hypertension in Saudi Arabia. Magri et al. described a KAP
questionnaire that was administered to New Hampshire PCPs to obtain insights into LD
diagnoses. Recently, Awad and Aboud (2015), Chien-Yun et al. (2012), and Ferrouillet et
al. (2015) also used a KAP survey to investigate health concerns.
In this study, I used the KAP model as the underlying theoretical framework in
this cross-sectional epidemiological study as a quantitative research method (Launiala,
2009). The KAP model served as a standard for this study because I collected significant
quantitative data to identify insights related to physician care for CLD/PTLDS patients
based on medical knowledge and practices. These data were beneficial to prove or
disprove this study’s hypotheses.
There are currently many knowledge gaps regarding the underlying agents that
may cause CLD/PTLDS in Connecticut residents. New information regarding what has
been or needs to be performed to identify possible risk factors about the disease’s origin
in Connecticut is important to discover the etiological agent, determine the distinctive
symptoms, and develop corroborative tests that yield an accurate diagnosis and treatment
by PCPs. However, the application of the KAP model was not used to answer questions
regarding the causative agent for CLD/PTLDS. Instead, the questionnaire focused on
obtaining documentation regarding the KAP of Connecticut PCPs who treat CLD/PTLDS
patients. PCPs (e.g., family/general, pediatrician, and internal medicine physicians) were
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chosen because they are typically the first resource for patients (Eldein, Mansour, &
Mohamed, 2013). The testable Research Questions and hypotheses were used to
determine if there are methods to improve the doctor-patient relationship in potential
CLD/PTLDS cases. This study’s findings may be useful if CLD/PTLDS is identified as a
distinct disease with a functional case definition in the future (Souri et al., 2017; Stricker
& Fesler, 2018). The survey data may produce significant information on the medical
care needs of CLD/PTLDS patients. Additionally, it is essential to determine whether
there are significant differences in the duration of prophylaxis given to CLD/PTLDS
patients. In this study, I applied the KAP model to test the hypotheses.
Nature of the Study
In this quantitative study, I employed a comparative cross-sectional research
design to determine whether there were significant differences regarding LD and
CLD/PTLDS KAP between the group of 285 Connecticut PCPs in Johnson and Feder’s
(2010) study and the 145 PCPs in this study. The comparison element of the study
pertained to the differences in categorical and ratio-coded dependent variables between
the two groups of PCPs. The study design was cross-sectional because the data were
collected from PCPs.
This study’s independent variable was the PCP groups—that is, those in Johnson
and Feder’s (2010) study and those in this study. This study had five dependent variables.
The first three dependent variables were categorically coded. The first three dependent
variables measured (a) the type of PCP (i.e., family/general practice, internal medicine,
pediatrics, other), (b) knowledge levels of LD, and (c) knowledge levels of CLD/PTLDS.

22
The last two dependent variables were ratio coded and measured the estimated number of
patients diagnosed with and treated for CLD within 3 years and the estimated average
course of antibiotic treatment (in weeks) for patients with CLD(PTLDS).
As the researcher of this study, I made similar attempts to replicate Johnson and
Feder’s (2010) sampling and methodological (i.e., recruitment, data collection,
measurement) procedures to make valid and appropriate comparisons between the data in
this study and that reported in their study. The participant inclusion criteria were the same
as those previously used. The criteria required that the physician (a) was certified to
practice medicine in the state of Connecticut, (b) currently practiced medicine in the state
of Connecticut, and (c) was a PCP with an identified PCP specialty (i.e., family medicine,
internal medicine, pediatrics, and others that included emergency medicine).
I utilized Johnson and Feder’s (2010) KAP survey and developed a survey packet
that included a KAP survey, a letter of introduction outlining the purpose of the study, an
informed consent form, and a stamped, addressed envelope for returning the
questionnaire. In alignment with Johnson and Feder, the study packet was mailed to 33%
of the PCPs whose work contact information was available from the CT DPH. Surveys
were expected to be returned from an equivalent number of PCPs
SPSS 24.0 software was used to enter and analyze the survey data. However,
because I was unable to obtain the entire data set used by Johnson and Feder (2010), it
was treated as the population when compared to the sample obtained in this study.
Sample-to-population comparisons require the use of specific statistical tests for
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hypothesis testing, which included Chi-square (χ²) goodness-of-fit tests and one-sample t
tests.
There are differences between LD and CLD (Crowder et al., 2014). There are also
differences between CLD, which is given the name PTLDS. However, I combined CLD
and PTDS as CLD/PTLDS to be inclusive for the purpose of this investigation. Other
definitions to clarify my use of terms are provided in this section.
Antibiotics: Antibiotics are classes of drugs prescribed to patients by a medical
doctor with the purpose to kill or inhibit the growth of disease-causing microorganisms.
Antibiotics (e.g., penicillin, streptomycin) must be given after a bacterial infection
(Hamilton & Wenlock, 2016).
Bias: Bias is the presence of systematic errors in the study design, conduct, or
analysis (Althubaiti, 2016).
Beliefs: Beliefs are traditional ideas that one can have regarding an issue. For
example, a medical procedure can be informed by what people believe is the right choice
of treatment (Launiala, 2009).
Chronic diseases: Chronic diseases are chronic illnesses classified as
noncommunicable diseases or degenerative diseases characterized by an uncertain
etiology, multiple risk factors, long latency period, prolonged time, and non-contagious
origin with some degree of degeneration and disability (Fradgley, Paul, & Byrant, 2015).
Chronic Lyme disease (CLD): CLD is the occurrence of a constellation of
persistent symptoms in patients with or without evidence of previous Borrelia
burgdorferi infection (Ali et al. 2014; Johnson & Feder, 2010). Though there are varying
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definitions for this term, CLD occurs when patients are diagnosed with and treated for
LD and may continue to experience worsening symptoms after treatment is received. In
other cases, there is no known etiologic agent or sign of the typical rash of LD or
information about laboratory testing related to Borrelia burgdorferi or B. mayonii
(Lantos, 2015a). In this study this term is used as CLD/PTLDS.
Erythema Migrans (EM): EM is a circular skin lesion that outwardly looks like a
red patch (rash) with a central clearing and appears as a bullseye after a deer tick bite
(Allen, Vin, Warner & Joshi, 2016; 2016; Torbahn et al., 2016).
Evidence-based medicine: Evidence-based medicine is the integration of the
current best research using clinical expertise, pathophysiology knowledge, and patients to
make the best medical decisions from observations and data obtained from clinical
studies (Cameron et al., 2014).
Immunity: Immunity is protection against a disease. There are two types of
immunity status: passive and active. The immunity protection status of a person is
indicated by the presence of antibodies in the blood and can usually be determined by a
laboratory test (Warrington, Watson, Kim, & Antonetti, 2011).
Infectious diseases: Infectious diseases are caused by pathogenic microorganisms
(e.g., bacteria, viruses, parasites, or fungi) that can be transmitted directly or indirectly
from one person to another (Nii-Trebi, 2017).
Lyme disease (LD): LD is the most common vector-borne infectious disease in the
United States. It is caused by the spirochete Borrelia burgdorferi or B. mayonii (Dolan et
al., 2017).
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Multi-system infectious disease syndrome: Multi-system infectious disease
syndrome is a term used mainly by Horowitz in treating patients for CLD (Horowitz &
Freeman, 2018).
Primary care epidemiology: Primary care epidemiology represents applications
and methods to collect the data of health problems encountered in a primary care
diagnosis setting (e.g., etiology, prevention, and diagnosis to improve their management).
(Mullan, 1984).
Physician: A physician is a certified medical doctor who is qualified to practice
medicine and take care of people or patients (e.g., conduct examinations, prescribe
medications, and order, perform, and interpret diagnostic tests; U.S. Labor Department,
2017).
Post-treatment Lyme disease syndrome (PTLDS): PTLDS is a term established by
the CDC in 2006 (Maloney 2016; Lacout, El Hajjam, Marcy, & Perronne, 2018) to refer
to a health condition in patients with LD who maintain symptoms for more than six
months after the first presentation of LD. In some cases, PTLDS is recognized by other
organizations and researchers as CLD. In this study this term will be apply as
CLD/PTLDS. PTLDS is accepted by the CDC and the Infectious Diseases Society of
America as a diagnostic term for patients whose symptoms persist after the typical 2 to 4
weeks of antibiotic treatment (Aucott, Rebman, Crowder, & Korte, 2013; Horowitz &
Freeman, 2018).
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Public health surveillance: Public health surveillance is the ongoing practice of
conducting the systematic collection, analysis, interpretation, and dissemination of health
data for planning, implementation, and evaluation (Choi, 2012, p. 1).
Risk factors: Risk factors are conditions or measurements associated with the
probability of disease or death and not necessarily recognized by people or patients
(Willadsen et al., 2016).
Surveillance: Surveillance within a medical domain refers to the continuous
methodical and systematic collection, analysis, and interpretation of health data essential
for the planning, implementation, and evaluation of public health practice. It is
thoroughly integrated with the timely dissemination of these data to those who need to
know (Adokiya, Awoonor-Williams, Beiersmann & Müller, 2015).
Zoonotic diseases: Zoonotic diseases are infectious diseases that can be
transmitted from animals to humans or vice versa (Scoth, Mattocks, Rabinowitz, &
Brandt, 2013).
Zoonotic infection agents: Zoonotic infection agents are viruses, bacteria, fungi,
and parasites that cause zoonotic diseases (Walter-Toews, 2017).
Assumptions
One of the main assumptions pertained to the use of CLD/PTLDS. For this study,
a priori existence of CLD/PTLDS as defined and diagnosed by the International Lyme
and Associated Diseases Society was accepted (Cameron et al., 2014), although the
International Lyme and Associated Diseases Society (2004) definition of CLD/PTLDS
contained no link to the etiologic agent of LD (e.g., through documentation of serologic
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evidence; Johnson & Feder, 2010). The International Lyme and Associated Diseases
Society asserts that a bacterium causes LD and can persist in patients after the traditional
28-day antibiotic treatment (Cameron et al., 2014; Johnson & Feder, 2010; Marzec et al.,
2017; Stricker & Johnson, 2008). They (ILADS) supported two main reasons why the
CLD/PTLDS term is preferred among health care providers as (a) patients with
CLD/PTLDS suffer from inclusive constitutional symptoms as musculoskeletal, and
neuropsychiatric symptoms, and (b) patients had used a multiples treatment (i.e.,
medicines and long courses of intravenous antibiotics).
I also assumed that the growth or reduction of the population of PCPs (family
physician, pediatrician, and internal medicine physicians) in Connecticut drastically
changed over time in the last 10 years but stays stable within less than 20% of variation
(Appendix C). In addition, I assumed that the external validity and the internal validity in
this study have limitations because the results were not representative for all medical
doctors in Connecticut that were listed in the CT DPH MD/DO of 2015 (i.e., all PCPs)
when comparing it with the CT DPH MD/DO of 2006 (Appendix E). However, I
assumed that PCPs survey responses in this study (2015) would be a representative of the
PCPs distribution (or responses) of 2006 because I followed the same sampling frame
that Johnson and Feder (2010) used. Additionally, I assumed that the data obtained from
this study could not be generalized to medical doctors working in other states in the
United States.
Despite these assumptions, I assumed that the study was appropriate to evaluate
the KAP of PCPs in regard to LD and CLD/PTLDS. I also assumed that the results of this
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study have a proper level of construct validity because I used the same survey, same
sample frame, and same protocols as Johnson and Feder (2010). The only variations were
the length of the invitation to participate or cover letter. Previous researchers used just
one short paragraph, whereas I used a whole page to comply with the Walden
Institutional Review Board (IRB). I also added two other questions at the end of the
questionnaire used in this study (Appendix A).
Scope and Delimitations
I sought information that can be used to help to resolve current disagreements
between PCPs and patients with CLD/PTLDS in Connecticut. Having a consensus among
PCPs about CLD/PTLDS may bring benefits to their medical practice and patients. The
data were from PCPs working in Connecticut in 2006 and 2015. The purpose of the study
was to identify whether there were significant differences after 10 years on the position of
PCPs on the KAP concerning the diagnosis and treatment of CLD/PTLDS in Connecticut
and to validate the results of Johnson and Feder’s (2010) study. Johnson and Feder
limited questions on LD and CLD/PTLDS to 3 years before the survey’s distribution, and
I followed the same procedure despite potential concerns for recall bias (Althubaiti,
2016).
This study had volunteer participation drawn from randomly selected certified
Connecticut PCPs to answer a mail survey related to LD and CLD/PTLDS. Many PCPs
in Connecticut may have differing positions in attentiveness to CLD/PTLDS as to how
they diagnose and treat patients with LD and CLD/PTLDS. To make this study as
objective as possible, I defined CLD/PTLDS in the survey cover letter, which was mailed
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with the survey as “the persistence (more than six months) of Borrelia burgdorferi
infection, despite multiple standard courses of antibiotics.” The term LD was not defined
in the cover letter or survey because this was not the focus of this study. Another reason
why I did not define LD is because I wanted to compare the outcomes published by
Johnson and Feder (2010) with the same questions (including one two questions about
LD in the survey) plus two more questions at the end to be in compliance with the
Walden IRB requirements for consent. Thus, I assumed that all study PCPs were
considering the same clinical definition of CLD/PTLDS when completing the survey.
The sample size for this study included randomly selected participants with
available mailing addresses. For this quantitative KAP survey, the subjects were medical
doctors from the active list of the Connecticut State Health Department Certified Medical
Doctors/Surgeons in 2015 (CT DPH, 2015). The exact number of CT DPH PCPs of 2015
who took part is discussed in Chapter 3. The CT DPH MD/DO of 2015 was made up with
the names of physicians, their work or practice addresses, medical license numbers, the
expiration of their medical license numbers, and their specialty.
The study was limited to PCPs working in Connecticut. Therefore, the criteria for
this target population included medical doctors who actively practiced medicine in 2015,
were licensed by the state of Connecticut, and practiced as pediatricians, family doctors,
or internal medicine doctors. PCPs’ names were collected from the certified list of
physicians working in the following categories in 2015: family doctors or general
medicine, pediatrics, and internal medicine. A purposeful selection (nonrandom)
identified the participants for this study within the three categories because it was the best
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method to find a representative volunteer sample of Connecticut physicians whose
practices were most likely to diagnose CLD/PTLDS or related conditions. Computer
randomization was used to eliminate selection bias and to obtain the correct number of
necessary participants. The variables studied were drawn from a population of health care
practitioners that worked as medical doctors. Johnson and Feder (2010) studied a similar
population in 2006 and selected participants using random selection. The investigative
period lasted no longer than 2 months and involved a one-time mailed survey. Thus, it
was essential to obtain the correct mailing addresses from the list of selected participants.
The exclusion criteria were medical doctors with a specialization in categories
other than the study’s specified groups of family or general physicians, pediatricians, and
internal medicine physicians. However, emergency physicians were accepted in this
study because the previous study also included them in the statistical analysis (Johnson &
Feder, 2010). Emergency physicians have a crucial role when dealing with prospective
LD patients since in some occasions many of them may show up at the hospital
emergency room looking for someone to remove ticks found on themselves or with EM
manifestations (Applegren & Kraus, 2017). Additionally, physicians have the best
intentions to help patients with the diagnosis and treatment of LD from the exposures of
ticks on individuals or with the rash to eliminate LD complications especially if such
patients may be living in geographical areas of endemic of Ixodes scapularis ticks
(Applegren & Kraus (2017).
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Limitations
The study was limited because I could not control all potentially confounding
factors if there were present in this cross-sectional research. Confounding variables or
confounders are often defined as the variables correlate (positively or negatively) with
both the dependent variable and the independent variable (Pourhoseingholi, Baghestani,
& Vahedi, 2012). Therefore, confounding factors can cause a false relation between an
exposure and an outcome, especially in clinical trials. Even though this study was not a
clinical trial, there is a study design limitation because the associations of exposure and
outcomes are simultaneously evaluated or measured. It is impossible to assess any
temporal relationships between exposures and outcomes in cross-sectional studies
(Carlson, 2009; Salem, 2015). Without longitudinal data, it is not possible to establish an
exact cause and effect relationship (Salem, 2015). However, cross-sectional studies are
less expensive than longitudinal studies.
The design of this study may have also produced selection bias because crosssectional studies rely on one-time responses and no other personal risks, behaviors, or
confounders. Another critical consideration is selection bias if proper randomization is
not achieved. A nonresponse from selected participants may produce bias because the
survey’s population was reduced (Thorpe et al., 2008).
Another important limitation is recall bias, which occurs when there are differing
levels of accuracy from the point from the informant (Althubaiti, 2016). Recall bias in
epidemiological and medical research may be due to difficulty in remembering previous
significant details related to the participant’s disease when responding to self-reporting
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surveys (Althubaiti, 2016). The recall period in this study was 3 years ago. Thus, this
period may cause less reliable recalled information given by the PCPs who participated in
this study. The study design in the questions used in the survey was 3 years ago because
it was stated in the survey used by the previous researchers (Johnson & Feder, 2010).
Self-selection is another form of bias that occurs when a complex decision is
made quickly by the respondents. In this study, a few survey responses stated indicated
that the PCPs had participated in the previous survey. In PCPs’ responses, there were a
large number of PCPs who did not believe in CLD/PTLDS as well others who stated they
believe in CLD as a new disease.
Other limitations pertained to the method of data collection. One of the
disadvantages of mailed surveys is that correct addresses are required for each participant
in addition to resources to cover delivery costs (Edwards, 2010). Consequently, an
individual other than the intended respondent may answer the survey. Participants
answering the questions in a retrospective survey may find that recalling previous actions
or past details related to their disease is challenging. The day and season period when the
survey was mailed out may also have caused limitations (PRA, n.d.). Another
disadvantage was that the cover letter was a whole page, which may have affected the
response rate. Medical doctors do not have much free time to read while serving their
patients; they work long hours, and the surveys were mailed at their workplaces
(Pedrazza, Berlanda, Trifiletti, & Bressan,2016).
Social desirability bias may also occur in administering questionnaires or surveys
when the data or responses to questions are affected by social desirability, approval, or
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the inability to be guaranteed anonymity or confidentiality (Althubaiti, 2016). The survey
responses of the instrument used in this study were to be answered without the name of
the PCPs participants to eliminate social desirability by using a previously conducted
survey for data collection of this study (Althubaiti, 2016). It is essential to avoid social
desirability bias when constructing a data collection method (Althubaiti, 2016). Social
desirability bias should not have affected this study because the survey was random and
was to be answered anonymously.
Another limitation of this study was the inability to corroborate the medical data
reported from the CT DPH and the CDC because there is not an approved case definition
for CLD (PTLDS). At this time, there is the confusion about how to employ the term
CLD/PTLDS. Consequently, there was a lack of known published reported surveillance
data on the term CDL or PTLDS. PTLDS is a term appropriate to be used to identify
patients afflicted with CLD (CDC, 2019a) for reasons that are explained in detail in
Chapter 2. Therefore, in this study both terms were considered similar as CLD/PTLDS to
be in accordance with the CDC, even residents in Connecticut preferred the term CLD
(Johnson & Feder, 2010).
Significance
Researchers from several scientific disciplines are currently investigating
CLD/PTLDS, which may lead to discoveries and knowledge about it and the health
controversy surrounding it. One of the primary areas of study in this research is the
potential close relationship between CLD/PTLDS and documented cases of LD in
Connecticut. LD can be a serious health problem if unrecognized and untreated (Ljøstad
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& Mygland, 2013). However, although there is a potential relationship with CLD/PTLDS
and LD, there is also a potential that CLD/PTLDS occurs without clinical or diagnostic
evidence of B. burgdorferi infection. Therefore, some researchers think that it is
inappropriate to use the term CLD, which implies a B. burgdorferi’s etiology (National
Institute of Allergy and Infectious Diseases, 2019).
This study may enable future researchers to identify a possible link between LD
and CLD/PTLDS. This may inform Connecticut residents about the severe health
implications that may affect them if a relationship between LD and CLD/PTLDS is
found. The number of LD cases in Connecticut has increased over the last 30 years. The
CT DPH has reported 2,108 confirmed and 810 probable cases of LD since 2013
(Garnett, Connally, Stafford, & Carter, 2011). Therefore, there is a need to determine
whether there is a relationship between misdiagnosis (or failure to receive an early
diagnosis and management) of LD and the presumed onset of CLD/PTLDS. The
prevention of CLD/PTLDS onset will protect patients from neurological complications,
central nervous system effects, and other complications such as arthritis (Bratton,
Whiteside, Hovan, Engle & Edwards, 2008). The results of this study may provide
physicians with knowledge for diagnosing, managing, and treating patients with LD and
CLD/PTLDS so that patients will not be misdiagnosed, poorly maintained, or
undertreated. This study may provide significant insights on this complex health issue
because it addresses information gaps (besides the intents of validation of the previous
research) about CLD/PTLDS as a potential persistent and contemporary public health
concern and how to avoid disability and morbidity. Additionally, many patients have
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become frustrated when they did not receive an accurate diagnosis and treatment for an
illness that they believed was CLD/PTLDS (Lantos, 2015a).
The potential benefits of this study also include increasing the awareness of
CLD/PTLDS within the Connecticut health professional community and to improve the
diagnosis barriers (e.g., lack of case definition, ICD-10 code, standardized medical
guidelines, better practices) that PCPs face when working with CLD/PTLDS patients.
This is significant because the doctor–patient relationship is the core of care in collecting
data, diagnosing, and helping patients heal (Dorr Goold & Lipkin, 1999, p. 27). This
study may result in benefits and social changes that will improve communication between
PCPs, public health organizations (e.g., CDC, World Health Organization, Council of
State and Territorial Epidemiologists, CT DPH, Connecticut Medical School),
professional medical societies, and people with presumed cases of LD and CLD/PTLDS.
It is essential that these public health organizations see the need to collect more
information and to create a database for surveillance purposes to document what is
happening to potential CLD/PTLDS patients.
The study may also advance current medical knowledge and show whether a
belief in CLD/PTLDS affects a physician’s KAP regarding the diagnosis, treatment, and
management of LD (within the context of the survey) and CLD/PTLDS. This study may
advance medical practices by providing an opportunity for PCPs to reach a consensus of
what they should do to help CLD/PTLDS patients. The study may also contribute
positive and constructive ideas for social change within the health care field by
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influencing PCP outcomes. Additionally, the findings of this study may encourage
changes in the protocol presently used by PCPs to help CLD/PTLDS patients.
Summary
CLD/PTLDS is a new health condition without a case definition (CDC, 2019a), so
it has not been defined, classified, or accepted as a reportable disease in Connecticut. It is
common practice in Connecticut for all certified physicians who examine or treat
patients’ reportable infectious diseases to report to the director of the DPH on any
notifiable mandated infections encountered. Researchers agree that CLD/PTLDS has not
garnered sufficient attention from health care professionals and that many people who
stated that they had CLD/PTLDS did so because of conflicting information as well as
because of the lack of a case definition for CLD/PTLDS (Henry & Carr, 2012; Johnson &
Feder, 2010; Lantos, 2015a; Stricker & Johnson, 2008; Stricker & Fesler, 2018).
This study was conducted to acquire new evidence-based knowledge to help the
medical community (particularly PCPs) determine whether there is a need to create better
practices to evaluate, diagnose, and treat potential CLD/PTLDS patients. The findings of
this study may also encourage PCPs to develop a case definition for CLD/PTLDS.
Additionally, if CLD/PTLDS is considered a distinct condition, a new surveillance
system could be used for chronic Lyme spectrum illness prevention. The study could
advance knowledge in the discipline by exploring the differences in KAP of two PCPs
distributions (2006 vs. 2015) in Connecticut.
Chapter 2 provides the literature review regarding the latest findings related to
CLD/PTLDS and why it is not currently a reportable disease. Chapter 3 describes the
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primary methodology used in this quantitative study. Chapter 4 contains the results and
includes statistical data analyses with corresponding figures and tables. Finally, Chapter 5
provides information about the public health implications, recommendations, and
concluding remarks about the KAPs on treating CLD/PTLDS patients in Connecticut.
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Chapter 2: Literature Review
Introduction
The prevalence of CLD/PTLDS remains relatively unknown in Connecticut.
Furthermore, there is currently a significant division between two professional medical
societies, the Infectious Diseases Society of America and the International Lyme and
Associated Diseases Society, about the guidelines for the diagnosis and treatment of
CLD/PTLDS (Davidsson, 2018; Feder et al., 2007; Johnson & Feder, 2010). The
diagnosis and treatment of CLD/PTLDS is now one of the most debated medical health
challenges in Connecticut and the rest of the United States (Feder et al., 2007; Lantos,
2015a). The controversy centers on whether CLD/PTLDS is a separate illness (Feder et
al., 2007; Johnson & Feder, 2010, Lantos, 2015a). The argument is caused by the lack of
information about the etiological agent, as well as a lack of reliable clinical testing, no
ICD code, and no standardized clinical guidelines for treatment. Medical doctors,
especially PCPs, may have different KAPs on the most appropriate treatment for
CLD/PTLDS (Johnson & Feder, 2010). A significant point of conflict among medical
doctors is over the practice of long-term treatment with IV therapy.
Another part of the debate is the many stories from CLD/PTLDS patients who
had positive and negative outcomes after receiving IV treatments with antibiotics such as
individuals afflicted with CLD/PTLDS who have contributed testimonials via social
media (e.g., Facebook, YouTube, blogs). An example on YouTube is the story of Monica
Amore (Amore, 2009). In Monica Amore’s testimonial, she reported the success of longterm IV antibiotic therapies, and she has been healthy and recovered. However, there are
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also negative stories about the adverse effects of long-term IV antibiotic therapy for
individuals diagnosed with CLD/PTLDS. In 2000, Patel, Grogg, Edwards, Wright, and
Schwenk (2000) presented a testimonial from a 30-year-old female who was diagnosed
with CLD/PTLDS. The woman received 27 months of IV treatments with cefotaxime and
died from septic thrombus infection that was not caused by CLD/PTLDS but rather from
a secondary infection from IV Groshong catheters that caused a fatal infection with
Candida parapsilosis (Patel et al., 2000).
To address these issues regarding the diagnosis and treatment of CLD, I
conducted this study to compare a sample of PCPs to those in a seminal study published
in 2010. In this chapter, I introduce for the consideration of the literature reviews these
subtopics as literature search strategy, theoretical foundation, problems with the case
definition of chronic lyme disease, controversy with the diagnosis of chronic Lyme
disease, controversy with bacteria and chronic Lyme disease diagnosis, relationship
between Lyme disease and Chronic Lyme disease , disagreement on treatment for Lyme
disease and Chronic Lyme disease, persistence of Borrelia burgdorferi after antibiotic
treatment, diagnosis, treatment, and management of Lyme Disease, Chronic Lyme
disease , diagnosis, treatment, and management of Post-Treatment Lyme Disease
Syndrome. The chapter ends with a summary and conclusion.
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Literature Search Strategy
The literature for this study was discovered with ProQuest Dissertations and
Theses, EBSCOHost, Google, Google Scholar, the Walden University Library, the
University of Connecticut’s Lyman Medical Library, and YouTube. Sources included in
the literature review were primarily published from 2006 to 2018. Search terms included
knowledge, attitudes, and practices of physicians; Lyme disease; chronic Lyme,
treatment, and management of LD and CLD/PTLDS; physicians who are undecided on
CLD/PTLDS; physicians who do not believe that chronic LD exists; and knowledge,
attitudes, and practices (KAP) theory. Statistical applications of SPPS used in public
health research were identified for this section of the literature review.
Additionally, the literature search was undertaken to collect information regarding
CLD and PTLDS, and CDL/PTLDS. The literature review included research on the
definitions of CLD and PTLDS; controversial issues regarding diagnosis; variability of
treatment for CLD or PTLDS; associations between LD and CLD; the persistence of the
B. burgdorferi after treatment with antibiotics; available clinical testing for CLD/PTLDS
and LD; problems for primary, family, and general care physicians, including
pediatricians and internal medicine physicians reporting on CLD/PTLDS; the latest
CLD/PTLDS research; research gaps for CLD/PTLDS; the relationship between biofilms
and CLD/PTLDS; and a review of research methods, including surveys, conducted on the
same or related subjects outside of Connecticut.
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Theoretical Foundation
Public health researchers have used the diffusion of innovations theory to ground
their research for adopting innovative procedures (e.g., taking antibiotics or medications,
accepting treatment for diseases like diabetes, etc.), which may lead to concrete, desired
changes in societal behavior for improving wellness in a community (Abdullah, Aziz,
Harum, & Burhanuddin, 2013; AL-Dharrab, Mangoud, & Mohsen,1996; Lien & Jiang,
2016; Zhang et al., 2015). In addition to the diffusion of innovations theory, I used the
KAP approach to understand PCPs’ KAP when they treat LD and CLD/PTLDS. The
diffusion of innovations theory can be applied to research assessing participants’ KAP in
public health settings (Launiala, 2009). KAP can also be applied when examining
physician behavior to improve health status (Awad & Aboud, 2015; Chien-Yun et al.,
2012; Fauman, 2006).
The KAP approach was the most appropriate method to examine the difference in
the KAP of PCPs concerning LD and CLD/PTLDS. This approach was informed by the
research questions and helped identify the research design decisions (i.e., the method of
inquiry, data collection, and analysis). Thus, for this study, the KAP approach was used
(see Figure 1) to test the research questions and hypotheses.
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Figure 1. The knowledge, attitude, and practice (KAP) diagram. Adapted from “A study
on Modification of Knowledge, Attitude, and Practice on Vocational High School
Electronic Courses Integrated with Nanotechnology Concept,” by Chien-Yun et al., 2012,
International Journal of Thermal & Environmental Engineering, 4, p. 74.
Problems with the Case Definition of Chronic Lyme Disease
PCPs are required to have a comprehensive knowledge of toxicology, pathology,
and clinical sciences to diagnose and treat patients following the laws and ethics of the
state in which they practice medicine (Grudniewicz et al., 2015). This study was focused
on the applications used in epidemiology with inductive and deductive applications to
gather new insights about CLD/PTLDS as a possible new health issue affecting residents
in Connecticut. The International Epidemiological Association (2017) defined
epidemiology as the “study of the occurrence and distribution of health-related events,
states, and processes in specified populations, including the study of the determinants
influencing such processes, and the application of this knowledge to control relevant
health problems.” This epidemiology definition emphasizes big data, genealogy, and
personalized medical therapies (Kuller, 2016).
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The initial step in conducting an epidemiological investigation on contagious
diseases or chronic diseases is to formulate a case definition . This initial step helps
identify the disease’s potential infectious agent or the risk factors, leading to a definite
diagnosis by a certified medical doctor or laboratory staff. A case definition identifies the
risk factors and may allow disease trends to be documented in most cases with electronic
reporting records or geographic information systems of ill patients. Once a disease has a
case definition, it can be reported to local, state, and federal agencies (Coggn, Martyn, &
Evanoff, 2005).
The next step requires physicians to diagnose and report details about the results
of physical and pathological examinations, diagnostic tests, and treatments administered
to patients (Rajkomar & Dhaliwal, 2011). A correct diagnosis helps health care
professionals identify the source, mode of transmission, and cause of the investigated
disease (Rajkomar & Dhaliwal, 2011). Without a case definition, professionals cannot
perform an effective analysis of the data obtained from the current or previously afflicted
members of the community.
Although CLD does not have an approved case definition, the CDC recognizes
PTLDS as a health condition (Borchers, Keen, Huntley, & Gershwin, 2015). Borchers et
al. (2015) described PLDS as a health condition found in patients treated with antibiotics
who continue to have persistent symptoms from a previous LD infection. The Infectious
Diseases Society of America accepts this definition of PLDS (also known as PTLDS).
Other researchers have defined CLD/PTLDS as a persistent infection caused by B.
burgdorferi that may or may not have laboratory or clinical evidence and that requires a
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more extended treatment period that uses intravenous and/or oral therapies (Johnson &
Feder, 2010). For example, Lantos et al. (2015b) described CLD/PTLDS as a health
condition present in some patients with prolonged, medically unexplained physical
symptoms and/or uncorroborated alternative medical diagnoses. Lantos and Wormser
(2014) and Chan et al. (2013) also found that a small group of individuals who thought
that they had CLD/PTLDS were also treated for coinfections, such as with Babesia,
Anaplasma and Bartonella. However, there is still an issue with defining CLD without
clinical laboratory evidence (Klempner et al., 2012).
There are many definitions of CLD/PTLDS, which reflects the issue of whether it
is a health condition or a disease and whether it deserves a new classification. For
instance, Ścieszka et al. (2015) suggested that PTLDS and PLDS are interchangeable
terms. Most people living in Connecticut are familiar with the terms CLD or PTLDS
(Feder et al., 2007; Johnson et al., 2014). Moreover, before the CDC, researchers have
rejected the CLD term and preferred the term tick-associated poly-organic syndrome
(Borchers et al., 2015; Clarissou et al., 2008). Regardless, ILADS (2004, 2005) defines
CLD as a blend of recurrent symptoms with debilitating subjective physical
manifestations that include extreme fatigue, arthralgia, myalgia, vague memory and poor
concentration, strong headaches, and irritability. However, the Infectious Diseases
Society of America (2017) does not acknowledge CLD term alone and has rejected this
definition (Johnson et al., 2014; Johnson & Feder, 2010; Johnson & Stricker, 2010).
Despite disagreements, one suggestion for a case definition for CLD is that it must meet
the following criteria: (a) the illness is present for at least a year, (b) there are persistent
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and significant neurologic involvements or active arthritic manifestations, and (c) patients
must still be infected with the B. burgdorferi bacteria following antibiotic treatment
(Burrascamo, 2008).
In Connecticut, CLD/PTLDS is currently a health condition without an acceptable
epidemiological case definition. CLD/PTLDS is not accepted, recognized, or reported in
the United States. Further, CLD/PTLDS patients in Connecticut and across the nation
struggle to obtain treatment for the disease, mainly due to a lack of acceptance by the
medical community. Therefore, evidence-based medical knowledge may yield scientific
information on the possible relationship between CLD/PTLDS and LD, which could
affect Connecticut residents.
Though there is no official definition to report cases of CLD/PTLDS, the latest
statistics from the CT DPH in 2017 show a decrease in the number of cases reported and
documented in the state (see Figure 2). Additionally, the latest statistics from the CT
DPH (2018) show a total of 1,363 confirmed cases and an overall incidence rate of 56.6
cases per 1,000,000. Most of the reported cases were from New Haven County.
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Figure 2. Lyme disease cases and rates (per 100,000) by count. From “Lyme Disease
Statistics,” by CT DPH, 2018 (https://portal.ct.gov/-/media/Departments-andAgencies/DPH/dph/infectious_diseases/lyme/stats/CTLDStats2017.pdf?la=en)
In addition to the cases of CLD in Connecticut, the ILADS (2004) estimated the
prevalence of CLD/PTLDS to be between 34% and 64% of studied cases in 1994 for
patients who were seen by a physician and thought they might have LD. It is suggested
that 10% to 20% of patients who underwent 2 to 4 weeks of treatment for LD had
persistent symptoms with or without the presence of B. burgdorferi (Adrion et al., 2015,
Maloney, 2016). However, the limited amount of scientific data on the topic has resulted
in differing physician opinions about the duration or the therapeutic window to treat
CLD/PTLDS patients (Feder et al., 2007; Lantos et al., 2015b; Ścieszka et al., 2015). But
De Long, Hsu, and Kotsoris (2019) estimated that in 2020, the prevalence of
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CLD/PTLDS in the United States will be higher than in 2016, with as many as 1,944,189
(95% CI: 1,619,988- 2,304,147) CLD/PTLDS cases. As indicated by this prevalence rate,
CLD/PTLDS is a concern not just for Connecticut, but the United States as a whole.
Controversy with the Diagnosis of Chronic Lyme Disease
A group of scientists and health professionals have suggested that CLD/PTLDS
occurs due to inappropriate antibiotic treatment of the LD-causing bacteria (ILADS,
2004, 2015). These health care professionals believe that the most efficient method to
treat and cure CLD/PTLDS is the use of long-term antibiotics (Cameron et 2014; ILADS,
2004, 2015). Most physicians who belong to the health professional group support
extended antibiotic treatment if needed by CLD/PTLDS patients (ILADS, 2004, 2015).
However, another group of scientists and health professionals consider CLD/PTLDS to
be multiple spectrum diseases that result from unknown causes and are unrelated to the
persistence of B. burgdorferi (Baker, 2012; Infectious Diseases Society of America,
2017; Marques, 2008). These professionals do not recommend long-term antibiotic
treatment for potential CLD/PTLDS patients (Infectious Diseases Society of America,
2006, 2015, 2017, 2019). These different perspectives and treatment approaches indicate
the need for a resolution to assist those with CLD/PTLDS such as identifying a pathogen
that causes CLD/PTLDS.
One of the reasons CLD/PTLDS is a controversial diagnosis is the absence of an
identified pathogen or other noninfectious agents that can show causation (Ali et al.,
2014; Auwaerter et al., 2011; Feder et al., 2007; Marques, 2008; Wormser, 2007). If the
pathogen or other noninfectious agents that cause CLD/PTLDS are unknown, it is
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impossible to determine which laboratory tools should be used to identify unknown
agents, particularly if they are biological in origin. Additionally, the lack of standardized
diagnostic criteria within the medical community makes it challenging for physicians to
provide treatment and manage CLD/PTLDS (Feder et al., 2007; Lantos, 2011; Ljostad &
Mygland, 2012; Stricker & Johnson, 2008). Another challenge associated with
CLD/PTLDS is the lack of information about the role of the autoimmune system
(residual or persisting antigens) and toxins produced in CL/PTLDS patients (Miklossy,
2012; Miller, 2016).
Controversy with Bacteria and Chronic Lyme Disease Diagnosis
When a bacteria diagnosis is needed, a patient’s blood sample is the standard for
obtaining and examining bacteria culture samples (direct cultures or indirect plus serum
analysis; Villa et al., 2017). Gold standard testing in microbiology is derived from Koch’s
work, which documented the protocols necessary to isolate pathogens and relate the
pathogens to a specific disease or to prove their microbial etiology or infectious origin in
outbreak cases (Mortimer, 2003). Koch’s protocols are the contemporary basis for direct
pathogen identification from cultures using microscopic and xenodiagnostic techniques
(Fredricks & Relman, 1996; Hess, 2017; Mortimer, 2003). Koch’s Postulates include the
following: (a) the bacterial agent must be present with every case of the disease, (b) the
microorganism must be isolated from a host source and grown purely by means of
laboratory in vitro techniques, (c) the same grown microorganism must be confirmed as
the symptom-causing agent when it was introduced into a healthy susceptible host, and
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(d) the same pathogen should be recovered again from the infected host (Fredricks &
Relman, 1996; Hess, 2017; Mortimer, 2003).
Other serology and immunology testing used to identify bacteria, parasites,
viruses, and diseases include agglutination methods, precipitation methods,
electrophoresis methods, labeling techniques in immunoassays and complement fixation,
and fluorescent antibodies (Villa et al., 2017). Measuring the levels of antibodies is
possible when identifying the bacteria that is resulting in the illness; the identification of
these antibodies is often used to prescribe the proper antibiotic treatment. Other
identification methods for disease-causing parasites in humans include using blood
smears and serology testing. Parasites are sensitive to antibiotics, and viral infections
require more complex methods than bacterial infections to be identified by DNA or RNA
cultures. Viral infections cannot be eliminated or cured with antibiotics.
A related issue is that PCPs need to have confidence in laboratory test results
because they are clinically relevant to giving the correct and precise diagnoses and
treatments to patients (Infectious Diseases Society of America, 2017). There is currently
no corroborating evidence regarding the relationship between bacterial infections and
CLD/PTLDS. Some scientists support the notion that two possible central pathways lead
to CLD/PTLDS in patients: (a) the persistent presence of bacteria following traditional
antibiotic treatment for LD or (b) late or delayed treatment of LD and other tickborne
infections. Due to the debate surrounding CLD/PTLDS, most physicians in the United
States, as well as Connecticut are divided as to whether CLD/PTLDS is a new disease
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distinct from other conditions or if it is related to B. burgdorferi, which results in LD
(Johnson & Feder, 2010).
Relationship Between Lyme Disease and Chronic Lyme Disease
LD is a tickborne disease that was discovered in 1977 in Connecticut when a
group of children and several adults suffered from swollen joints (Berndtson, 2013;
Johnson & Feder, 2010; Herrington et al., 1977). B. burgdorferi is a spirochete that
causes LD (Johnson & Feder, 2010; Owen, 2006) and was discovered by William
Burdgdorferi (Berndtson, 2013; Johnson et al., 1984; Tilly, Rosa, & Stewart, 2008). In
1977, LD became the most reported vector-borne disease in the United States (Johnson &
Feder, 2010; Magriet al., 2002; Hickling & Stromdahl, 2012). In 2010, there were more
than 30,158 reported cases of contracted LD in the United States (Overstreet, 2013).
However, LD is more prevalent in the Northeastern region of the United States
(Overstreet, 2013). LD was classified as a reportable disease in Connecticut in 1991,
according to the CDC (Bratton et al., 2008). In 2017, the age groups most affected by LD
in Connecticut were those who were older than 60 and younger than 10 (see Figure 3).
Unlike CLD/PTLDS, LD has a known etiological agent, and its early diagnosis followed
by antibiotic treatment is effective.
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Figure 3. Lyme disease incidence rates by age group, 2017. From “Lyme Disease
Incidence by Ten Year Age Groups, Connecticut, 2017*” by CT DPH, year 2017
(https://portal.ct.gov/-/media/Departments-andagencies/DPH/dph/infectious_diseases/lyme/stats/LD-Incidence-Ten-Year-Age-Group2017.pdf?la=en)
Researchers who argue for the existence of CLD/PTLDS believe that
CLD/PTLDS patients are infected with the same bacterium that causes LD (Auwaerter,
2007). However, as cases of CLD /PTLDS continue to emerge in Connecticut (Johnson et
al., 2014) even after antibiotic treatment, physicians believe that the bacteria remain
active (Branda et al., 2018). This belief suggests that the traditional regimen of two to
four weeks of oral antibiotics (typically doxycycline or amoxicillin) is ineffective in
eliminating the bacteria (Ljostag & Mygland, 2013). Other researchers believe that it is
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possible to contract CLD/PTLDS without a visible tick bite or without having presented
the EM rash—a hallmark indicator of LD.
Biofilm Formation and Borrelia burgdorferi
Biofilms are produced by bacteria responsible for infections such as periodontitis,
chronic otitis, endocarditis, and lung and gastrointestinal infections (Stricker & Johnson,
2011). According to Barthold (2014), B. burgdorferi does not form a biofilm as it grows
in the collagenous connective tissue. However, other researchers have discovered that
CLD/PTLDS is related to the formation of biofilms in humans after an infection with B.
burgdorferi at the “persister stage” (Sapi et al., 2012; Stricker & Johnson, 2011). Sapi et
al. (2016) suggested that B. burgdorferi may initiate a biofilm response due to the
presence of motile spirochetes that transform into cystic, granular, or “cell-walldeficient” forms when it encounters various unfavorable environmental conditions. Sapi
et al. (2012) hypothesized that B. burgdorferi can form a biofilm during in vitro and in
vivo studies. Moreover, Theophilus et al. (2015) indicated the possible presence of
antibiotic-resistant B. burgdorferi persister cells. Theophilus et al. (2015) claimed that
biofilms explain the LD relapse after antibiotic treatments. There is no effective treatment
for biofilms (Stricker & Johnson, 2011).
Disagreement on Treatment for Lyme Disease and Chronic Lyme Disease
There is no universal agreement within the medical community on how to treat
CLD/PTLDS (Maloney, 2016). Numerous questions were raised by Barbour (2015) and
other health professionals concerning the treatment practices for LD and CLD/PTLDS,
including (a) the effectiveness of shorter or longer periods of antibiotic treatment, (b)
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whether one antibiotic is more effective than a combination of two medicines delivered
simultaneously, (c) whether patients without typical symptoms or a confirmed bacterial
agent present should be treated, and (d) whether conventional methods are better to treat
people with LD or CLD/PTLDS than unconventional methods of modern medicine.
Although CLD/PTLDS is assumed to be a bacterial infection-based disease, there is no
conclusive evidence regarding its origin. The ingestion or inhalation of pathogens, as well
as trauma, needle sticks, arthropod bites, or sexual transmission are all bacterial infection
routes. The most common hypothesis for CLD/PTLDS transmission is that it is related to
an arthropod bite, which is typical for in medically important diseases with rare or
unknown cures (e.g., malaria) (Duron & Hurst, 2013).
The most commonly documented treatment practices for patients with
CLD/PTLDS are related to persistent symptoms of the LD bacteria. Some researchers
and health professionals assert that LD and other tick-borne coinfections may be
connected to the etiological agent(s) of CLD/PTLDS (Cameron, 2010; ILADS, 2015).
Most known bacterial diseases are cured with the use of antibiotics; however, it is also
essential to take steps to prevent antibiotic resistance (Foxman & Martin, 2015).
Antibiotics (antibacterial or bactericidal agents) are selective toxicity chemical
substances produced by microorganisms or plants with the ability to kill or inhibit
another type of organism. There are antibiotics that kill the bacteria (i.e., bactericidal) and
those that inhibit bacterial growth but do not kill bacteria (i.e., antibacterial) (Davies &
Davies, 2010). Antibiotics that kill bacteria use the following mechanisms of action: (a)
inhibition of bacterial cell wall synthesis (i.e., cephalosporin, carbapenems,
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monobactams, vancomycin, cyclosserine, and bacitracin), (b) inhibition of protein
synthesis (i.e., aminoglycosides, tetracyclines, chloramphenicol, erythromycin,
clindamycin, and linezolid),(c) inhibition of nucleic acid synthesis (i.e., sulfonamides and
trimethoprim), (d) inhibition of the DNA synthesis of quinolones and flucytosine, and (e)
inhibition of mRNA synthesis (i.e., rifampin) (Davies & Davies , 2010).
Certain antibiotics act as agents that alter cell membrane function (e.g.,
polymyxins) (Brown, & Dawson, 2017), whereas other antibiotics have a mechanism for
altering fungal cell membranes (Ost et al., 2016). The latter include amphotericin B,
nystatin, and azoles (Serhan, Stack, Perrone, & Morton, 2014). In 1928, Alexander
Fleming discovered penicillin, one of the most common antibiotics (Davies & Davies,
2010).
Penicillin is bactericidal but only kills when the infected cells grow; this occurs
through inhibiting the peptidoglycan biosynthesis for the bacteria’s cell walls. Penicillin
has been an effective treatment for Gram-positive bacteria and some spirochetes (e.g.,
syphilis), as well as some Gram-negative bacteria (Zaffiri, Gardner, & Toledo-Pereyra,
2012). Penicillin has also been used to treat patients with LD (Wormser et all., 2000;
Wormser et al., 2006). The traditional treatment for LD at the early stages, however, is
with oral antibiotics, such as doxycycline (100 mg twice per day), cefuroxime (500 mg
three times per day), or amoxicillin (500 mg twice per day) for a period of 21 days in
patients who exhibit EM (Wright et al., 2012; Gasmi et al., 2017). Physicians who treat
those with late-stage LD prefer to use ceftriaxone (2 g intravenously per day) and
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penicillin G (Wright et al., 2012). Some researchers have stated that doxycycline cannot
be used as an effective oral antibiotic to cure late-stage LD (ILADS, 2004).
The preferred antibiotic to treat LD in children and pregnant women is
amoxicillin (Wormser et al., 2006), although intravenous ceftriaxone or penicillin have
been found to be most satisfactory in treating patients in the late stages (ILADS, 2004).
Patients treated with proper antibiotics in the early stages usually recover rapidly and
completely. Antibiotics commonly used in oral treatment include doxycycline,
amoxicillin, cefuroxime axetil, azithromycin, and penicillin (Torbahn et al., 2016).
Patients with certain neurological or cardiac illnesses may require intravenous treatment
with antibiotics, including ceftriaxone or penicillin (Barbour, 2015; Burrascano, 2008;
Cameron, 2009; ILADS, 2014; Wills et al. 2016).
Studies suggest that the presence of the bacteria that causes LD may persist after
treatment (Cameron, 2009; Wills et al., 2016). Gene mutation is a potential explanation
for why the B. burgdorferi strain is resistant to certain antibiotics (Barbour, 2015). For
example, it can change its morphology (i.e., pleomorphic) depending on surrounding
environmental conditions, as does B. burgdorferi sensu lato, which creates complications
for the development of an effective vaccine (Meriläinen et al. 2015). There is controversy
regarding the safety levels and protocol of antibiotic use against tickborne diseases,
including LD and CLD/PTLDS (Barbour, 2015).
Researchers and patients advocate for extended antibiotic use for CLD/PTLDS
patients (Wright et al., 2012). These supporters believe that the prolonged symptoms of
late LD, CLD/PTLDS are related to autoimmune responses triggered by an association
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with B. burgdorferi and reactions with human leukocyte antigen haplotypes (Wright et
al., 2012). Researchers and patients who advocate for extended antibiotic use for people
with CLD/PTLDS also advocate for prolonged antibiotic use in late stage LD patients;
these people are often members of ILADS (2004; 2015). However, the American
Academy of Neurology, the American Academy of Pediatrics, the College of
Rheumatology, and the Infectious Diseases Society of America do not support the use of
prolonged antibiotic treatment (Wright et al., 2012). Questions remain regarding the safe
lengths of time that humans should receive prolonged antibiotics for LD, CLD/ PTLDS
(Cameron, 2006, 2010; Delong et al., 2012; Klempner et al., 2001; Klempner et al., 2013,
Krupp et al., 2003; Stricker, 2007).
The National Institute of Allergy and Infectious Diseases (2019), as part of the
National Institute of Health, sponsored four placebo-controlled clinical studies to
evaluate the effectiveness of prolonged antibiotic treatment following standard
recommended treatment regimens in patients with persistent symptoms related to those
caused by B. burgdorferi (National Institute of Allergy and Infectious Diseases, 2019)
The National Institute of Health (2019) showed that prolonged antibiotic treatment in
these patients was not more beneficial than the short-term therapy given to patients by
most U.S. doctors. According to Klempner et al. (2013), the findings suggest that there is
no justification for the medical community to treat patients with extended periods of
antibiotics administered by intravenous routes (Klempner et al., 2013).

57
Persistence of Borrelia burgdorferi after Antibiotic Treatment
LD is the most common arthropod vector-borne disease in the United States and
is transmitted to humans through the bite of an infected I. scapularis tick (Stricker &
Fesler, 2018, Wright et al., 2012). However, not all I. scapularis ticks carry B.
burgdorferi. The CDC (2017b) issued a press release on the discovery of another type of
bacteria, Borrelia mayonii, which causes LD. I. scapularis acquires the infected
spirochete through blood contact with small mammals, particularly Peromyscus leucopus,
a white-footed mouse (Bratton et al., 2008; Tracy & Baumgarth, 2017; Vuong et al.,
2017). The spirochete grows in the tick’s midgut and is transmitted to humans through
the tick’s salivary glands (Patton et al., 2011; Talwani, & Gilliam, 2012; Tabbasam,
Malik, Asghar, Paracha, & Nazir, 2016; Wright et al., 2012).
Infected individuals commonly have early flu-like symptoms, such as headache,
muscle and joint pains, fever, and malaise (Torbahn et al., 2016); therefore, it is helpful if
they are aware of a previous bite. In other cases, the best tool that physicians and health
professionals have at their disposal to diagnose LD is an early visual sign of the EM rash
(Gasmi et al., 2017; Lantos et al., 2015c; Wright et al., 2012). This EM rash is not visible
or present in all individuals infected with B. burgdorferi (Allen et al., 2016).
Furthermore, EM is not easy for all physicians and health professionals to identify if the
patient has multiple skin rashes (Kemperman, Bakken, & Kravitz, 2008).
The recognition of EM by physicians and other health care professionals is
essential, as there are no certified clinical serology tests that identify the spirochete in
patients’ blood or the antibodies produced when B. burgdorferi is present during the first
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two weeks of infection (Gasmi, 2017; Kemperman et al., 2008). It is possible to perform
additional testing for LD between the third and sixth week after a B. burgdorferi
infection. Testing would include an enzyme-linked immunoassay (ELISA) to show
positive cases and a Western blot to corroborate these cases (Aguero-Rosefield, Wang,
Schwartz & Worsmer, 2005; Dessau, Bangsdborg, Ejlertsen, Skarphedinsson, &,
Schonheyder, 2010; Ogden et al., 2017).
B. burgdorferi persists in patients with continuous LD or PLTDS, which others
may argue is a CLD/PTLDS symptom (Cameron, 2010). There are key aspects to
consider when conducting clinical or epidemiological investigations regarding the
persistence of B. burgdorferi and its relationship to late LD and CLD/PTLDS. It is
necessary to assess the following: (a) the history of tick exposure, (b) the history of living
in or having traveled to an endemic area for ticks, and (c) the history of the presence of
the EM rash (Fallon et al., 2008).
There are concerns regarding the persistent presence of B. burgdorferi after early
and late-stage treatment (Berndtson, 2013; Cameron, 2010; ILADS, 2014; Middelveen et
al., 2018). Scientists have found that B. burgdorferi can evade the immune system in
mammals making its eradication difficult in later stages (Barbour, 2012; Norris, 2014).
Some patients have alluded to this reason for why they became sick; this assertion is also
consistent with the opinion of CLD/PTLDS (Allen et al., 2016; Berndtson, 2013). B.
burgdorferi possesses unique properties related to its virulence genes and outer bacterial
membrane protein, making its eradication more difficult than other known spirochete
infections (Tilly et al., 2008).
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Several studies on laboratory animals (e.g., mice, dogs, and monkeys) document
the persistence of B. burgdorferi after antibiotic treatment (National Institute of Health,
2015). Some of these studies on laboratory animals found the presence of its DNA after
antibiotic treatment. However, this presence of its DNA cannot indicate a genetic product
of an active bacterial infection (Feder et al., 2007; Tabbasam et al., 2016).
Embers et al. (2012) used toxicological techniques of xenodiagnoses and indirect
fluorescent antibody staining to test the hypothesis that the spirochete in animal tissue
persists after antibiotic treatment. Embers et al. (2012) performed two experiments using
xenodiagnoses. The results of those two xenodiagnoses studies show the presence of
debris or DNA material from B. burgdorferi. Although this DNA material was found, and
pieces of the spirochete were hidden in the tissue, it is not entirely certain whether the
same DNA material was viable, attenuated, or dormant (Lyer et al., 2013). Additionally,
B. burgdorferi was found to integrate unique properties into its bacterial loci to create
genetic changes that interfere with antibiotic treatment effectiveness (Lyer et al., 2013).
Molecular biology studies can be used to help researchers understand certain
behavioral aspects of B. burgdorferi when an antibiotics regimen is used to eradicate the
infection. These molecular biology studies shine a light on LD patients under treatment,
the effectiveness of late treatment, and the possible relationship between CLD/ PTLDS.
In conclusion, a significant debate continues on the existence of B. burgdorferi and its
ability to cause chronic symptoms in untreated or undertreated patients, whether at the
early or late stages of LD (Stricker & Johnson, 2013).
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Clinical Testing to Diagnose Infections of Lyme Disease and Its Relationship to
Testing for Chronic Lyme Disease
Although CLD/PTLDS has no known etiological agent, testing may be
challenging and may not be specific, nor is there a diagnostic for it (CDC, 2019). Many
PCPs may diagnose and treat a late LD infection (ILADS, 2014, Lantos, 2015a). LD has
signs and symptoms that are less specific than other bacterial infections; thus, it is
inevitably difficult to diagnose. Laboratory testing is recommended only for patients who
notice the typical symptoms of LD (Gasmi et al., 2017). To understand the complexity
and irregularity of testing for LD, it is essential to discuss its etiological agent, B.
burgdorferi (Burrascano, 2008; Hyde, 2017; Wormser et al., 2006).
B. burgdorferi is a motile (Sultan et al., 2013, 2015) spirochete with the following
attributes: irregular, loosely coiled, helical, weakly Gram-negative, size range from 0.20
to 0.30 µm in diameter, and 10 to 40 µm in length (Aberer & Duray, 1991; Marquez,
2015; Meriläinen et al. 2015). This spirochete has complex nutritional demands and is
very challenging to cultivate in vitro using Barbour-Stoener Kelly (BSK) medium
(Aberer & Duray, 1991; Marques, 2008; Sultan et al., 2015). Isolation of B. burgdorferi
from the EM rash is possible, but there is less opportunity for isolation in late-stage LD
infections (Moore et al., 2016).
Not all people exposed to the spirochete will develop an infection or present with
the typical EM rash (Gasmi et al., 2017). Therefore, people may be unaware of a B.
burgdorferi infection in the early stages. The longer an infection with LD continues, the
more difficult it is to find the most suitable clinical and serology tests to facilitate its
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diagnosis. Consequently, there is a need to have well-trained medical and laboratory staff
in areas where LD persists until new medical advances can corroborate the etiological
agents for CLD/PTLDS.
The microscopic examination of blood or tissues from patients with LD is not
recommended because B. burgdorferi is rarely found in clinical specimens (Wormser et
al., 2006). Culturing is not a common practice for clinical samples obtained from patients
because B. burgdorferi is difficult to isolate and observe under a microscope and because
it has a low growth process (Marques, 2008; Sultan et al., 2015). B. burgdorferi is also
difficult to grow in vitro (Marques, 2018), as it requires special media or nutrients.
Molecular diagnostic techniques for the diagnosis of LD, such as the use of nucleic acid
amplification techniques for DNA or RNA, have lower sensitivity than the culture
techniques for special properties, such as the motility of B. burgdorferi (Eshoo et al.,
2012; Marques, 2015; Sultan et al., 2015). Unlike other bacterial infections where
pathogen detection is performed directly or indirectly from a culture, LD diagnosis is not
determined using the direct presence of the bacteria (Marquez, 2015).
LD has three distinct stages of pathogenic development on a patient after a
positive tick bite (Applegren & Kraus, 2017). The first stage or early stage is described
mainly as the recognition of symptoms as fever, headache, fatigue, pain in the joins and
the present of the EM (Nadelman et al, 2012). The second stage is described as when B.
burgdorferi spreads throughout the whole body of the sick person. At this second stage,
patients may exhibit symptoms like arthritis, meningitis, myocarditis, from weeks to
months from the initial infection (Applegren & Kraus, 2017). In the third stage of LD,
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patients have chronic symptoms as chronic arthritis, neurologic defects, or skin lesions
(Applegren & Kraus, 2017).
In the early stage of LD infection, the bacteria hide (move) into the inner cells
(inside the cell membrane) of the human host (Eshoo et al., 2012; Porcella & Schwan,
2001). This movement causes the bacteria not to be free in the bloodstream as many other
infections (i.e., syphilis). Thus, a direct blood test to identify the infection by morphology
of B. burgdorferi is not applicable at early stages and late stages of LD where the bacteria
has moved to the organs of the central nervous systems (Applegren & Kraus, 2017). The
early stage of LD diagnosis is based on the presence of antibodies found in the serum of
samples from patients during the early stages of infection (Borchers et al., 2015;
Burrascano, 2008).
However, if the serology testing of antibodies is conducted early when the EM
rash is present or immediately after the tick bite, the results may have very low sensitivity
and may occasionally be reported as negative (see Figure 4). Lantos et al. (2015c) also
discussed the validity of serology testing in low-prevalence regions where the prevalence
of ticks and LD is low and in which health professional may have a greater difficulty in
making an accurate LD diagnosis.
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Figure 4. Sensitivity/specificity of commercial two-tier testing for convalescent/late state
Lyme disease in the United States. Adapted from “Two-Tiered Lab Tests Miss More
Than 50% Of The Cases Of Lyme Disease,” by L. Johnson, n.d.
(https://www.lymedisease.org/lyme-basics/resources/two-tiered-lab-tests-miss-50percent-of-lyme/)
Due to these difficulties, Connecticut physicians cannot diagnose early LD based
on laboratory testing of patient blood samples. Clinical testing used in most of the United
States and Connecticut is based on the presence of the EM rash and immunological and
DNA applications. Some of these clinical tests are based on elevated sedimentation,
elevated IgM levels, and mildly elevated hepatic transaminase (SGPT/ALT) levels.
Common immunological assays used after two weeks of LD infection include
indirect fluorescent antibody staining, staining methods, and the enzyme-linked
immunosorbent assay (ELISA), as well as western blot for corroboration (Aguero-

64
Rosenfeld et al., 2005; Liu et al., 2016). The most common tests used to diagnose LD are
the indirect immunofluorescence assay and enzyme-linked immunosorbent assay (Liu et
al., 2016). ELISA is the most sensitive test for most stages of LD because it uses purified
or recombinant antigens. Serology testing is weak and unreliable for testing the early
stages due to problems with sensitivity, cross-reaction activity from bacteria other than
those being screened, and the need to create a single method to detect infection (Liu et
al., 2016).
The ELISA test kit, also called the C6 peptide test (Chan et al., 2013; Wright et
al., 2012), has been used since 2000, but the sensitivity is higher (60%) in patients and
may still yield false positives. This ELISA test kit has better sensitivity than the two-tier
ELISA test, although it was not tested in children (Chan et al., 2013; Lipsett et al., 2015).
Lloyd and Hawkins (2018) reported that the C6 peptide test had a different sensitivity of
66.7% to 75%. Lloyd and Hawkins (2018) suggested that the reason for the variation may
be due to the ribosomal spacer type (RST) genotype.
The ELISA test has been used as a screening assay, as it has a specificity rating of
90%-100% (Ljøstad & Mygland, 2013). The infection must be older than two weeks to
measure the level of antibodies raised against the pathogens. Health care practitioners
recommend that people test for IgM antibodies after the second week of exposure, as they
may last up to four weeks post infection (Gasmi et al., 2017). Western blot is used to
confirm a positive ELISA reaction (CDC, 1995, 2005; Ogden et al., 2017).
Antigenic heterogeneity B. burgdorferi and other species affect the test’s
sensitivity (Bonin, 2016; Branda, Linskey, Kim, & Steere, 2011). The variability of
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ELISA and Western blot kits to test for LD depends on the infection’s stage and the
species of Borrelia. Various types of ELISA have been validated and approved by the
FDA and accepted by the CDC (CDC, 1995; CDC, 2005).
This form of antibody testing uses blood serum samples from people presumed to
have LD; however, it is not as sensitive as other serum commercial kits that are currently
used for other diseases (e.g., syphilis). A commercial kit with two-tier testing often
includes two steps: an EIA or immunofluorescent assay indirect fluorescent antibody
staining that is followed by supplemental IgM and IgG immunoblots or western blot that
use antibodies for LD. These antibodies depend on the manufacturer and location due to
the geographic variability of the Borrelia species (Bonin, 2016; Branda et al., 2011;
Gasmi et al., 2017; Wormser et al., 2013). However, in the United States, two-tier testing
for LD according to the CDC’s established criteria has a sensitivity close to or higher
than 68% with a specificity of 99.5% (Wormser et al., 2013).
Branda et al. (2011) examined an alternative two-tiered strategy. The purpose of
Branda et al.’s (2011) study was to investigate the sensitivity of the three testing
strategies. Branda et al. (2011) randomly selected 1,246 healthy people and 54 patients in
a hospital. Specificity was measured, and the study found that the positive predictive
value was 70%.
However, internal validity should have been examined. The mortality threat may
occur when uncommitted participants withdraw from a study (Branda et al., 2011). A
total of 1,246 healthy individuals and 54 patients were randomly selected in the hospital;
consequently, the results and findings cannot be generalized to other hospitals.
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Nonetheless, this study was reported two decades after the testing for LD was initiated;
the two-tiered testing with immunoblotting remains the standard for evaluation in testing
patients for LD.
A clinician cannot accept ELISA and Western Block molecular test outcomes in
two-tier testing for LD alone because they may yield false positive results (Marquez,
2015). These false positive results may be due to pre-existing conditions, such as EpsteinBarr virus or Helicobacter pylori. A false positive result is an issue because patients who
do not have LD may show a positive test.
People who are aware of tick bites may be tested again for an increase in the B.
burgdorferi antibodies after the first two weeks since ELISA and western blot tests may
cause false negatives (Marquez, 2018). The proper time for testing with a two-tier kit for
LD is between two and four weeks after the bite; this is when the antibodies for Borrelia
species will develop and produce higher IgM than IgG. The low sensitivity of most twotier testing systems commercially used in the United States for testing LD remains an
issue because uninfected individuals may yield a positive test result. Additionally, others
with early B. burgdorferi symptoms can be missed.
Testing should never be performed in the absence of appropriate history and
clinical LD symptoms (Erthel, Nelson, & Carter, 2012). However, most laboratory
clinicians prefer to use molecular biology tests with blood samples for bacteria diagnosis.
Problems remain for testing serum samples from patients. Tests using serum samples
from patients may yield a false positive due to issues with the specificity and sensitivity
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of these tests, which can have cross-reacting antibodies against spirochetes in the normal
flora (Ljøstad & Mygland, 2013).
Additionally, a polymerase chain reaction test is available to detect the tickborne
bacteria (Greenwich Press, 2017; Hickling & Stromdahl, 2012). A polymerase chain
reaction positive test performed on ticks is not a direct indication of LD infection.
Instead, tick polymerase chain reaction testing for B. burgdorferi (Maurin, 2012) can
provide valuable information about the probability of contracting an illness, especially if
the tick was fully engorged and attached to a human host for over 48 hours (Marquez,
2015; Gasmi et al., 2017).
Although the CDC does not support the testing of ticks (CDC, 2017b), the
Connecticut Agricultural Station (2019) and the Greenwich Health Department in
Connecticut (2015) provide this service to the public. It may be beneficial to investigate
whether the number and results of tick tests in Connecticut correspond with the highest
incidence of LD. Borrelia DNA can be detected by a polymerase chain reaction test of
synovial fluid and cerebrospinal fluid (e.g., CSF, synovial fluid, and blood) with varying
levels of success (Bratton et al., 2008; Ljøstad & Mygland, 2013; Wright et al., 2012). It
is important to note that B. burgdorferi is challenging to consistently cultivate from the
synovial fluid (Marquez, 2015).
Polymerase chain reaction tests help identify bacteria species that are causing an
infection (Maurin, 2012; Scott et al., 2017). The incubation period is 3 to 30 days after an
infectious tick bite (CDC, 2017b; Kemperman, Bakken, & Kravitz, 2008). There is no
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evidence for the person-to-person transmission of LD. There are some claims of
maternal-to-child transmission, although there is little evidence (CDC, 2017b).
It is challenging to use microscopy, serology, or molecular testing to yield an
accurate CLD/PTLDS diagnosis due to the lack of consensus between medical
communities, as well as a lack of scientific evidence regarding its etiological agent(s).
Scientists believe that CLD/PTLDS develops due to various factors related to the
antibiotic treatment of B. burgdorferi in patients who were either undertreated, untreated,
or treated late (Cameron, 2006; Wright et al., 2012). It is inappropriate and complicated
to apply the same criteria used by most certified clinical labs to test for late-stage LD
with a combination of ELISA and western blot tests (Ogden et al., 2017). Laboratory
testing for B. burgdorferi is not standardized at the national level (Auwaerter, 2007).
There is no known distinct testing method for CLD/PTLDS apart from the limited
relationship to the approved serological testing for traditional cases of LD (Sigal, 2003;
Strasheim, 2014).
Most patients with CLD/PTLDS have been accurately diagnosed based on the
continuous symptoms that they have presented to a Lyme-literate medical doctor (Baker,
2012). The ILADS favors the use of long-term antibiotics and refers to many patients
with CLD/PTLDS to Lyme-literate medical doctors, which is opposed by the Infectious
Diseases Society of America. Infectious Diseases Society of America-affiliated
physicians believe that long-term antibiotics are not a beneficial treatment for those who
have late LD or CLD/PTLDS (Infectious Diseases Society of America, 2006, 2012, 2017;
Marquez, 2008). Patients suffering from late cases of LD and CLD/PTLDS continue to
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be symptomatic and seek a correct diagnosis and appropriate treatment for their condition
at considerable personal and financial cost.
Problems for Physicians Reporting Chronic Lyme Disease
Unanswered questions remain regarding the existence of CLD/PTLDS. Therefore,
the medical community is divided on the best approach for a diagnosis when presented
with CLD/PTLDS symptoms. The root of the controversy lies in the fact that CLD lacks
reliable biological markers and diagnostic tests to identify its origin.
Most patients visit a health professional for two reasons: to follow up with health
plan appointments (e.g., annual checkups, surgeries, births) or to address immediate
sickness. In both circumstances, patients may leave a health professional’s office with a
known diagnosis and an appropriate treatment to follow. In Connecticut, patients who
believe that they have CLD/PTLDS do not encounter a fair process when visiting health
care professionals and complain that they were denied or received limited or improper
health care.
Physicians face difficulties in diagnosing CLD/PTLDS due to the lack of a
clinical definition, symptom continuity, and systematic evidence that B. burgdorferi is
associated with the etiology of CLD/PTLDS. Lantos (2011) found no proof that the
bacteria that causes LD were present in certain patients who claimed to have
CLD/PTLDS. These patients who claimed to have CLD/PTLDS had pre-existing
conditions, such as rheumatoid arthritis, degenerative diseases of the spine, multiple
sclerosis, or amyotrophic lateral sclerosis. Lantos’s (2011) study also noted late-stage
symptoms of LD, including severe pain in the joints and knees (e.g., in patients with
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arthritis), chronic neurological complaints, short-term memory loss, cognitive issues,
shooting pain, or numbness and tingling in the hands and feet. Lantos (2011) randomly
selected patients who may have had CLD/PTLDS in the United States and successfully
tested the research question; however, validity was mentioned in the study.
According to the Infectious Diseases Society of America (2017), patients who
suffer from CLD/PTLDS have symptoms similar to the degenerative effects of untreated
long-term LD. Therefore, there is confusion among Connecticut physicians as well as
patients who believe that their illness is related to CLD/PTLDS or other diseases
associated with LD. Many patients complain that their doctors refuse to diagnose and
treat CLD/PTLDS and thereby withhold care. Patients’ firsthand feelings are a result of
their doctors’ lack of knowledge about CLD/PTLDS and coinfections from I. scapularis
bites (Cameron, 2010). If this is the case for health professionals who treat CLD/PTLDS
patients, addressing physician education and training to ensure medical practice
consistent with preventive care guidelines may be essential to aid in accurate diagnoses
and to keep patients healthy (Gasmi et al., 2017; Strumpf, 2011).
Diagnosis, Treatment, and Management of Lyme Disease, Chronic Lyme Disease
There have been limited studies demonstrating the frequency of health
practitioner diagnosis, treatment, and management of tick-borne disease, and, specifically
for this study’s purpose, about LD and CLD/PTLDS. PCPs may have difficulty in
treating LD patients despite confirmation of the etiological agent and established
antibiotic treatment regimens. Many areas remain open to exploration on how to control
an LD infection that went untreated. CLD/PTLDS has many gaps and unanswered
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questions, and there is a lack of information regarding the frequency of PCP diagnoses
that use reliable and distinct laboratory testing.
Johnson and Feder (2010) found that fewer than 3% of physicians diagnosed
patients with CLD/PTLDS in Connecticut. Johnson and Feder (2010) also discovered that
49% of physicians did not treat their patients for CLD/PTLDS because they did not
believe it existed. Johnson and Feder (2010) performed descriptive statistics (but did not
conduct MANOVA or t-tests). MANOVA is the most appropriate tool to measure
differences between physicians because it assesses the effects of dependent variables
simultaneously. T-tests can be valuable when using continuous data if the studied
population is normally distributed (Parab & Bhalerao, 2010). If it not normally
distributed, the data analysis should be complemented with non-parametric tests.
Ferrouillet et al. (2015) conducted a 2012 descriptive cross-sectional study to
determine the knowledge and practices (in regards to the diagnosis and management of
cases of LD using serology testing) of family physicians in two settings: (a) in one region
with known infected ticks (Montérégie) and (b) in regions without infected ticks (Estrie
and Lanaudière) in Southern Quebec, Canada. Ferrouillet et al. (2015) invited family
participants to take part in the study by in-person invitations. A self-survey with 19
questions on two pages was given to those who accepted the invitation to participate. The
survey questions were divided into three sections: (a) their experience with LD in the
previous year, (b) questions regarding their knowledge, and (c) questions regarding their
need for information.

72
A descriptive analysis on the two regions compared them using Fisher’s exact test
with SAS version 9.4. The participation rate in this study was 59% of the 201
participants. Ferrouillet et al. (2015) concluded that 201 participants were appropriate for
representing the population of family physicians since the response rate of the survey was
significant as a high response (n= 151 out of 201) among the primary care family
physicians of Montérégie (p. 1). Some of the results were as follows: 56% never
considered the diagnosis of LD, and 80% never prescribed antibiotics for LD patients.
These results showed the based for internal validity. Ferrouillet et al. (2015) by
conducting this study stated the importance that PCPs’ knowledge and practices needed
optimize the management of individual patients with LD.
Moreover, Ferrouillet et al.’s (2015) study’s results were similar to Johnson and
Feder’s (2010) results. Johnson and Feder’s (2010) study had identical conclusions
regarding the differences in the KAPs of physicians related to LD and CLD/PTLDS.
Johnson and Feder (2010) tested the assumption that there were significant differences in
the KAP of physicians regarding the diagnosis, treatment, and management of LD. The
hypothesis stated that there would be significant differences between PCPs concerning
the diagnosis, treatment, and management of LD.
To test the hypothesis, Johnson and Feder (2010) performed descriptive statistics.
Johnson and Feder (2010) randomly selected 3091 physicians and asked them to
complete a mail survey. However, Johnson and Feder’s (2010) study did not publish how
the survey was developed, and its validity published.
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Both Johnson and Feder’s (2010) study and Ferrouillet et al.’s (2015) study focus
on the differences in the KAPs of physicians regarding the diagnosis, treatment, and
management of LD and CLD/PTLDS. The former discovered that there were significant
differences. The latter also found that there were significant differences in the way
physicians diagnosed and prescribed antibiotic treatment to potential LD patients. As
evident in the study by Magri et al. (2002), most physicians preferred to recommend the
LD vaccine to patients when the vaccine was still in use; it is essential to note that the
vaccine is no longer prescribed to patients in the United States.
Magri et al.’s (2002) conclusion differs from Johnson and Feder’s (2010) study
and Ferrouillet et al.’s (2015) study. Magri et al. (2002) tested if there were significant
differences in the KAPs of physicians concerning the diagnosis, treatment, and
management of LD by performing Chi-square tests. Magri et al. (2002) randomly
selected 600 physicians in New Hampshire and asked them to complete a survey.
However, internal validity should have been examined. Selection bias can occur
when there are differences between physicians who return their questionnaires and
physicians who do not answer their surveys. The mortality threat may occur when
uncommitted physicians withdraw, such as in this study.
Diagnosis, Treatment, and Management of Post-Treatment Lyme Disease Syndrome
As stated in Chapter 1 and in this chapter, the term PTLDS (instead of CLD) it is
more favorable used by the medical community (not the sick patients) (Delong, Hsus, and
Kotsoris, 2019). Rebman et al. (2017) stated that 10 to 20% of patients after receiving
treatment for LD experience multiple symptoms that sometimes the health professionals
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find symptoms that vary from one patient to another) as prolonged fatigue, neurological
dysfunction pains, that persist after being treated for LD (Delong et al., 2019a). There is
no definite data collection or reporting it to the CDC as it is done for other infectious or
chronic diseases. Nonetheless, Delong et al. (2019a) estimated an increase in the number
of patients diagnosed with PTLDS from 2016 to 2020, with 68, 603 cases of PTLDS
expected in 2020 (Delong et al., 2019a).
Thus, as well as CLD, there is not much information about how to conduct a
standardized diagnosis and treatment to cure such patients with PTLDS (Delong et al.,
2019). Rebman et al. (2017) stated the importance of investigating the clinical symptoms
in patients living with PTLDS since it affects their quality of life. PTLDS bring financial
burden to those patients with it; the problem is such a financial burden has never been
investigated in the United States (Delong et al., 2019). But if PTLDS it turns out one day
to be related to LD and CLD, it can cause more than a billion of dollars as it now the cost
for health for patients known with LD (Delong et al., 2019). Therefore, in this study,
although is investigating the validity of the finding founds by Johnson and Feder (2010)
in regards to the diagnosis of CLD in Connecticut, it enhances insights about what would
be the best implications or suggestions to recommends to PCPs in Connecticut to deal
with cases of PTLDS (CLD). One clear objective recommendation is to have PCPs to
accepts the term PTLDS to be able to create pathways to collect, document, and report
possible cases of people sick with PTLDS (or CLD) that will eventually enable
epidemiologists to how it is transmitted, what are the risk factors, and best treatment
practices unknown presently. Further studies would be needed to find standardized
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evidence based medical in regards to PTLDS to be substitute among professionals for
CLD. Therefore, the term CLD/PTLDS was used concisely trough out the paper to
recognized that is better for the future to recognized CLD/PTLDS as just “PTLDS”. More
on this topic is presented in chapter 5.
Summary and Conclusion
Johnson and Feder (2010) found that there were significant differences in the
KAPs of PCPs regarding the diagnosis, treatment, and management of LD and
CLD/PTLDS. Ferrouillet et al. (2015) also found that there were significant differences in
the knowledge and practices of physicians concerning how physicians diagnosed and
gave antibiotic treatment to potential LD patients. However, Magri et al. (2002)
determined that most physicians preferred to recommend the LD vaccine to patients. It is
necessary to examine the gap to yield new opportunities for future research if the topic of
research has not been addressed appropriately by other researchers.
The study can help CT PCPs recognize PTLDS as a more appropriate diagnosis
for those patients presumed has CLD. CT PCPs have difficulty dealing with the diagnosis
and treatment of CLD/PTLDS patients. Thus, PTLDS can serve as a diagnosis for
patients with CLD/PTLDS until more is known about it. Chapter 3 provides an overview
of the research methods designed for the quantitative study and includes a discussion on
the method of the study and the appropriateness of the design and data collection.
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Chapter 3: Research Method
Introduction
Medical disagreements regarding CLD/PTLDS are caused by the unavailability of
an acceptable standardized protocol to diagnose and treat it (Lantos, 2015a). Numerous
medical doctors do not consider CLD/PTLDS an illness, which may be due to physician
unawareness of evidence-based medical knowledge that corroborates the causal agent or
the lack of surveillance systems that suggest that it is a new disease (Baker, 2008;
Cameron, 2010; Feder et al., 2007; Johnson & Feder, 2010; Katz, 2007; Lantos, 2011,
2015a; McClellan, 2012; Wormser & Shapiro, 2009). Consequently, the cause, origin,
and diagnostic criteria of CLD/PTLDS are unclear because most medical practitioners do
not have data to guide treatment for affected patients (Lantos, 2011, 2015a).
The purpose of this quantitative nonexperimental, cross-sectional, comparative
research was to validate Johnson and Feder’s (2010) study and determine whether there
were significant differences between two Connecticut PCPs regarding their knowledge,
diagnosis, and treatment of LD and CLD (PTLDS). Statistical comparisons were made
between survey responses provided by Connecticut PCPs in Johnson and Feder’s study
and the current study. I used the Connecticut knowledge, attitude, and practice (CT-KAP)
survey, which was used by Johnson and Feder and was in the public domain for exact
data comparisons.
This study’s data may help physicians evaluate the current guidelines and
methods for the diagnosis and treatment of CLD (PTLDS) patients. Within the limitation
of having no approved case definition for CLD (PTLDS), in the survey mailed out, it was
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defined “as the persistence (more than six months) of Borrelia burgdorferi infection,
despite multiple standard courses of antibiotics).” Medical doctors are trained to conduct
diagnosis using ICD codes, but in this study, an ICD code was not provided because it is
not approved for CLD (PTLDS). This limitation accounts for the low response in this
study, because some PCPs may not have felt comfortable to answer the KAP
questionnaire or survey without knowing an ICD code with a definition associated for
CLD/PTLDS, though I did provide a brief definition.
This chapter presents the study’s methodology. The chapter begins with a
summary of the research design and provides a rationale for its selection. The chapter
continues with a discussion of the methodology with emphasis on the study population,
sample, sampling procedures, participant recruitment and data collection procedures, the
operationalization of study variables, the instrument and questions used to measure them,
and the data analysis plan. Threats to validity of the study are then discussed, as are the
ethical procedures of the study. A summary concludes the chapter.
Research Design and Rationale
I used a nonexperimental, cross-sectional, comparative (i.e., ex post facto)
research design to examine whether there were significant differences regarding
CLD/PTLDS KAPs between the sample of Connecticut PCPs who participated in
Johnson and Feder’s (2010) research and those who participated in this study. The study
included five research questions. The independent variable for all research questions was
the PCP group in this study compared to those who participated in Johnson and Feder’s
research. I used this the first research question acted as a validity check to examine
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whether the two physician groups (the independent variable) had significant frequency
distribution differences concerning the dependent variable of PCP types (i.e., family
medicine, internal medicine, pediatric, other). The second research question helped
examine whether the two PCP groups (the independent variable) had significant
frequency distribution differences across three knowledge of LD categories (the
dependent variable). The third research question helped examine whether the two
physician groups (the independent variable) had significantly different frequency
distributions across the knowledge of the four CLD (PTLDS) categories (the dependent
variable). The fourth research question helped examine whether the two physician groups
(the independent variable) significantly differed concerning the average number of
patients they diagnosed as having CLD (PTLDS) within 3 years (the dependent variable).
The fifth and final research question helped examine whether the two Connecticut PCPs
(the independent variable) significantly differed concerning the average course of
antibiotic treatment (in weeks) among the patients they diagnosed as having CLD/PTLDS
within 3 years.
The quantitative approach in this study was guided by the positivist paradigm,
which states that a single, objective, and measurable reality exists (Bowling, 2014; de
Villiers, & Fouché, 2015). Quantitative research involves the scientific method where
researchers develop questions and hypotheses that pertain to the tested theory or theories,
use valid and reliable measures to obtain numerical data, and perform statistical analyses
of numerical data; researchers then use the results to determine whether to reject or
accept the null hypotheses (Bowling, 2014; de Villiers & Fouché, 2015). I chose the
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quantitative research method over the qualitative method because it involves the
scientific method to answer research questions. Hypotheses for each research question
were formulated, and numerically-based data from surveys that were given to study
participants (i.e., Connecticut PCPs) were collected. Statistical analyses from the data
gathered in this study were conducted. Direct adjustment was conducted with population
proportion 2015 to allow the PCP categories subgroups rates to have the same general
trend as the population-proportion of 2006 PCP categories (Pagano-Gauvreau, 2000)
before the data analysis was conducted.
Quantitative studies are delineated into three types: experimental, quasiexperimental, and nonexperimental (Bowling, 2014; Patten & Newhart, 2017). The
quantitative experimental research design is used in studies where the researcher
randomly selects participants from the population and randomly assigns them into study
conditions such as an intervention group that receives some treatment and a control group
that does not. The quantitative experimental research design is most appropriate for
examining whether one or more dependent variables differ across intervention and
control groups of participants. Nonexperimental research designs pertain to studies where
neither random selection of participants is conducted nor when random assignment to
conditions is relevant or applicable.
Further, nonexperimental research designs are commonly delineated into three
types: (a) descriptive, in which the researcher presents and describes a phenomenon using
descriptive statistics (as opposed to inferential); (b) correlational, in which the researcher
wants to determine whether one or more independent variables (i.e., predictor variables)
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are significantly associated with or related to one or more dependent variables (i.e.,
criterion variables) and utilizes inferential statistics such as correlational or regression
models to determine the significance of these relationships; and (c) comparative, or ex
post facto, in which the researcher wants to determine whether one or more naturally
occurring groups (i.e., the independent variables) significantly differ in one or more
dependent variables, which are also naturally occurring, and utilizes inferential statistics
such as Chi-squares, t tests to determine if significant differences exist (Patten &
Newhart, 2017; Reio & Reio, 2016). Naturally occurring refers to groups that cannot be
manipulated. I did not choose a descriptive nonexperimental design because it does not
involve inferential statistics (Reio & Reio, 2016). A correlational design was also not
applicable because I did not determine temporal sequences or causal relationships
between independent and dependent variables.
A comparative quantitative research design was suitable for this study to assess
the validity of Johnson and Feder’s (2010) study. I examined whether two naturally
occurring groups of Connecticut PCPs (i.e., the independent variable) significantly
differed among four dependent variables: (a) the type of PCP they identify as, (b)
knowledge regarding LD and CLD(PTLDS), (c) the number of patients identified as
having LD and CLD (PTLDS) per PCPs, and (d) the average course of antibiotic
treatment (in weeks). These dependent variables are also naturally occurring. This study
differs from other comparative studies in that the data were gathered at the same time
from the groups of the study’s focus. I compared the data collected from a new sample of
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Connecticut PCPs to the archival proportion, frequency, and mean level data reported in
Johnson and Feder’s study conducted with Connecticut PCPs.
Finally, this study was designed to collect data from a single point in time and is
therefore considered a cross-sectional study. Although data obtained in this study were
compared to responses provided by Connecticut PCPs in Johnson and Feder’s (2010)
study, this study is not longitudinal. These two naturally occurring groups of Connecticut
PCPs were not comprised of the same physicians, and they were not followed over the
past 10 years, as would be done in a longitudinal study. Therefore, it was necessary to
assess whether each study group (2006 and 2015) was representative of the Connecticut
PCP population at the time of each survey so the appropriateness of generalization of the
results (external validity) could be assessed.
Methodology
A quantitative, cross-sectional, comparative study was implemented similar to
Johnson and Feder’s (2010) study. The population of 2015 Connecticut PCPs was
randomized using the same computer software (Excel) that Johnson and Feder used to
obtain the 33% of PCP in the categories needed for the study to obtain the study sample.
Participant recruitment and data collection procedures were also aligned. The study
instrument was the CT-KAP 2006 questionnaire, and study variables were
operationalized by survey item response coding. Further information is provided in the
data analysis plan in this chapter.
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Population
The population for this epidemiological investigation included 5,231 PCPs
licensed to practice in the state of Connecticut as of 2015, based on information from the
CT DPH (2015), which contained data on Connecticut physicians CT DPH MD/DO
including physician work addresses for the 17,464 certified physicians who actively
practiced medicine. Of these 17,464 physicians, 5,231 were classified as PCPs in the
categories of primary health care practice specialties of pediatrics, primary/general/family
medicine, and internal medicine as the main sampling frame needed to conduct the study
(CT DPH, 2015). See Appendix F for the description of the sampling frame and PCPs for
2006 (Johnson & Feder, 2010) and 2015 (the current study).
The final population accountable for the data analysis in this study were 145 PCP
survey responses (2015) and 285 PCP survey responses (2006). The total number of
PCPs of 2006 was 15,424. Of these 15,424 physicians (MD/DO), 3,091 were classified as
PCPs in the categories of primary health care practice specialties of pediatrics,
primary/general/family medicine, and internal medicine as the main sampling frame
needed to conduct the study (Benson & Eberle, 2009; CT DPH, 2006). The population
proportion of 2006 was derived from the historical data in Johnson and Feder’s (2010)
study. Adjustment to the population proportion of 145 was conducted to make the data
analysis appropriate, and the adjustment factor was 1.97 (285/145, 1.9655 = 1.97, 1.97 X
145 = 285). To be more specific, the 2006 population proportion derived from Johnson
and Feder’s study consisted of 57 family physicians, 113 internal medicine physicians,
107 pediatricians, and eight others (i.e., emergency physicians). In contrast, the 2015

83
population proportion in this study comprised 28 family physicians, 63 internal medicine
physicians, 48 primary physicians, and six others (i.e., emergency physicians) before
adjustments. After adjustments were made to bring the 145 PCP responses to be
standardized for appropriate comparisons, the population proportion consisted of 55
family physicians, 124 internal medicine physicians, 48 pediatricians, and 12 others (i.e.,
emergency physicians). See Table 6 for more details.
Sample and Sampling Procedures
The recruitment of a sample of Connecticut PCPs were intended to form a similar
sample size and type as that of Johnson and Feder’s (2010) study. This study had the
same inclusion/exclusion criteria for study participants as Johnson and Feder. Thus,
adaption to the inclusion and exclusion criteria from those pages were applied (see Tables
4 and 5). The 2006 PCP population made up of 285 survey responses in the categories of
family medicine practitioner, internist, pediatrician, or other PCPs (i.e., emergency
physicians) after accounting for inclusion criteria. In this study, there were 145 PCP
survey responses (population proportion) in 2015 for the data analysis (in the following
categories: family medicine practitioner, internist, pediatrician, or other primary care
practitioners). Physicians with specialization in areas unrelated to the primary care
categories of pediatrics, family medicine, or internal medicine as explicitly described in
the CT DPH database were excluded from this study. In alignment with the previous
study, in this study, the sample frame was limited to physicians who are certified and
actively practice primary care in Connecticut.
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Johnson and Feder (2010) did not describe how they conducted the validation of
the 2006 CT-KAP survey, but I assumed that it was validated because they were medical
doctors. This lack of validity criteria is a basis to conduct a validity check to see if the
PCPs in Johnson and Feder’s study and in this study have changed after 10 years and to
find the internal and external validity of the data for this study. Although the internal and
external validity were not documented or not published, their survey will have a higher
degree of internal validity because their response rate was 39.1 %, and the survey
response rate with the 2015 population proportions in this study was 11.9%. In this study,
the validation of data is presented in Chapter 4.
The overall sample size had similar population proportion based on the z score
test. However, I still adjusted the 145 sample of PCP survey responses to the 285 sample
of PCP survey responses before the data analysis because “equivalence testing performs
best when sample sizes are equal” (Rusticus & Lovato, 2014, p. 1). A G*Power (Faul,
Erdfelder, Lang, & Buchner, 2007) power analysis for a one-sample t test was used to
determine the sample size needed to achieve adequate power for this study. The
significance (alpha) level was set to p < 0.05, and power was set to 0.80. Because
previous literature on LD and related disorders have reported small effect sizes, the effect
size was set to small (Cohen’s d = 0.165; Larsen, MacDonald, & Plantinga, 2014; Tonne,
2017). Based on the power analysis result, a sample size of n = 300 PCPs working in
Connecticut was needed for the study (see Appendix H).
Because the 2015 PCP study population proportion did not achieve the sample
size projected (N = 300), it was assumed that the margin of error in this study was greater
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than the 285 PCP survey population proportion of 2006. The margin of error formula is
margin of error = z * √p * (1 – p) / √n. The margin of error in this study was 0.01%, p = <
0.05, 95% CI = 1.96. Further, under the expectation to receive 300 PCP survey responses
and only receiving 145, the margin of error was ± 5.86%. Moreover, in this study when
calculated for the 145 PCP survey responses with p < 0.05 (z score 1.96), the calculated
margin error was ± 8.138%. In contrast, the margin of error for the samples in the
Johnson and Feder (2010) 2006 population proportions of 285 was ±4.726%; therefore,
the smaller sample size in this study had a larger margin of error. The larger the sample
size, the smaller the margin of error. Thus, when the two cluster samples were added (i.e.,
n =145 for 2015 and n = 285 for 2006 = n = 430), the calculated margin of error was ±
4.73% (see Appendix G).
The sample was expected to be similar or greater in proportion to (with a response
rate of 39.1%) Johnson and Feder’s (2010) study sample to achieve equal representation
and accurate data analysis. However, because the 2015 PCP proportion sample consisted
of 145 from 179 PCP survey responses, I assumed that this response rate might affect the
representation (internal validity) of the population in this study. The 2015 PCP specialty
categories also had dissimilar frequency proportions in contrast to the 2006 PCP specialty
categories. Z scores as presented in Chapter 4 show the variations within the PCP
categories (see also Tables 4 and 5). Therefore, the n = 145 sample proportion of 2015
was adjusted for the data analysis stated the status of representation in this study before
the data analysis was conducted. The adjustment was done using the larger number of P1 /
P2. Thus, P1 (285) / P2 (145) = 1.97.
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Regarding sampling procedures, Johnson and Feder’s (2010) sampling frame was
from the CT DPH (2006) database of 3,091 PCPs licensed to practice in the state of
Connecticut, which I also used for this study. Johnson and Feder used random sampling
to select 33% of the 3,091 Connecticut PCPs (n = 1,034), whose data were available in
the CT DPH database as the recruitment sample. The same random sampling strategy
technique was also employed in this study. A randomization method was employed via a
random number generator set between 1 and 5,231; these numbers corresponded to the
numbered database entries of the 5,231 Connecticut PCPs. In this study, 1,726 physicians
were randomly selected as the 33% of the Connecticut PCPs, whose data were available
in the CT DPH (2015) database. These physicians made up the sample of participants
necessary for this study (see Appendix E).
I mailed a study materials packet that included an informed consent form,
directions on completing the study survey, the survey itself, and a stamped and addressed
envelope to the physicians at their work addresses. As per the directions in the packet,
physicians were asked to return the completed CT-KAP questionnaire using the stamped
envelope, which was mailed to a designated P.O. box address. The questionnaire
directions and CT-KAP questionnaire itself were identical to those used by Johnson and
Feder (2010). Additionally, two other questions were included on whether the physician
participated in Johnson and Feder’s study (i.e., Yes or No) and to give consent to
participate in this study (see Appendix A).
The consent form included my professional contact information, the reason for
conducting the study, and information about (a) the goals and purpose of the study, (b)
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the role of the study participant (i.e., what the physician were required to do), (c) the
benefits and risk of participating in the study, (d) the procedures employed in the study to
maintain confidentiality and anonymity, and (e) the voluntary nature of the study (i.e., the
right of the physician to not participate in the study and/or to refuse to answer any
questions on the CT-KAP questionnaire). Participants were not asked to sign their name
on the consent form or to mail it back to maintain physician confidentiality and
anonymity; instead, they were asked to check Yes or No on the consent form that was
found in the mail out. If any physician selected No or did not mark the answer on the
question as consent to participate yet returned a completed questionnaire, their data were
not used in the study. It was not possible to mail reminder notices to encourage
participation.
Johnson and Feder’s (2010) study reported that of the 1,034 study packets mailed
to the PCPs, 191 (18.5%) were returned unopened due to an incorrect address, which
reduced the recruitment sample to 843 Connecticut PCPs (Johnson & Feder, 2010). A
similar percentage (or proportions) rate of the 1,726 study materials packets was expected
to be returned due to incorrect address, resulting in a recruitment sample of 1,507
physicians. Johnson and Feder (2010) reported that, of the 843 survey packets received
by the physicians, only 330 surveys were returned (a 39% response rate; see Tables 4 and
5). Johnson and Feder’s (2010) final response rate was 33.5%; 285 of the 843 surveys
mailed to “Connecticut Primary Care Physicians 2018” were returned and had useable
data. As response rates in health care and medicine studies using mailed questionnaires
are notoriously low (i.e., approximately 30%), a response rate of 30% was anticipated (n
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= 422) (Halbesleben & Whitman, 2013; Johnson & Wislar, 2012; Phillips, Friedman, &
Durning, 2017).
Additionally, the study survey included a question inquiring as to whether the
physician participated in Johnson and Feder’s (2010) study. If a physician had
participated, his or her response was used in this study. The likelihood that the same
physicians in Johnson and Feder’s (2010) study would also be recruited into this study
was low, mainly since they and the researcher employed random sampling to obtain the
initial recruitment sample. The expected sample of 422 physicians was large enough to
allow for the removal of any of these cases – as well as the removal of cases with
incomplete or otherwise unusable data – while achieving the desired sample size of 300.
Johnson and Feder (2010) did not seek to obtain equal numbers of PCPs per
specialty category. Consequently, it was not sought in this study to align with Johnson
and Feder’s (2010) previous approach. The first research question was developed to act
as a validity check and determine if the proportion of physicians per primary care
category in this study was significantly different from those reported by Johnson and
Feder (2010). In this study, it was hoped that this study sought to identify no significant
differences in the proportion of physicians per primary care category because a lack of
significance indicates that the two samples were similar.
The original data set used in Johnson and Feder’s (2010) study was not fully
accessible to the researcher. Therefore, the proportion, frequency, or mean level data that
were reported in Johnson and Feder’s (2010) study were also used in this study. The
inability to access Johnson and Feder’s (2010) full study data set required that the
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statistical analyses used to test study hypotheses also treated the proportion, frequency, or
mean data reported in their study as the expected or population data.
Instrumentation Operationalization of Study Variables
The instrument used in this study was Johnson and Feder’s (2010) 9-item CTKAP 2006 questionnaire on LD and CLD/PTLDS (see Appendix A). Murray and Feder
(2001) developed and validated the CT-KAP questionnaire, and it was further refined in
the study by Magri et al. (2002). Murray and Feder (2001) reported a 56% response rate,
receiving completed questionnaires from 320 out of 573 PCPs in Connecticut that were
solicited to participate. Of the 320 physicians in Murray and Feder’s (2001) study, 267
(83%) reported having diagnosed patients with LD, a valid percent in a geographical
region with a high LD prevalence rate. Most physicians said that they followed the
established clinical guidelines for treating patients with LD; for example, the average
course of antibiotic treatment was 21 days (Murray & Feder, 2001).
There is nearly a 20-year history of using the CT-KAP questionnaire in
surveillance and epidemiological and clinical research studies on LD but little on CLD.
Studies have provided evidence that the CT-KAP questionnaire provides a valid and
reliable assessment of physicians’ KAP regarding LD and CLD/PTLDS (Brett, Hinckley,
Zielinski-Gutierrez, & Mead, 2014; McKinney et al., 2008). There is evidence of
construct validity of the CT-KAP; that is, it effectively measures the KAP of physicians’
clinical approach to CLD/PTLDS. Magri et al. (2002) provide evidence of criterionrelated discriminant validity of the CT-KAP: they found that there was a significantly
higher percentage (or proportions) of physicians with patients diagnosed with LD in high-
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versus low-endemic areas (53.2% as compared to 29.1%, p = 0.0003). McKinney et al.
(2008) note considerable overlap in KAP questions between the CT-KAP and related
physician LD KAP questionnaires, providing evidence of the criterion-related concurrent
validity of the CT-KAP.
The independent variable of this study was the physician group that is, the group
of Connecticut PCPs who participated in Johnson and Feder’s (2010) research and those
who participated in this study. The inability to fully access and use Johnson and Feder’s
(2010) data set precludes the ability to analyze data at the item level for the group of
Connecticut PCPs who participated in Johnson and Feder’s (2010) study and those who
participated in this study. Johnson and Feder’s (2010) group was treated as a population,
allowing for the use of proportion, frequency, and mean level data reported in their study.
The response codes for each and all the nine items on the CT-KAP questionnaire was the
same, which allowed the comparisons between the group of Connecticut PCPs who
participated in Johnson and Feder’s (2010) study and those who participated in this study
to be made. The following section presents each dependent variable and its coding.
Figure 5 presents a summary of the study independent and dependent variables, which are
further discussed in the following sections.
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DV1: PCP Specialty

DV2: Knowledge of LD

DV3: Knowledge of CLD
Independent Variable:
CT PCPs 2006 and 2015
DV4: N of patients with
LD

DV4: N of patients with
CLD

DV5: Course of
antiobiotic treatment

Figure 5. Study independent and dependent variables.
Dependent variable 1: Primary care physician specialty. The first dependent
variable of PCP specialty was measured using CT-KAP item two: “What is your
specialty?” This CT-KAP item two was coded as a categorical (nominal) item, where 1 =
Family Medicine, 2 = Internist, 3 = Pediatrician, and 4 = Other Primary Care.
Dependent variable 2: Physician knowledge of Lyme disease. The second
dependent variable of physician knowledge of LD was assessed using CT-KAP item 3:
“How would you describe your knowledge of Lyme disease?” This CT-KAP item 3 was
coded as a categorical (nominal) item, where 3 = I know the symptoms and feel
comfortable diagnosing it, 2= I know the symptoms but don’t feel comfortable
diagnosing it, and 1 = I don’t know the symptoms and don’t feel comfortable diagnosing
it.
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Dependent variable 3: Physician knowledge of chronic Lyme disease. The
third dependent variable of physician knowledge of CLD (PTLDS)was assessed using
CT-KAP item four: “How would you describe your knowledge of CLD (PTLDS)?” This
CT-KAP item four is coded as a categorical (nominal) item, where 4 = I know the
symptoms and feel comfortable diagnosing it, 3 = I know the symptoms but don’t feel
comfortable diagnosing it, 2 = I don’t know the symptoms and don’t feel comfortable
diagnosing it, and 1 = I don’t believe it exists.
Dependent variable 4: Mean number of patients diagnosed and treated with
Lyme disease and chronic Lyme disease. The fourth dependent variable of mean
number of patients diagnosed and treated with LD and CLD (PTLDS) was measured
using CT-KAP item seven: “Over the past 3 years, approximately how many patients
have you diagnosed and treated with Lyme disease? “Over the past 3 years,
approximately how many patients have you diagnosed and treated with Lyme disease?”
This CT-KAP item seven was a ratio-coded variable that ranged from 0 to n.
Dependent variable 5: Average total course of antibiotic therapy (in weeks)
for patients with chronic Lyme disease. The fifth dependent variable of average total
course of antibiotic therapy (in weeks) was assessed using CT-KAP item seven a: “What
has been the average total course (in weeks) of antibiotic therapy for patients with CLD
(PTLDS)?” This CT-KAP item seven a was a ratio-coded variable that ranged from 0 to
n.

93
Data Analysis Plan
The statistical software used to conduct all data analyses was SPSS 24.0. The data
analysis plan involved a sequential process. Study participants used a paper questionnaire
that necessitated the entry of questionnaire data into an SPSS 24.0 data set. Before
entering these data, the researcher reviewed the surveys received from the physicians.
Questionnaires with incomplete or otherwise unusable data were discarded, as were
surveys in which the participant did not provide consent in the study. The researcher
denoted the number of discarded questionnaires and the reasons why they were discarded
(see Chapter 4).
The researcher assigned to each questionnaire an ID number and collated the
questionnaires in order of the ID number. The data were documented and organized using
SPSS 24.0 to create the data set, which was kept on a password-protected jump drive (not
a computer hard-drive). The jump-drive was stored in a locked file cabinet at the
researcher’s home office in a separate compartment from paper questionnaires. The
researcher reviewed the data and data set before and after the data were entered,
searching for any data entry errors. Frequencies were performed on all item responses
and conducted unusual cases analytics to ensure that all data entry errors were addressed.
Descriptive statistical analyses were conducted on all data, reporting responses for
each of the first nine question items of the 2018 CT-KAP questionnaire. While certain
CT-KAP 2018 items were used to measure dependent variables, descriptive statistics
were used for all nine items. The researcher ran and reported the frequencies/percentages
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of responses on categorical (nominal) variables as well as the mean, median, standard
deviation, and minimum and maximum values for the ratio-coded variables.
The first, second, and third research questions required conducting Chi-square (χ²)
goodness-of-fit tests. The fourth and fifth research questions required one-sample t-tests.
The appropriate effect size and power calculation results augmented the statistical
findings for each research question.
Cohen’s W is the indicator of effect size for a Chi-square (χ²) goodness-of-fit test
(Cohen, 1988; Cunningham & McCrum-Gardner, 2007; NCSS, n.d.). The mathematical
formula for Cohen’s W is

²̸

(Cohen, 1988; NCSS, n.d.). Cohen’s d is the indicator of

effect size for a one-sample t-test (Cohen, 1988; Lakens, 2013). The mathematical
formula for Cohen’s d for a one-sample test (i.e., Cohen’s dz) is [t]/√n, where [t] is the
absolute t-value (i.e., no negative values used), and n is the sample size (Cohen, 1988;
Lakens, 2013). Power was determined from the effect size and sample size values.
Research Questions Hypotheses and Statistical Analyses
The purpose of this quantitative comparative (i.e., ex post facto) study was to
examine if significant differences regarding knowledge, diagnosis, and treatment of LD
and CLD/ (PTLDS exist between two groups of Connecticut PCPs – those who
participated in Johnson and Feder’s (2010) study and those who participated in this study.
The study posed five research questions with associated null and alternative hypotheses.
These are restated below, followed by the proposed statistical analysis for each research
question.
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Research Question 1: Are the frequency distributions of the 2015 sample of
Connecticut PCPs across the four primary practice specialty areas (i.e., family medicine,
internal medicine, pediatrics, other) significantly different from the distributions of the
2006 (Johnson & Feder, 2010) sample of Connecticut PCPs?
H01: The frequency distributions of the 2015 sample of Connecticut PCPs across
the four primary practice specialty areas (i.e., family medicine, internal medicine,
pediatrics, other) are not significantly different from the distributions of the 2006
(Johnson & Feder, 2010) sample of Connecticut PCPs.
Ha1: The frequency distributions of the 2015 sample of Connecticut PCPs across
the four primary practice specialty areas (i.e., family medicine, internal medicine,
pediatrics, other) are significantly different from the distributions of the 2006 (Johnson &
Feder, 2010) sample of Connecticut PCPs.
Analysis: Chi-square (χ²) goodness-of-fit test. The researcher treated Johnson
and Feder’s (2010) physician data as population data and used data from CT-KAP
questionnaire item two. Chi-square (χ²) goodness-of-fit test was done by comparing the
frequency/proportion distributions of physicians in each of the four specialty areas to the
frequency/proportion distribution values reported in Johnson and Feder’s (2010) study.
This research question was unique, as it is the only one in the study in which the null
hypothesis was intended to be retained or failed to be rejected.
Research Question 2: Are the frequency distributions of the 2015 sample of
Connecticut PCPs across the two knowledge of LD categories (i.e., know symptoms of
LD and feel comfortable diagnosing and treating LD vs. know LD but do not feel
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comfortable diagnosing and treating LD) significantly different from the distributions of
the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs?
H02: The frequency distributions of the 2015 sample of Connecticut PCPs across
the two knowledge of LD categories (know symptoms of LD and feel comfortable
diagnosing and treating LD versus know LD but do not feel comfortable diagnosing and
treating LD) are not significantly different from the distributions of the 2006 (Johnson &
Feder, 2010) sample of Connecticut PCPs.
Ha2: The frequency distributions of the 2015 sample of Connecticut PCPs across
the two knowledge of LD categories (know symptoms of LD and feel comfortable
diagnosing and treating LD versus know LD but do not feel comfortable diagnosing and
treating LD) are significantly different from the distributions of the 2006 (Johnson &
Feder, 2010) sample of Connecticut PCPs.
Analysis. Chi-square (χ²) goodness-of-fit test. In this study, Johnson and Feder’s
(2010) physician data were treated as population data. Chi-square (χ²) goodness-of-fit test
was conducted by comparing the distributions of responses on CT-KAP questionnaire
item three in this study data to the distribution values reported by Johnson and Feder
(2010).
Research Question 3: Are the frequency distributions of the 2015 sample of
Connecticut PCPs across the three knowledge of CLD/PTLDS categories (do not believe
CLD exists, do not feel comfortable diagnosing and treating CLD/PTLDS, and feel
comfortable diagnosing and treating CLD/PTLDS) significantly different from the
distributions of the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs?
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H03: The frequency distributions of the 2015 sample of Connecticut PCPs across
the three knowledge of CLD/PTLDS categories (do not believe CLD exists, do not feel
comfortable diagnosing and treating CLD/PTLDS, and feel comfortable diagnosing and
treating CLD/PTLDS) are not significantly different from the distributions of the 2006
(Johnson & Feder, 2010) sample of Connecticut PCPs.
Ha3: The frequency distributions of the 2015 sample of Connecticut PCPs across
the three knowledge of CLD/PTLDS categories (do not believe CLD/PTLDS exists, do
not feel comfortable diagnosing and treating CLD/PTLDS, and feel comfortable
diagnosing and treating CLD/PTLDS) are significantly different from the distributions of
the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs.
Analysis. Chi-square (χ²) goodness-of-fit test. The 2006 physician data were
considered population data. Chi-square goodness-of-fit test was completed using the
distribution data of physician responses per knowledge category for CT-KAP
questionnaire item four and the distribution values reported by Johnson and Feder (2010).
Research Question 4: Is the estimated average number of patients diagnosed as
having CLD/PTLDS within a 3-year period by the 2015 sample of Connecticut PCPs
significantly different from the average number of patients diagnosed as having
CLD/PTLDS within a 3-year period by the 2006 (Johnson & Feder, 2010) sample of
Connecticut PCPs?
H04: The estimated average number of patients diagnosed as having CLD/PTLDS
within a 3-year period by the 2015 sample of Connecticut PCPs is not significantly
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different from the average number of patients diagnosed as having CLD/PTLDS within a
3-year period by the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs.
Ha4: The estimated average number of patients diagnosed as having CLD/PTLDS
within a 3-year period by the 2015 sample of Connecticut PCPs is significantly different
from the average number of patients diagnosed as having CLD/PTLDS within a 3-year
period by the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs.
Analysis. One-sample t-test. The 2006 (Johnson & Feder, 2010) physician data
were considered population data. One-sample t-test was used to test the difference
between the study sample mean score for CT-KAP questionnaire item seven and the
mean of 3.00 CLD cases reported per physician by Johnson and Feder (2010).
RQ5. Is the estimated average course of antibiotic treatment (in weeks) for
patients diagnosed as having CLD/PTLDS by the 2015 sample of Connecticut PCPs
significantly different from the average course of antibiotic treatment (in weeks) for
patients diagnosed as having CLD/PTLDS by the 2006 (Johnson & Feder, 2010) sample
of Connecticut PCPs?
Research Question 5: Is the estimated average course of antibiotic treatment (in
weeks) for patients diagnosed as having CLD/PTLDS by the 2015 sample of Connecticut
PCPs significantly different from the average course of antibiotic treatment (in weeks) for
patients diagnosed as having CLD/PTLDS by the 2006 (Johnson & Feder, 2010) sample
of Connecticut PCPs?
H05: The estimated average course of antibiotic treatment (in weeks) for patients
diagnosed as having CLD/PTLDS by the 2015 sample of Connecticut PCPs is not
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significantly different from the average course of antibiotic treatment (in weeks) for
patients diagnosed as having CLD/PTLDS by the 2006 (Johnson & Feder, 2010) sample
of Connecticut PCP.
Ha5: The estimated average course of antibiotic treatment (in weeks) for patients
diagnosed as having CLD/PTLDS by the 2015 sample of Connecticut PCPs is
significantly different from the average course of antibiotic treatment (in weeks) for
patients diagnosed as having CLD/PTLDS by the 2006 (Johnson & Feder, 2010) sample
of Connecticut PCP.
Analysis. One-sample t-test. The Johnson and Feder (2010) physician’s data were
considered the population data. One-sample t-test was used to test the difference between
the study sample mean score for CT-KAP questionnaire 2018 item seven a and the mean
of 20 weeks of antibiotic treatment by physicians in Johnson and Feder’s (2010) study.
The two primary statistics used to test the hypotheses were the Chi-square (χ²)
goodness-of-fit test and the one-sample t-test. The non-parametric Chi-square (χ²)
goodness-of-fit test was used to determine if the frequency distribution of responses on a
categorical variable for a sample is significantly different from the expected or population
distribution (Salkind, 2016). The primary assumption to be met for a Chi-square (χ²)
goodness-of-fit test is that each variable category must have a sample size no smaller than
five (Salkind, 2016). This assumption was met in this study. The smallest sample size per
category was six, in reference to the number of PCPs who identified as other.
The one-sample t-test was used to determine if a sample variable mean score is
significantly different from a known population mean score (Treiman et al., 2015). The
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two fundamental assumptions of the one-sample t-test were that the dependent variable
was measured using a ratio or interval scale and that the dependent variable had a normal
distribution (Treiman et al., 2015). In this study, one-sample t-tests were used with ratiocoded dependent variables.
The assumption of normality was addressed by examining the skewness of the
variables by computing zskewness values (i.e., by dividing the variable skewness by the
skewness standard error; Kim, 2013). For medium-sized samples – that is, samples
between 50 and 300 – a zskewness greater than 3.00 indicates variable skewness and a
violation of the normality assumption (Kim, 2013). The assumption of normality was
further tested by (a) conducting Kolmogorov-Smirnov tests, (b) utilizing SPSS 24.0
unusual cases function to identify outliers, and (c) computing box-plots.
As stated by Cousineau and Chartier (2010), “there is no single solution” to
dealing with outliers (p. 66). There are three standard options to address outliers: (a)
winsorizing the outlier (i.e., replacing the outlier value with the next lowest or highest
score), (b) transforming the variable (i.e., using loglinear or square root transformations),
or (c) removing the outliers (Cousineau & Chartier, 2010; Kim, 2013; Pollet & van der
Meij, 2017). However, Winsorization and transformation of values do not always solve
outlier issues (Cousineau & Chartier, 2010; Kim, 2013; Pollet & van der Meij, 2017).
The option for dealing with outliers selected for this study was removal of the
outliers, especially as statistical findings may differ substantially based on whether
“outliers are included or excluded” (Pollet & van der Meij, 2017, p. 54). A concern with
removing outliers is that it may result in the loss of too many data points until the
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statistical analysis cannot be conducted or is no longer applicable to the data set
(Cousineau & Chartier, 2010; Kim, 2013; Pollet & van der Meij, 2017). However, onesample t-tests were conducted for the fourth and fifth research questions, as it was
important in this study to replicate the analyses conducted by Johnson and Feder (2010)
and to address the null and alternative hypotheses for them.
Threats to Validity
Three types of validity in quantitative research studies pertain to study limitations
in relation to the research methodology and design: (a) internal validity, or the degree to
which it can be stated that the observed effects on the dependent variable(s) are due to the
independent variables and not to uncontrolled confounding variables; (b) external
validity, or the ability to generalize study results to the population or other samples,
settings, and times; and (c) construct validity, or how well a study instrument
operationally captured the constructs under study (Patten & Newhart, 2017). The internal
and external validity were assessed by comparing the number or proportions of PCP
survey responses and the PCP categories of 2006 (from the official list of CT MD/DO,
and the ones that responded to the survey) and 2015 (from the official list of CT MD/DO,
and the ones that responded to the survey). The calculations for internal and external
validity are presented in Chapter 4. The internal and external validity was measure in this
study when answering Hypothesis questions. Quantitative studies have threats to internal,
external, and construct validity, but they differ according to the type of quantitative
research design employed in the study (Reio & Reio, 2016). Threats as they pertain to
internal, external, and construct validity are discussed in the following sections.
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Threats to Internal Validity
Threats to internal validity are participant or study factors that compromise the
ability to state that dependent variable effects were the result of the independent variable
(Patten & Newhart, 2017). If a cross-sectional study has high level of internal validity
will be measure in great part from the strength of the interferences of the study (Carlson,
& Morrison, 2009). Most threats to internal validity concern experimental or quasiexperimental studies, but there are threats to the internal validity of nonexperimental
research studies as well (Patten & Newhart, 2017). These threats to the internal validity
of nonexperimental research studies include the following: (a) bias due to confounding,
(b) self-selection bias, and (c) social desirability response (Patten & Newhart, 2017).
Bias due to confounding is the inability to conclude that the dependent variable
effects are a result of the independent variable due to an unmeasured extraneous variable
that was significantly associated with the independent and dependent variables (Bergman,
2011). A potential source of confounding bias in this study is that physicians who
participated in Johnson and Feder’s (2010) study may have been recruited into this study.
There were a total of 14 PCP surveys responses of PCPs who believed they took the
survey of 2006. Some of these respondents were not 100%, but they marked in the
question 10 of the 2015 KAP survey used in this study as Yes.
Self-selection or volunteer bias occurs in studies that rely on a convenience
sample as opposed to a random selection of study participants; participants who volunteer
for a study tend to differ in “relevant clinical characteristics” from those who do not
participate (Tripepi, Jager, Dekker, & Zoccali, 2010, p. 98). The self-selection bias may
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be minimized by focusing on a subset of physicians—namely, PCPs in the state of
Connecticut—and utilizing random selection to obtain the study recruitment sample.
Klabunde, Willis, and Casalino (2013) identified four primary reasons why physicians do
not participate in survey studies: (a) “lack of time,” (b) perceptions that the study or study
questionnaire has little value or importance, (c) confidentiality and anonymity concerns,
and (d) views that the study questionnaire is “biased or not providing a full range of
responses” (p. 286). Physicians who complete and mail the study survey may have more
time in their schedule to complete the questionnaire and more positive attitudes about the
study and/or study questionnaire and may be more assured that confidentiality will be
maintained in the study than physicians who do not participate.
Another threat to the internal validity of nonexperimental studies (as this crosssectional study) is social desirability response bias, or when the study participant
provides answers to survey items that are socially acceptable irrespective of the truth
(Bowling, 2014). As this study was a cross-sectional study, I am as the main researcher
did not manipulate the independent variables and the random method used helped to
control the present of extraneous variables. Nonetheless, social desirability response bias
is more likely to occur when participants are asked sensitive questions – for example,
questions about their weight, physical and mental health problems, and attitudes toward
coworkers and supervisors (Klabunde et al., 2013). This study used a cross-sectional
study (nonexperimental) to examine the physician’s (PCPS in the categories family,
internal medicine, pediatricians) work-related KAPs regarding LD and CLD. While the
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study survey inquiries about controversial topics, it does not ask about personal or
sensitive topics. Consequently, social desirability bias may be lessened.
The informed consent process wherein participants are informed about study
confidentiality may further help reduce social desirability bias (Bowling, 2014).
Conclusively, social desirability on self-reporting can affect the outcomes in the study in
regard to the external and internal validity (Althubaiti, 2016). Althubaiti (2016) stated
that an excellent way to eliminate the threat of social desirability not to affect the internal
validity of a study is to validate the survey instrument before the data collection stage
when possible. However, validating the survey instrument before the data collection stage
is not applicable for cross-sectional study and better for experimental studies.
Threats to External Validity
External validity pertains to the ability to generalize study results beyond the
study sample to the population (or other samples), to different points in time, and to other
settings (Bowling, 2014). The external validity of a study is highly dependent upon the
degree to which the study participants represent the population (Bowling, 2014). Random
sampling to obtain the recruitment pool of physicians may increase the external validity
of the study, as it can focus on a specific population of physicians. However, results from
this study cannot be generalized to PCPs licensed to practice in states other than
Connecticut, to physicians who are not PCPs, or to other health care workers (e.g., nurse,
physician assistants), regardless of their specialty area. Results from this study cannot be
used to predict physician responses on the CT-KAP or be compared to other LD or CLD
questionnaires.
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Threats to Construct Validity
Construct validity indicates that the study instrument is measuring the constructs
it is intended to measure (Patten & Newhart, 2017). The inadequate explication of
constructs, or the incorrect or inexact operationalization of study constructs, is a threat to
construct validity (Patten & Newhart, 2017). The threat of inadequate explication of
constructs is minimized in this study by a valid and reliable questionnaire. This study
may be influenced by the construct validity threat of mono-method bias, or the use of a
single type (vs. multiple types) of measurement (Patten & Newhart, 2017), primarily
because individual items are used to measure study constructs. Conclusions from results
can only be drawn concerning items on the CT-KAP questionnaire 2015.
Ethical Procedures
In conducting this study, the I adhered to the ethical standards for research with
human subjects. I sought IRB approval from the Walden University IRB before
implementing any part of this study. The study and data collection were approved by the
Walden University IRB. Walden University’s approval number for this study was 06-0518-023461. I applied the highest level of ethical considerations to maintain the integrity
of this study, especially with regard to informed consent and participant privacy and
confidentiality, the management of data, data analyses, and the disposal of study
materials (i.e., the checked consent forms, paper questionnaires, and data sets).
Per ethical guidelines for human subjects research, I required that study
participants read and sign an informed consent form. The informed consent form
included information on (a) the goals and purpose of the study, (b) the role of the
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participants in the study, (c) their rights as human subjects, and (d) benefits and risks of
participating in the study. I included my contact information (i.e., email and phone
number) as well as the contact information for the Walden University IRB administrator
on the consent form to enable physicians who had questions or concerns about the study.
Only three physicians called with some questions regarding the study, and I received no
emails from any physicians. The physicians had to check Yes next to the informed
consent form statement to indicate they consented to participate in the study. I discarded
any returned surveys if the PCP did not provide consent by checking Yes.
The CT-KAP questionnaire did not contain any questions that could identify the
physician. While I knew names and work addresses of the 1,726 physicians of whom I
mailed the survey packet, it was impossible to ascertain who did or did not complete and
return the CT-KAP survey. I stored survey forms with the checked consent question mark
from the CT-Survey of 2015 (conducted in 2018) in a locked file cabinet in a home work
office.
After I entered the data from the paper questionnaires into an SPSS 24.0 data set,
the data were checked carefully to avoid errors in the data entry process. The data set was
stored on a password-protected jump-drive (not a computer hard drive), which was kept
in a locked file cabinet separate from the consent forms and paper questionnaires. The
informed consent forms and surveys are to be shredded, and the jump-drive is to be
destroyed five years after completion of this study. Data from the study were reported on
the aggregate level in the dissertation and any subsequent journal articles or conference
presentations.
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Summary
This quantitative study utilized a nonexperimental, cross-sectional, comparative
research design to determine if two groups of Connecticut PCPs significantly differ in
their knowledge, diagnosis, and treatment of LD and CLD/PTLDS. CLD/PTLDS
definition was stated in the cover letter of the consent letter, which was mailed with the
survey for this study. Survey responses provided by 145 Connecticut PCPs who
participated in this study were compared to the frequency, proportion, and mean level
data reported by Johnson and Feder (2010) in their research with 285 Connecticut PCPs.
The methodological practices, including the study participant recruitment and data
collection procedures, were aligned with the practices outlined by Johnson and Feder
(2010). The study used the CT-KAP questionnaire that Johnson and Feder (2010)
utilized. One of two added questions (11) asked whether the physician took part in the
previous study and was included on the questionnaire.
Data from physicians who participated in the previous study were used. The
information from this study was expected to update the PCPs positions on CLD/PTLDS
(e.g., see Chapter 4 and 5) and help to inform the need for the development of
CLD/PTLDS diagnosis and treatment protocols since it lacks a case definition, reliable
laboratory tests, surveillance, and standardized treatment practices as most identified
infectious diseases do (National Institute of Allergy and Infectious Diseases, 2019;
Wharton et al., 1990). This chapter provided a comprehensive review of the study
methodology. The following chapter focuses on the study findings.
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Chapter 4: Results
Introduction
CLD/PTLDS may be a new health condition (Marzec et al., 2017) that lacks a
case definition, reliable laboratory tests, an ICD-10 code, data collection and
surveillance, and standardized treatment practices (Infectious Diseases Society of
America, 2006; Lantos, 2015a, National Institute of Allergy and Infectious Diseases,
2019). Johnson and Feder (2010) addressed this confusion regarding CLD/PTLDS by
examining the knowledge and practices of LD and CLD/PTLDS diagnosis and treatment
in 285 Connecticut PCPs. However, there has not been assessment of Connecticut PCPs’
KAPs regarding LD and CLD/PTLDS since Johnson and Feder’s seminal study.
In this study, I utilized a nonexperimental, cross-sectional, and comparative
research design to validate Johnson and Feder’s (2010) study outcomes. The key element
of this study was to determine whether there were any significant differences between the
two groups of Connecticut PCPs (i.e., the 2006 and 2015 samples) regarding their KAP
responses on the diagnosis, treatment, and management of LD and CLD/PTLDS. I
followed the same participant recruitment and data collection procedures as Johnson and
Feder. I also utilized their KAP survey, which can be validated by statistically similar
findings between the two Connecticut PCP groups (using the CT DPH bases for 2006 and
2015). Any significant differences between the two PCP groups suggest a need to
conduct studies to further explore PCPs’ KAPs regarding CLD/PTLDS. The data
obtained in this study from the PCP survey responses were compared to the data

109
published in 2010. For purpose of representation, the data in this study was adjusted to
the factor of 1.97 (see Table 6).
This study had five research questions. The first research question acted as a
validity check to determine if the proportions of PCP specialties across this and the 2006
study specialty were similar, which they were. The second research question focused on
PCP knowledge differences on LD. The last three questions helped examine knowledge,
attitude, and treatment differences regarding CLD/CLD. The research questions and
hypotheses were as follows:
Research Question 1: Are the frequency distributions of the 2015 sample of
Connecticut PCPs across the four primary practice specialty areas (i.e., family medicine,
internal medicine, pediatrics, other) significantly different from the distributions of the
2006 (Johnson & Feder, 2010) sample of Connecticut PCPs?
H01: The frequency distributions of the 2015 sample of Connecticut PCPs across
the four primary practice specialty areas (i.e., family medicine, internal medicine,
pediatrics, other) are not significantly different from the distributions of the 2006
(Johnson & Feder, 2010) sample of Connecticut PCPs.
Ha1: The frequency distributions of the 2015 sample of Connecticut PCPs across
the four primary practice specialty areas (i.e., family medicine, internal medicine,
pediatrics, other) are significantly different from the distributions of the 2006 (Johnson &
Feder, 2010) sample of Connecticut PCPs.
Research Question 2: Are the frequency distributions of the 2015 sample of
Connecticut PCPs across the two knowledge of LD categories (i.e., know symptoms of
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LD and feel comfortable diagnosing and treating LD vs. know LD but do not feel
comfortable diagnosing and treating LD) significantly different from the distributions of
the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs?
H02: The frequency distributions of the 2015 sample of Connecticut PCPs across
the two knowledge of LD categories (know symptoms of LD and feel comfortable
diagnosing and treating LD versus know LD but do not feel comfortable diagnosing and
treating LD) are not significantly different from the distributions of the 2006 (Johnson &
Feder, 2010) sample of Connecticut PCPs.
Ha2: The frequency distributions of the 2015 sample of Connecticut PCPs across
the two knowledge of LD categories (know symptoms of LD and feel comfortable
diagnosing and treating LD versus know LD but do not feel comfortable diagnosing and
treating LD) are significantly different from the distributions of the 2006 (Johnson &
Feder, 2010) sample of Connecticut PCPs.
Research Question 3: Are the frequency distributions of the 2015 sample of
Connecticut PCPs across the three knowledge of CLD/PTLDS categories (do not believe
CLD exists, do not feel comfortable diagnosing and treating CLD/PTLDS, and feel
comfortable diagnosing and treating CLD/PTLDS) significantly different from the
distributions of the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs?
H03: The frequency distributions of the 2015 sample of Connecticut PCPs across
the three knowledge of CLD/PTLDS categories (do not believe CLD exists, do not feel
comfortable diagnosing and treating CLD/PTLDS, and feel comfortable diagnosing and
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treating CLD/PTLDS) are not significantly different from the distributions of the 2006
(Johnson & Feder, 2010) sample of Connecticut PCPs.
Ha3: The frequency distributions of the 2015 sample of Connecticut PCPs across
the three knowledge of CLD/PTLDS categories (do not believe CLD/PTLDS exists, do
not feel comfortable diagnosing and treating CLD/PTLDS, and feel comfortable
diagnosing and treating CLD/PTLDS) are significantly different from the distributions of
the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs.
Research Question 4: Is the estimated average number of patients diagnosed as
having CLD/PTLDS within a 3-year period by the 2015 sample of Connecticut PCPs
significantly different from the average number of patients diagnosed as having
CLD/PTLDS within a 3-year period by the 2006 (Johnson & Feder, 2010) sample of
Connecticut PCPs?
H04: The estimated average number of patients diagnosed as having CLD/PTLDS
within a 3-year period by the 2015 sample of Connecticut PCPs is not significantly
different from the average number of patients diagnosed as having CLD/PTLDS within a
3-year period by the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs.
Ha4: The estimated average number of patients diagnosed as having CLD/PTLDS
within a 3-year period by the 2015 sample of Connecticut PCPs is significantly different
from the average number of patients diagnosed as having CLD/PTLDS within a 3-year
period by the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs.
Research Question 5: Is the estimated average course of antibiotic treatment (in
weeks) for patients diagnosed as having CLD/PTLDS by the 2015 sample of Connecticut
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PCPs significantly different from the average course of antibiotic treatment (in weeks) for
patients diagnosed as having CLD/PTLDS by the 2006 (Johnson & Feder, 2010) sample
of Connecticut PCPs?
H05: The estimated average course of antibiotic treatment (in weeks) for patients
diagnosed as having CLD/PTLDS by the 2015 sample of Connecticut PCPs is not
significantly different from the average course of antibiotic treatment (in weeks) for
patients diagnosed as having CLD/PTLDS by the 2006 (Johnson & Feder, 2010) sample
of Connecticut PCP.
Ha5: The estimated average course of antibiotic treatment (in weeks) for patients
diagnosed as having CLD/PTLDS by the 2015 sample of Connecticut PCPs is
significantly different from the average course of antibiotic treatment (in weeks) for
patients diagnosed as having CLD/PTLDS by the 2006 (Johnson & Feder, 2010) sample
of Connecticut PCP.
This chapter starts with information on the data collection procedures, the initial
and final response rate, and the specialty description of the 145 PCPs in this study. As
this is a validation of Johnson and Feder’s (2010) study, the discussion is focused on the
similarities and differences found in this study with regard to study sample sizes and
response rates. This chapter also provides a comprehensive examination of the
descriptive and inferential statistical findings in this study. The presentation and
discussion of these findings regarding the research questions comprise most of the
Results section. The chapter concludes with a summary.
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Data Collection
The data collection period for this study was June 18, 2018 to August 20, 2018.
The data collection methods aligned with those conducted by Johnson and Feder (2010;
see Chapter 3). The two groups under examination are the 285 PCPs (from the PCP
sample of 2006) study and the 145 PCPs (from the sample of PCP of 2015) in this study.
As this was a validation study, it was important to replicate the same sampling frame
used by Johnson and Feder’s research methodology, including the use of same survey
instrument. Two extra questions were added to assess if the participants took the same
survey before (Question 10) and to follow Walden University IRB requirements related
to consent (Question 11) any relation with the variables in this study (see Appendix A).
The first step of the study was to determine if the 2006 and 2015 samples of
Connecticut PCPs similarly represented Connecticut PCPs, especially regarding specialty
areas. The first step of the validity process was to determine if the 2006 and 2015
samples adequately represented the population of Connecticut MDs/Dos as listed in the
CT DPH database. The CT DPH MD/DO database had contact information on 15,424
PCPs for 2006 and 17, 464 PCPs for 2015. I mailed out CT-KAP surveys from the total
list of MD/DO that were preselected of 2006 and 2015 populations proportions (see
Figures 6 and 7).
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Percentages from the the PCPs in scpecialty categories
of 2006 (3,091) and 2015 (5,231) extracted from the
full list of MD/DO of 2006 and 2015
80%

69% 65.40%

60%
40%
20% 19.10%
20%

10% 10.40%

0%
Family

Internal Medicine

CT-DPH Official List of 2006

Pediatricians

CT-DPH Official List of 2015

Figure 6. PCP Distributions from databases of CT DP MD/DO of 2006 and 2015.
Database information was adapted from this study from the CT DPH List of Certified
Medicare MD/DO. Database information were used to select the 33% of the PCPs in the
list of 2006 (15,424) and in 2015 (15,464).
PCPs found in the list of MD/DO in 2006 and 2015 in
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Figure 7. Frequency of specialty groups within the PCP category in distribution
databases of MD/DO of 2006 and 2015. A Chi-square test result indicated that the two
databases frequencies of 2006 and 2015 were not similar (χ2 (2) = 102, p < .05)
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Therefore, the distribution of the three categories in year 2006 is not the same as the
distribution in year 2015 taken from the original databases.
To further investigate the similarities and differences of categories, z tests were
used to test which category differed between 2006 and 2015. Table 3 shows the results of
the z test for each category. The proportions of internal medicine were not significantly
difference between 2006 and 2015. Similarly, the proportions of family medicine were
not significantly difference between 2006 and 2015. However, the proportions of
pediatrician category were significantly different between the two years (z = 2.492, p =
0.012). Specifically, the percentage of pediatrician in 2006 (10.10%) was significantly
less than that in 2015 (10.96%).
Table 3
Z Scores of Distributions from CT DPH Databases in 2006 and 2015
Category

z

p

Inference

Internal medicine
3.463
< 0.050
Significant difference
Family medicine
0.503
0.617
No significant difference
Pediatrician
1.062
0.289
No Significant difference
Other PCPs
10.05
< 0.050
Significant difference
Note. Pediatrician specialty and family were similar in the two population proportions of
2006 versus 2015, respectively (z = 1.062, p = 0.289; z = 0.0503, p = 0.617). The internal
medicine specialty and the other PCPs specialty were no similar, respectively (z = 3.463,
p < 0.050; z = 10.05, p < 0.050).
Therefore, it was found that the CT DPH MD/DO of 2015 was independent but
not 100% similar to the CT DPH MD/DO of 2006. These findings are important to
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answer the hypotheses, especially for Research Question 1 where the values to from the
PCP population proportions were received in both surveys. Though the fact that the PCPs
distributions or proportions were not the same in this validity study may have affected
some results, the same protocols were followed to avoid bias (selection, information bias,
and confounding; Kukull & Ganguli, 2012). It is important to maintain the correct
association of the variables under the study to avoid errors in outcome frequencies
exposures (Kukull & Ganguli, 2012). The selection of participants using randomization
gave equal participants the capacity to take part in the study, which allows for inferences.
One of the main criteria for sampling was to take the 33% of the group (PCPs in 2006
and PCPs in 2015). I also conducted a chi-square test to determine if this study was
representative of the PCP sample or proportion found by Johnson and Feder (2010). The
chi-square results indicated that the PCPs sample or proportion in this study was similar
in terms of being representative of the PCPs of 2006. More of this discussion will be
present when answering Research Question 1.
Tables 4 and 5 provide a review of the survey dissemination data, including the
total number of potential participants, the selected number of potential participants, and
the number and percentages (or proportions) of surveys sent and received in both studies.
Johnson and Feder (2010) used the CT DPH MD/DO of 2006, whereas this study
included the CT DPH MD/DO of 2015. The total number of Connecticut PCPs denoted
in the CT DPH MD/DO of 2006 DPH list was 3,091, and the total number in the CT DPH
MD/DO of 2015 list was 5,231. As per their research methodology, Johnson and Feder
(2010) randomly selected 33% of the PCPs, which was 1,034. In this study, 33% of the

117
PCPS were also randomly selected, which was 1,726. Johnson and Feder reported an
initial response rate of 39.1%, or 330 PCPs who completed and returned a study survey.
In this study the initial response rate was 11.9% or 179 PCPs who returned a completed
study survey. Therefore, the response rate was lower than the previous study done 10
years ago (see Table 4).
Table 4
Comparisons of Survey Dissemination Data
Category
Total number of the PCPs from the
CT DPH database
Number of PCPs on DPH-Certified
list before randomization (original
list).
Randomly selected PCPs who were
sent the study survey packet (33% of
the original categorical list).
Study survey packets returned to
researcher due to wrong address.
PCPs who received study survey
packets.
PCPS who returned study survey
packets.
Final population (proportion) of the
number of PCP responses used for
data analysis

PCP sample
of 2006
15,424

PCP sample
of 2015
17,464

z

p

Inference

3,091

5,231

20.64

< .001

1,034 (33%)

1,726 (33%)

0.25

.804

Dissimilar
(see Figure
8)
Similar

191 (18.5%)

219 (12.7%)

4.06

< .001

Dissimilar

3.75

< .001

330 (39.1%)

1,507
(87.3%)
179 (11.9%)

14.20

< .001

Dissimilar

285

145

1.59

0.118

Similar

843 (81.5%)

Dissimilar

Note. The data show the similarities of the two PCP responses received of the two PCP
distributions of 2006 and 2015. The additional parameters presented in this table were
closely similar in percentages (or proportions) based on the nonsignificance z scores.
The z-test procedure for testing the equality of two proportions was used to
compare the responses to the survey between 2010 and 2015. The z-test statistic was
computed as z = (p1 – p2) / SE (p1-p2) where p1 is the estimate of the proportion in of
2006 (presented by Johnson & Feder, 2010) and p2 is the estimate of the proportion of
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PCPs of 2015(in this study). SE (p1-p2) is the standard error of the difference in two
proportions and can be estimated as: SE (p1-p2) =

1−

+

where n1, and

n2 are sample sizes in 2006 and 2015, respectively.
The tests were performed at .05 level of significance which implies that the null
hypothesis of equality of proportions will be rejected if the p value of the test is less than
.05. The percentage of randomly selected PCPs of 2006 survey who were sent the study
survey packet was 33.5% and it was very similar with the PCPs sample of 2015 (33.2%).
Results of z test showed no significant difference in percentage of randomly selected
PCPs who were sent the study packet between 2006 and 2015 (z = 0.427, p = .669). The
percentage of study survey packets returned to the researcher due to wrong address was
18.5% in 2010 and the corresponding percentage in 2015 was (12.7%). Results of z test
showed a significant difference in the two percentages between 2006 and 2015 (z =
4.198, p < .001). Specifically, the percentage of study survey packets returned to the
researcher due to wrong address was significantly higher in 2006 sample compared with
the 2015 sample (the difference in the proportions was 5.8%, 95% confidence interval for
difference in percentage was 3.1% to 8.6% indicating that at 95% confidence, the
difference in the percentage of survey packets returned due to wrong address was
between 3.1% to 8.6%).
The percentage of randomly selected PCPs who received the survey packets was
81.5% od 2006 sample and the corresponding percentage of the 2015 sample was 87.3%.
Results of z test showed a significant difference between the two proportions in 2010 and
2015 (z = 3.748, p < .001). Specifically, the proportion of randomly selected PCPs who
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received the survey packets was significantly lower in 2006 sample compared with 2015
sample. The difference in the two proportions was – 5.3%, 95% confidence interval of
the difference in proportions was -8.0% to -2.5% indicating that at 95% confidence, the
difference in the proportion of randomly selected PCPs who received the survey packets
in 2006 sample compared with the 2015 sample is between 2% to 8%.
The percentage of PCPs who returned the survey packets was 39.1% of 2006
sample and the corresponding percentage of 2015 sample was 11.9%. Results of z test
showed a significant difference in the proportions between 2006 and 2015 samples (z =
14.200, p < .001). Specifically, the proportion of PCPs who returned the survey packets
of 2006 sample was higher compared with that in 2015 sample. The difference in the
proportions was 21.6%, 95% confidence interval for difference in proportions was 18.6%
to 24.6% indicating that at 95% confidence, the difference in the proportion of randomly
selected PCPs who returned the survey packets in 2006 sample compared with that in
2015 sample was between 18.6% to 24.6%. More surveys were returned in this study due
to wrong addresses than the one of 2006. This fact implies in this study the percent of
nonresponse may be greater than in the previous study. Additionally, the facts of having
more survey returned because wrong address may imply that fact maybe a greater
number of PCPs moved out and maybe retired. Returned survey can increase the percent
of error in regard to the margin error in this study and decrease the reliability.
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Table 5
Comparison of Surveys Received and Discarded
Category

Johnson & Feder
(PCPs 2006
sample)
330

Current Study 2015 PCPs
sample
179

χ2

p

Inference

Number of
1.509 .219
Returned Study
Surveys. (Similar).
Number of
45 (13.6%)
34 (19%)
Discarded Surveys
Rationale for
Z
p
Discarding Survey
Data*
Physician who
20 (44.4%)
16 (47.0 %)
0.231 .817
Similar
completed survey
was not a PCP.
PCP reported
10 (22.2%)
10 (29.4 %)
0.727 .233
Similar
he/she was no
longer in practice
PCP had not
5 (11.1%)
3 (8.8%)
0.334 .739
Similar
diagnosed patients
within the last 3
years.
Undecipherable
8 (17.8%)
1 (2.9%)
2.055 .039 Dissimilar
survey responses.
Health care
2 (4.4%)
0 (0.0%)
1.245 .213
Similar
provider other than
PCP answered
survey.
Note. *Percentages (or proportions) are derived from the respective 45 or 34 discarded
surveys. The 0.0% values could not be used for z tests using SPSS. Nonetheless, it was
calculated here with the value that was no 0 to compensate the analysis.
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As illustrated in Table 5, A Chi-square (χ²) test of independence was used to test
the difference in distribution of surveys received and discarded for 2006 versus 2015
PCPs. In the study by Johnson and Feder, (2010) 86.4% of surveys were returned and
13.6% were discarded. In the current study, 81% of surveys were returned and 19% were
discarded. Results of the Chi-square (χ²) test for independence showed that there was no
significant difference in the distribution of surveys returned or discarded between the two
samples (2006 and 2015) (χ2 (1) = 1.509, p = .219). Z tests for testing the equality of two
proportions was also used to compare which rationale of discarding the surveys was
significantly different between 2006 sample and 2015 sample. Z-test statistic was
computed as Z = (p1 – p2) / SE (p1-p2) where p1 is the estimate of the proportion of
2006 sample and p2 is the estimate of the proportion in 2015 sample. SE (p1-p2) is the
standard error of the difference in two sample proportions and can be computed using the
following formulae: SE (p1-p2) =

1−

+

where n1, and n2 are the sample

sizes in 2006 sample and 2015 sample , respectively. This test was carried out at .05
level of significance which implies that the null hypothesis of equality of proportions will
be rejected if the p value of the test is less than .05.
The percentage of surveys discarded because the physician who completed the
survey was not a PCP was 44.4% in the 2006 sample and the corresponding percentage in
the 2015 sample that was 47.1%. Results of the z test indicated no significant difference
between the two proportions (z = 0.231, p = .817).
The percentage of surveys discarded because the PCP reported he/she was no
longer in practice was 22.2% for the 2006 sample and the corresponding percentage in

122
2015 sample was 29.4%. Results of the z test indicated no significant difference between
the two proportions (z = 0.727, p = .233). This may suggest that medical doctors may had
changed their medical specialty from PCPs to other types of medical doctors (i.e. in this
study in the exclusion list two PCPs stated they were now cardiologists, others stated they
were neurologists, etc.). This fact may imply LD and CLD are terms more popular among
doctors and patients presently than in 2006 (i.e. as the CDC had documented how LD
cases had increased after 2006; see Figure 3).
The percentage of surveys discarded because the PCP had not diagnosed the
patients in the last three years was 11.1% in the 2006 sample and the corresponding
percentage in the 2015 sample was 8.8%. Results of the z test indicated no significant
difference between the two proportions (z = 0.334, p = .739).
The percentage of surveys discarded because of undecipherable survey responses
was 17.8% in the 2006 sample and the corresponding percentage in 2015 sample was
2.9%. Results of the z test showed a significant difference between the two proportions (z
= 2.055, p = .039). Specifically, the proportion of surveys discarded because of
undecipherable survey responses was significantly higher in the 2006 sample compared
with 2015 sample. The difference between the two years was 14.8%, 95% confidence
interval for difference was 0.7% to 28.9% indicating that at 95% CI, the difference in
percentage of surveys discarded because of undecipherable survey responses between
2006 sample and 2015 sample was between 0.7% to 28.9%.
The percentage of surveys discarded because the health care provider other than
PCP answered the survey was 4.4% in 2006 sample and the corresponding percentage in
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2015 sample was 0%. Results of the z test indicated no significant difference between the
two proportions (z = 1.245, p = .213).
The percentage of surveys discarded because the PCP did not provide informed
consent was 0%% for the 2006 sample, and the corresponding percentage in 2015 sample
was 11.8%. Results of the z test showed a significant difference between the two
proportions (z = 2.361, p = .018). Specifically, the proportion of surveys discarded
because PCP did not provide informed consent was significantly lesser in 2006 sample
compared with 2015 sample. The difference between the two samples was 11.8%, (95%
CI: -21.53% to -2.0% at 95% CI, the difference in percentage of surveys discarded
because the PCP did not provide informed consent for the 2006 versus and 2015 sample
was between -21.53% to -2.0%.
For each research question, a post hoc power analysis was conducted after the
analysis to determinate the degree of probability that the results could be said to be true.
The post hoc effect size and power are reported in this study in those research questions
needed.
Descriptive statistics: PCP specialty. Table 6 provides the PCP specialty group
frequencies and percentages, and Figure 8 details the frequencies per PCP specialty
category. The largest group of PCPs in this study self-identified as internists (n = 63,
43.4%). Forty-eight (33.1%) reported that they were pediatricians, while 28 (19.3%) were
family physicians. Six (4.1%) reported having another primary care specialty (i.e., all six
reported being in emergency medicine). The data was adjusted to present the
representation of 2015 in contrast with 2006 population frequencies. The 2006 PCP
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frequencies and percentages (or proportions) of 2006 specialty of n = 285 from the study
done by Johnson and Feder (2010) are presented in Table 7.
Table 6
Frequencies for Primary Care Physician Specialties in 2015
PCP Specialty

Frequency
(n)
63

2015 Nonadjusted
proportion
(%)
43.4%

2015
Adjusted
Frequency
(%)
124

2015
Adjusted
Proportion
(%)
43.4%

CT DPH
MD/DO)
of
2015(%)
65.4%

Internist
Pediatrician

48

33.2%

94

33.2%

19.1%

Family physician

28

19.3%

55

19.3%

10.4%

Other (i.e.,
Emergency
Physicians)

6

4.1%

12

4.1%

5.1%

Note. The 2015 PCPs of 2015 in the categories presented here internist, pediatrician,
family physician, pediatrician and other were adjusted to present the representation status
of it in this study. The percentages (or proportions) did not change, but the frequencies of
PCPs did. The respective frequencies presented here from 2015 data were 63, 48,28, and
6. When the data was adjusted by a factor of 1.97 (285/145) the frequencies of PCPs in
this study are 124, 94, 55, and 12. Samples were similar after adjusted Samples had
different frequencies (X2) = 0.0017, p < 00001, no significant at p < 0.05. Therefore, the
it may limit generalizations and the external validity of the data found in this study.
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Table 7
Frequencies for Primary Care Physician Specialties in 2006
PCP Specialty
Internist

Frequency
(n)
2006 study
113

Proportion
(%)
2006 study
39.6

CT DPH
MD/DO) of
2006(%)
69*

Pediatrician

107

37.5

20*

Family physician

57

20

10*

Other (i.e., Emergency
8
2.9
1*
Physicians)
Note. * The whole data of MD/DO was not available to me. Therefore, estimation was
adapted from figures from three sources (a)
http://www.publichealth.uconn.edu/assets/primarycarereport_02_09.pdf, (b)
https://portal.ct.gov/DPH/Practitioner-Licensing--Investigations/PLIS/LicensingStatistics, and (c) data from the Johnson and Feder (2010). Therefore, it was found that
samples had different frequencies (X2

=

2706, p < 00001, significant at p < 0.05. Thus

the 2006 population proportion who participated in Johnson and Feder study (n = 285)
was not similar to the list of 2006 CT Md/DO of 2006. Therefore, the external validity is
limited within these populations.
Comparison of PCP specialty groups between the PCPs in this study and the 285
PCPs from Johnson and Feder (2010) study is the topic of the first research question (see
Figure 8). The percentages (or proportions) of PCPs by specialty were compared to the
percentage of the 5,231 PCPs in the CT DPH (2015) database of active registered
medical doctors (including PCPs) in Connecticut (see Table 6). The data in Table 6
establish the true state of representation in this study when comparing the PCP data
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obtained with the original CT DPH MD/DO of 2015. The CT DPH MD/DO keep
changes within less than 20% (see Appendix D).

65.4

70
60
50

43.4

40

33.2

Study Percentage

30

CT-DPH Percentage
19.1

19.3

20
10.4
10

4.1 2.8

0
Internist

Pediatrician

Family
Physician

Other (i.e.,
Emergency
Physician)

Figure 8. Primary care physician specialty category frequencies from 2015 survey
responses versus CT DPH List of Certified MD/Surgeons. The PCPs distribution in this
study and the CT DPH (MD/DO of PCPs) were not similar. Therefore, the it may limit
generalizations and the external validity of the data found in this study. The x-axis is the
PCPs categories of 2015. The y-axis is the percentages of those PCPs categories.
Results
This section contains descriptive and inferential findings from the present study
and opens with a summary of key descriptive statistics. The remaining sections are
devoted to the statistical analyses and findings to address the study’s questions. The data
obtained did not require adjustments. Because this was a validation study, it was
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important to ensure that the 2006 and 2015 samples were equivalent. As presented in
Figure 9, the two groups of PCPs had similar sampling frames. The z test was not
significant (z =1.50, p = 0.118). There were no significant differences between the sample
proportion of 2006 (n = 285 PCPs) and sample proportion of 2015 (n = 145 PCPs; see
Figure 9).

Frecuencies of PCP categories found from the 2006 and
2015 study data (*Adjusted).
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124
113

120

107
94

100
80
60

57

55

40
20

8

12

0
Family

Internal Medicine

Pediatrician

2006

Other

2015

Figure 9. Data of primary care physician proportions from Johnson and Feder (2010).
The proportions from Johnson and Feder had a population proportion of 285, and this
study had 145 PCP responses. After adjustment of the data was done with a factor of
1.97, the frequencies of 2006 PCP were similar to the 2015 PCP obtained in this study.
Taking the responses more in detail when looking to the category data, the data
frequencies showed to be similar. (X2

=

2.1871), p-value 0.534502. The result

is not significant at p < .05. The null hypothesis is accepted.

128
Prior to hypothesis testing, descriptive statistics were computed for the five
research questions in this study. Of the 145 PCPs in this study, 79.3 (n = 115) stated they
knew LD symptoms and felt comfortable diagnosing LD. Almost half (n = 70, 48.3%) of
the PCPs reported that they do not believe CLD/PTLDS exists. A third (n = 44, 30.3%)
reported that they believe CLD/PTLDS may exist but are not comfortable diagnosing
CLD/PTLDS. The smallest group of PCPs (n = 31, 21.4%) reported feeling comfortable
diagnosing and treating CLD/PTLDS. Due to the substantial differences in responses for
all three groups, which resulted in high variance and substantial skewness, the
frequencies and proportions of responses are reported (see Figures10 through 13).
Results for Physicians who Believe Chronic Lyme Disease Does Not Exist
Of the 70 PCPs who reported not believing that CLD/PTLDS exists, 69 (98.6%)
reported the number estimated patients they diagnosed and treated for LD. The mean
number of patients diagnosed and treated for LD was M = 28.00 (Md = 15.00, SD =
42.09). Figure 11 presents (as an asymmetrical bar chart that was converted) in a box plot
of the estimated number of patients (cases) diagnosed with and treated for LD in the past
3 years greatly differed across the individual PCPs who believed CLD/PTLDS does not
exist with a range from no patients (cases) to 300 patients (cases). See Figure 10.
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Figure 10. Boxplot of number of estimated patients (cases) diagnosed with and treated
for Lyme disease in past 3 years. Based on n = 69 PCPs who stated they did not believe
CLD/PTLDS exists. Case #5 through Case #78 had between 50 and 100 patients
diagnosed and treated for LD, while Case #63 had 300 patients diagnosed and treated for
LD in the past 3 years. Scaling is asymmetric.
In Johnson and Feder’s (2010) study, results showed that PCPs diagnosed a total
of 11,970 cases for LD. Sixty-nine (24.2%) PCPs estimated they had diagnosed and
treated 10 to 20 patients for LD in the past 3 years. Six (8.6%) PCPs estimated having
diagnosed and treated no patients for LD in the past 3 years. Five (7.1%) PCPs each
estimated having diagnosed and treated five or 25 patients for LD in the past 3 years.
There were between one and three PCPs, who estimated the numbers of patients they had
diagnosed with and treated for LD. Moreover, in the 2006 sample, the two (2) PCPs who
believed CLD/PTLDS existed, had a mean average of 3.1 patients.
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Results for Physicians who were Unsure and Uncomfortable Diagnosing Chronic
Lyme Disease
All 44 PCPs who felt uncomfortable diagnosing CLD estimated the number of
patients they treated for LD in the past 3 years. The mean number of patients diagnosed
and treated for LD for these 44 PCPs was M = 18.86 (Md = 10.00, SD = 23.19). Figure 13
presents the estimated number of patients diagnosed and treated for LD for these 44
PCPs. The estimated number of patients (cases) diagnosed with and treated for LD in the
past 3 years by the 44 PCPs who were unsure that CLD exists and felt uncomfortable
diagnosing CLD greatly ranged from no patients (cases) to 100 patients (cases). The
largest groups of PCPs were eight (18.2%) and estimated having diagnosed and treated
no patients for LD. The next largest groups of PCPs were 5 (11.4%) and estimated having
diagnosed and treated 5 or 20 patients for LD in the past 3 years. Four (9.1%) PCPS
estimated having diagnosed and treated 30 patients for LD in the past 3 years. There were
between 1 and 3 PCPs who estimated the numbers of patients they had diagnosed with
and treated for LD. See Figure 11.
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Figure 11. Boxplot of the number of patients estimated to have been diagnosed with and
treated for LD in past 3 years. Based on n = 44 PCPs who stated they believe CLD may
exist but felt uncomfortable diagnosing CLD. Case #38 had 80 patients diagnosed and
treated for LD while Case # 113 had 100 patients diagnosed and treated for LD in the
past 3 years.
Results for Physicians who were Comfortable Diagnosing and Treating Chronic
Lyme Disease
Of the 31 PCPs who reported feeling comfortable diagnosing and treating patients
for CLD, 28 (90.3%) provided the estimated number of patients they diagnosed as having
LD in the past three years. The mean number of patients diagnosed and treated for LD for
these 28 PCPs was M = 26.75 (Md = 20.00, SD = 23.47). Figure 14 presents the
frequencies of the number of patients estimated to have been diagnosed and treated for
LD, as reported by these 28 PCPs who responded. Responses as to the number of patients
(cases) estimated to have been diagnosed with and treated for CLD/PTLDS in the past 3
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years ranged from no patients (cases) to 100 patients (cases). Three (9.7%) of the PCPs
each estimated having diagnosed and treated 20 or 30 patients for LD in the past 3 years.
Between 1 and 2 PCPs each respectively estimated having diagnosed and treated between
0 and 100 patients for LD in the past 3 years.

Figure 12. Boxplot for estimated number of patients (cases) diagnosed with and treated
for LD in past 3 years. Based on n = 28 PCPs who stated they diagnosed and treated
patients for LD. Case #138 had 100 patients diagnosed with and treated for LD in past 3
years.
The estimated number of patients diagnosed with and treated for CLD in the past
3 years were also calculated for the group of 31 PCPs who stated they diagnosed and
treated patients for CLD/PTLDS. All 31 PCPs that provided an answer; the mean number
of patients diagnosed and treated for CLD/PTLDS in the past three years was M = 5.84
(Md = 3.00, SD = 10.15). Figure 15 provides the frequencies of patients diagnosed and
treated for CLD/PTLDS in the past three years. The range of estimated patients
diagnosed with and treated for CLD/PTLDS in the past 3 years was from 0 to 51 patients.
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The largest group was the 7 (22.6%) PCPs who estimated diagnosing 0 or 3 patients for
CLD/PTLDS in the past three years, respectively. Four (12.9%) PCPs estimated having
diagnosed and treated patient for CLD/PTLDS within the past three years. Three (9.7%)
PCPs estimated diagnosing and treating 5 patients for CLD/PTLDS in the past three
years. Two (6.5%) PCPs estimated diagnosing and treating 2 or 10 patients each for
CLD/PTLDS in the past three years. One PCP each estimated having diagnosed and
treated 4, 10, 11, or 51 patients for CLD/PTLDS in the past 3 years.

Figure 13. Box plot of estimated number of patients (cases) diagnosed with and treated
for CLD/PTLDS in past 3 years. Based on n = 31 PCPs who stated they diagnosed and
treated patients for CLD/PTLDS. Case #129 had 20 patients, Case #122 had 25 patients,
and Case #137 had 51 patients diagnosed with and treated for CLD/PTLDs in the past
three years.
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Dependent Variable Descriptive Statistics
This study had two dependent variables: the estimated number of patients
diagnosed and treated for CLD/PTLDS in the past three years and the estimated course of
antibiotic treatment (in weeks), as reported by the PCPs who felt comfortable diagnosing
CLD/PTLDS. Table 8 provides the descriptive statistics for the 31 PCPs who reported
feeling comfortable diagnosing and treating patients for CLD/PTLDS. One (3.2%) PCP
estimated diagnosing and treating 51 patients for CLD/PTLDS in the past 3 years (i.e.,
the maximum score). Twenty-four of the 31 (77.4%) PCPs who reported feeling
comfortable diagnosing and treating CLD/PTLDS answered the question about average
antibiotic treatment (in weeks). The descriptive statistics for the course of antibiotic
treatment (in weeks) dependent variable were recorded (Table 8). The estimated average
(mean) course of antibiotic treatment was 12.33 weeks (Md = 8.00, SD = 12.34). Two
(6.5%) PCPs reported an antibiotic treatment course of no weeks (i.e., the lowest value),
and one PCP (3.2%) reported an antibiotic treatment course of 52 weeks (i.e., the highest
value).
Table 8
Estimated Number of Patients Diagnosed and Treated by Primary Care Physicians who
Reported Feeling Comfortable Diagnosing and Treating Chronic Lyme Disease

Number of patients
diagnosed and treated
for CLD
Course of antibiotic
treatment (in weeks)

n

M

Md

SD

Min

Max

31

5.84

3.00

10.15

0.00

51.00

24

12.33

8.00

12.34

0.00

52.00
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Testing of the Normality Assumption
An assumption of the independent samples t-test is that the data is normally
distributed. Normality – must show a normal distribution= around the mean (Kim, 2013).
Samples, Zskewness values, Kolmogorov-Smirnov (K-S) tests, and boxplots were calculated
to test the normality assumption for the variables of CLD/PTLDS case numbers and
course of antibiotic treatment (in weeks). Zskewness values were computed by dividing the
variable skewness value by the skewness standard error (see Table 9). The number of
patients diagnosed and treated for CLD/PTLDS in the past three years had a zskewness value
of 8.10, indicating a violation of the normality assumption. Thus, the normality
assumption was not met and for the analysis of this data it was required to conduct a nonparametric testing. The significant K-S test, shown in Table 9, provided confirmation of
variable skewness and resultant non-normality for the course of antibiotic treatment (in
weeks) variables. The assumption of normality was met. The zskewness value for the
antibiotic treatment course variable was 3.57, also indicative of skewness.
Table 9
Test Values for Estimated Number of Patients Diagnosed and Treated by Primary Care
Physicians Comfortable Diagnosing and Treating Chronic Lyme Disease

Number of patients
diagnosed and treated for
CLD
Course of antibiotic treatment
(in weeks)

N

Zskewness

K-S Value (p)

31

8.10

0.32 (p = .001)

24

3.57

0.22 (p = .004)
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The SPSS unusual cases function indicated that the number of patients diagnosed
and treated for CLD/PTLDS variable had three outlier cases with values of 20, 25, and
51, respectively. Figure 14 presents the boxplot with outliers. Note that the case ID is
presented in the boxplot not the actual variable score. SPSS output does not give the
outlier values, but it does provide ID numbers of the cases. Case 15 had a score of 20,
case 8 had a score of 25, and case 23 had a score of 51. The SPSS unusual cases function
indicated that the course of antibiotic treatment (in weeks) variable had one outlier case.
Figure 15 presents the boxplot with outliers. Case 123 had a score of 52 weeks.

Figure 14. Course of antibiotic treatment in weeks (n = 24). The horizontal line in the
box interior represents the estimated median. Outlier 123 represents the score of 52
weeks.
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Figure 15. Course of antibiotic treatment in weeks (n = 24). The horizontal line in the
box interior represents the estimated median. Outlier 123 represents the score of 52
weeks.
The data collected in this study yielded a non-normal distribution of values for the
estimated number of course of antibiotic treatment PCPs used with patients with CLD
from the distribution of PCPs in 2018. Since the estimated samples mean came from a
small sample size, it was necessary to eliminate outliers to make an estimated sample
mean closer to the true value.
The removal of the three outliers for the number of patients diagnosed and treated
for CLD/PTLDS variable reduced the zskewness value to 2.93, which was lower than the
critical value of 3.00. The removal of the outliers may result in the loss of data points in
this study. It will also affect the mean and median values. When one is removing higher
values, like it is the case here, the mean and the media will decrease, but the mean will
decrease by more than the media. The K-S test remained significant (K-S (28) = 0.219, p
=0.001). The removal of the one outlier for the course of antibiotic treatment (in weeks)
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reduced the zskewness value to 1.87, which was below the zskewness critical value of 3.00.
Moreover, the K-S test was marginally significant, (K-S (23) = 0.18, p = 0.054). The
boxplot indicated no outliers for the number of patients diagnosed and treated for
CLD/PTLDS variable (see Figures 16 & 17).

Figure 16. Number of patients diagnosed and treated for CLD/PTLDS (n = 28). The
boxplot indicated no outliers for the course of antibiotic treatment (in weeks) variable, as
seen in Figure 17.
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Figure 17. Course of antibiotic treatment in weeks (n = 23). The exclusion of outliers
may cause the loss of data and may limited the finding in this study since the survey
response was low. Results need to be taking with caution.
Descriptive statistics for the estimated number of patients diagnosed and treated
for CLD/PTLDS and course of antibiotic treatment (in weeks) variables with outliers
removed are presented in Table 10. The estimated average (mean) number of patients
diagnosed and treated for CLD/PTLDS was M = 3.04 (SD = 3.13), which is very similar
to the median value of Md = 3.00. The estimated number of patients diagnosed and
treated for CLD/PTLDS ranged from 0 to 11. The estimated course of antibiotic
treatment variable mean was M = 10.61 (Md = 8.00, SD = 9.19). Antibiotic treatment
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course ranged from 0 to 32 weeks. The non-skewed dependable variables with mean
scores of 3.04 and 10.61 were used for hypothesis testing of Research Questions 4 and 5.
Table 10
Descriptive Statistics for Estimated Number of Patients Diagnosed and Treated with
Outliers Removed

Number of patients
diagnosed and treated
for CLD
Course of antibiotic
treatment (in weeks)

n

M

Md

SD

Min

Max

28

3.04

3.00

3.13

0.00

11.00

23

10.61

8.00

9.19

0.00

32.00

Answers to the Research Questions
Research Question 1
The first research question posed in this study was as follows: “Are the frequency
distributions of the 2015 sample of Connecticut PCPs across the four primary practice
specialty areas (i.e., family medicine, internal medicine, pediatrics, other) significantly
different from the distributions of the 2006 sample of Connecticut PCPs?”
In this study, the sample was comprised of 28 (19.3%) family physicians, 63
(43.4%) internists, 48 (33.1%) pediatricians, and 6 (4.1%) other PCPs (i.e., emergency
medicine). As this study treated Johnson and Feder’s (2010) 2006 physician data as
population data, a Chi-Square (χ²) goodness-of-fit test was conducted to address the first
research question. A Chi-square (χ²) goodness-of-fit test computes the expected sample
frequencies (numbers) per variable categories based on population category proportions
and compares these computed frequencies to the actual observed sample group
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frequencies (Sharpe, 2015). The expected frequencies (ns) denoted in the following chisquare table represent the expected number of participants per category based on the
2006 and 2015 survey proportions. A non-significant chi-square value (p > 0.05)
indicates that the sample frequency distributions are similar between the 2006 sample
(done in 2008) and the 2015 sample (done in 2018).
The chi-square (χ²) test conducted for Research Question 1 was not significant (χ²
(3, n = 145) = 1.41, p = .703) Therefore, the null hypothesis was accepted since there
were no significant differences and the alternative hypothesis was rejected. The actual
observed PCP group specialty proportions were similar for the 2006 and 2015 samples
(see Table 11). This research question was unique, as it was the only one in the study in
which the null hypothesis failed to be rejected. The non-significant findings indicate that
the 2015 PCP specialty proportional distribution in this study was similar to the historical
data of 2006 (Johnson & Feder, 2010).
Table 11
Chi-Square Test for Primary Care Physician Frequencies in 2006 Versus 2015
Observed (n)

Expected (n*)

Family Physician

28

29

Internist

63

59

48

52

6

5

Pediatrician
Other PCP

Chi-Square (χ²)
1.410
Df
3
Significance (p)
.703
Note. PCP Categories for the 2006 and 2015 samples were similar
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Research Question 2
The second research question pertained specifically to LD: “Are the frequency
distributions of the 2015 sample of Connecticut PCPs among the two knowledge of LD
categories (i.e., know symptoms of LD and feel comfortable diagnosing and treating LD
vs. know LD but do not feel comfortable diagnosing and treating LD) significantly
different from the distributions of the 2006 sample of Connecticut PCPs?” In the 2006
study, 282 (98.9%) of PCPs reported knowing symptoms of LD and feeling comfortable
diagnosing and treating LD while 3 (1.1%) PCPs reported knowing LD symptoms but not
feeling comfortable diagnosing LD. The frequencies of PCPs per knowledge of LD
categories are presented in Figure 18 and Table 12.
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Figure 18. Frequencies of primary care physicians per knowledge of Lyme disease
categories in this and the 2006 study. Chi-square (χ²) results were significant (χ² (df1, n =
145) = 536.83, p < 0.001).
The observed frequency of 30 PCPs in this study who reported knowing the
symptoms of LD but not feeling comfortable diagnosing LD was significantly higher than
the expected frequency of 2 PCPs who reported knowing LD but not feeling comfortable
diagnosing LD. Moreover, the observed frequency of 115 PCPs in this study who
reported knowing the symptoms of LD and feeling comfortable diagnosing LD was
significantly lower than the expected frequency of 144 PCPs who reported feeling
comfortable diagnosing LD. Results of the Chi-square(χ²) test were significant (χ² (1, n =
145) = 536.83, p <.001). Due to the significant findings, the null hypothesis was rejected
(failed to be retained) and the alternative hypothesis was retained for the second research
question, denoting significant differences in the frequencies of PCPs who felt
comfortable (or not) diagnosing LD across the two studies.
Table 12
Chi-square (χ²) Goodness-of-fit Test: Observed and Expected Comfort in Diagnosing LD
Categories (n = 145)
Observed (n)

Expected (n*)

Not comfortable diagnosing LD

30a

2a

Comfortable diagnosing LD

115b

144b

Chi-square (χ²)
df

536.83
1

144
Significance (p)
<0.001
Note. *The expected frequencies are derived from the category percentages (or
proportions) reported by Johnson and Feder (2010). They are not the actual frequencies.
a
The observed frequency of 30 is significantly higher than the expected frequency of 2.
b
The observed frequency of 115 is significantly lower than the expected frequency of
144.
Cohen’s w (Cohen, 1988; Cunningham & McCrum-Gardner, 2007; NCSS, n.d.)
was calculated. The mathematical formula for Cohen’s w is

²̸

(Cohen, 1988; NCSS,

n.d.). Cohen’s w was 1.9, a very large effect size (Cohen, 1988; NCSS, n.d.). Like
Cohen’s d, Cohen’s w can be greater than 1.00, and it indicates a large magnitude in the
frequency or proportion differences between the sample and population (Becker, 2000;
Cohen, 1988). A post hoc power analysis using G*Power was conducted on the total
sample of 145, with an effect size of 1.9, α err prob of .05, and df of 1. The output
provided a noncentrality parameter λ of 523.45, critical χ² of 3.84, and the power was
very high, 1- β= 1.00.

Research Question 3
The third research question was as follows: “Are the frequency distributions of
the 2018 sample of Connecticut PCPs across the 3 knowledge of CLD/PTLDS categories
(i.e., do not believe CLD exists, do not feel comfortable diagnosing and treating
CLD/PTLDS, and feel comfortable diagnosing and treating CLD/PTLDS) significantly
different from the distributions of the 2010 sample of Connecticut PCPs?” Of the 145
PCPs in this study, 70 (48.3%) PCPs reported that they do not believe CLD/PTLDS
exists, 44 (30.3%) reported that they believe CLD/PTLDS may exist but are not
comfortable diagnosing CLD/PTLDS, and 31 (21.4%) reported feeling comfortable
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diagnosing CLD/PTLDS. Johnson and Feder (2010) reported that, of the 285 participants
in their study, 142 (49.8%) PCPs reported that they felt CLD/PTLDS did not exist, 137
(48.1%) stated that they believed CLD/PTLDS might exist but did not feel comfortable
diagnosing CLD/PTLDS, and 6 (2.1%) PCPs reported that they felt comfortable
diagnosing CLD/PTLDS. The frequencies of PCPs per knowledge of CLD categories are
presented in Figure 19.
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Figure 19. Frequencies of primary care physicians per knowledge of chronic Lyme
disease categories. Results from the Chi-square (χ²) goodness-of-fit test, were significant
(χ² (2, N = 145) = 265.41, p < 0.001).
A Chi-square (χ²) goodness-of-fit test was conducted to address the third research
question. Results from the Chi-square (χ²) goodness-of-fit test were significant (χ² (2, n =
145) = 265.41, p <.001) (see Table 14). The observed frequency of 44 PCPs in this study
who reported that they believe that CLD/PTLDS may exist but do not feel comfortable

146
diagnosing CLD/PTLDS was significantly lower than the expected frequency of 70 PCPs
who reported that they believe that CLD/PTLDS may exist but do not feel comfortable
diagnosing CLD/PTLDS, which was based on the population percentages (or
proportions) derived from Johnson and Feder’s (2010) of the historical data. Moreover,
the observed frequency of 31 PCPs in this study who reported feeling comfortable
diagnosing CLD/PTLDS was significantly higher than the expected frequency of 3 PCPs
who reported feeling comfortable diagnosing CLD/PTLDS, which was based on the
population percentages (or proportions) derived from Johnson and Feder’s (2010) from
the historical data. The observed frequency of 70 PCPs who believed that CLD/PTLDS
does not exist was similar to the expected frequency of 72, which was also based on
Johnson and Feder’s (2010) databased on the historical data. Due to the significant
findings, the null hypothesis was rejected (failed to be retained), and the alternative
hypothesis was retained for the third research question, indicating significant differences
the frequency of PCPs who felt comfortable (or not) diagnosing CLD/PTLDS across
studies.
Table 13
Chi-square (χ²) Goodness-of-fit Test: Observed and Expected Comfort in Diagnosing
CLD/PTLDS Categories (n = 145)
Observed (n)
70

Expected (n*)
72

Not comfortable diagnosing CLD

44a

70a

Comfortable diagnosing CLD

31b

3b

Do not believe CLD exists

Chi-square (χ²) goodness-of-fit test
df

265.41
2
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Significance (p)
<0.001
Note. *The expected frequencies are derived from the category percentages (or
proportions) reported by Johnson and Feder. They are not the actual frequencies.
a
The observed frequency of 44 is significantly lower than the expected frequency of 70.
b
There observed frequency of 31 is significantly higher than the expected frequency of 3.
The Cohen’s was 1.35, a very large effect size (Cohen, 1988; NCSS, n.d.). Like
Cohen’s d, Cohen’s w can be greater than 1.00, and it indicates a large magnitude in the
frequency or proportion differences between the sample and population (Becker, 2000;
Cohen, 1988). A post hoc power analysis using G*Power was conducted on the total
sample of 145, with an effect size of 1.35, α err prob of .05, and df of 1. The output
provided a noncentrality parameter λ of 264.26, critical χ² of 3.84, and the power was
very high (1- β=1.00).

Research Question 4
The fourth research question was as follows: “Is the average number of patients
diagnosed as having CLD/PTLDS within a 3-year period by the 2018 sample of
Connecticut PCPs significantly different from the average number of patients diagnosed
as having CLD/PTLDS within a 3-year period by the 2010 sample of Connecticut
PCPs?” This research question required comparisons of data from the PCPs who reported
feeling comfortable diagnosing CLD/PTLDS to data from the population of PCPs who
reported feeling comfortable diagnosing CLD/PTLDS in Johnson and Feder’s (2010)
study.
A one-sample t-test, using data from the adjusted diagnosed or treated for
CLD/PTLDS PCPC group mean (outliers removed) was conducted to address the fourth
research question. In Johnson and Feder’s (2010) study, the average number of patients
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diagnosed and treated for CLD/PTLDS in past years by these 6 PCPs was M = 3.10.
Consequently, the test value mean was 3.10. Results from the first one-sample t-test were
not significant (t (27) = -0.11, p = 0.914). The estimated mean number of patients
diagnosed and treated for CLD/PTLDS in the past three years as reported by the 28 PCPs
(M = 3.04) was not significantly different than the mean of 3.10, as reported in Johnson
and Feder’s (2010) study.
Research Question 5
The fifth research question was as follows: “Is the average course of antibiotic
treatment (in weeks) for patients diagnosed as having CLD/PTLDS by the 2018 sample
of Connecticut PCPs significantly different from the average course of antibiotic
treatment (in weeks) for patients diagnosed as having CLD/PTLDS by the 2010 sample
of Connecticut PCPs?” The fifth research question required comparing data from the 23
PCPs (one outlier removed) that provided an answer to the antibiotic treatment course
variable. The population was the 6 PCPs who reported feeling comfortable diagnosing
CLD/PTLDS in Johnson and Feder’s (2010) study.
To address the fifth research question, a one-sample t-test, using the antibiotic
course of treatment (in weeks) variable estimated mean of 9.74, was conducted. In
Johnson and Feder’s (2010) study, the estimated average course of antibiotic treatment
(in weeks) for the 6 PCPs who felt comfortable diagnosing and treating patients for
CLD/PTLDS M = 20.00. Consequently, the test value mean was 20.00. Results from the
second one-sample t test were significant (t (22) = -4.90, p < 0.001). The estimated
average course of antibiotic treatment (in weeks) as reported by the 23 PCPs in this study
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(M = 10.61) was significantly lower than the mean of 20.00 weeks, as reported in
Johnson and Feder’s (2010) study. Consequently, the null hypothesis was retained, and
the alternative hypothesis was rejected.
Summary
The purpose of this nonexperimental cross-sectional comparative research study
was to determine if two groups of PCPs working in Connecticut – the 285 PCPs in
Johnson and Feder’s (2010) study and the 145 PCPs in this study – reported significant
differences in their KAP in the diagnosis, treatment, and management of LD (LD) and
CLD/PTLDS. Data collection occurred in the summer of 2018, utilizing a USPS-mailed
survey process. Of the 1,726 survey packets mailed to the PCPs, 219 (12.7%) were
returned due to an incorrect address. 1,507 (87.4%) PCPs received the study packet via
USPS mail. The number of survey packets returned to the researcher was 179, resulting
in an initial 11.7% response rate. The removal of 34 surveys from the data set for various
reasons (e.g., the PCP not providing informed consent, PCP was retired) yielded a final
sample of 145 and a final response rate of 11.9%.
Due to the inability to obtain Johnson and Feder’s raw data, the comparison data
were drawn from the information presented in Johnson and Feder’s (2010) their
published study. The data from their study were treated as population data, and these data
from the 285 PCPs were compared to the data from the sample of 145 PCPs in this study.
The five research questions were answered using population-based statistical analyses,
namely Chi-square (χ²) goodness-of-fit tests and one- sample t-tests. These inferential
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analyses coupled with descriptive statistical analyses yielded pertinent information on
key LD and CLD/PTLDS diagnosis and treatment factors.
The first research question inquired as to whether the PCP specialty area
frequency distributions (i.e., family medicine, internal medicine, pediatrics, other) of the
145 PCPs in this study were significantly different from the PCP specialty area frequency
distributions of the 285 PCPs in Johnson and Feder’s (2010) study. Results from a (χ²)
goodness-of-fit test were not significant. This research question was unique, because it
was the only one in the study in which the null hypothesis failed to be rejected. The
nonsignificant findings indicated that the PCP specialty frequency distributions of family
physicians, internists, pediatricians, and other PCPs (i.e., emergency medicine) in this
study were similar to the PCP specialty frequency distributions in Johnson and Feder’s
(2010) study.
The second research question examined if the knowledge of LD category
frequency distributions in this study significantly differed from the LD knowledge
category frequency distributions in Johnson and Feder’s (2010) study. Results from the
Chi-square (χ²) goodness-of-fit test, which was conducted to address the second research
question, were significant. There was a significantly lower frequency of PCPs (n = 115,
79.3%) in this study who reported that they knew LD symptoms and felt comfortable
diagnosing LD than the frequency of PCPs (n = 282, 98.9%) who reported that they knew
LD symptoms and felt comfortable diagnosing LD in Johnson and Feder’s study. Due to
the significant findings, the null hypothesis was rejected (failed to be retained) for the
second research question.
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The third research question examined if the frequency distributions across the 3
knowledge of CLD/PTLDS categories in this study were significantly different from the
CLD knowledge category frequency distributions in Johnson and Feder’s study. Results
from the Chi-square (χ²) goodness-of-fit test conducted to address the third research
question were significant. There was a significantly higher frequency of PCPs (n = 31,
21.4%) in this study who reported feeling comfortable diagnosing CLD/PTLDS as
compared to the frequency of (2.1%) PCPs who reported feeling comfortable diagnosing
CLD/PTLDS in Johnson and Feder’s (2010) study. There was a significantly lower
frequency of PCPs (n = 44, 30.3%) in this study who believed CLD/PTLDS might exist
but did not feel comfortable diagnosing CLD/PTLDS as compared to the frequency of
137 (48.1%) PCPs in Johnson and Feder’s study who stated that they believed
CLD/PTLDS might exist but did not feel comfortable diagnosing CLD/PTLDS. It should
be noted, however, that the frequency distributions of PCPs who reported that they did
not believe CLD/PTLDS exists were similar for both studies: 70 (48.3%) PCPs in this
study and 142 (49.8%) PCPs in Johnson and Feder’s study reported that CLD/PTLDS did
not exist. Due to the significant findings, the null hypothesis was rejected (failed to be
retained) for the third research question.
The fourth research question inquired as to whether the average number of
patients diagnosed as having CLD/PTLDS within a 3-year period as reported by the PCPs
in this study significantly differed from the average number of patients diagnosed as
having CLD/PTLDS within a 3-year period as reported by those in the previous study.
This research question required statistical comparisons of data from the 31 PCPs who
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reported feeling comfortable diagnosing CLD/PTLDS to data from the population of 6
PCPs who reported feeling comfortable diagnosing CLD/PTLDS in Johnson and Feder’s
study. Statistical testing for skewness (i.e., computation of zskewness values and K-S test)
revealed that the number of patients diagnosed and treated for CLD/PTLDS among these
31 PCPs was considerably skewed. The removal of 3 outliers reduced the degree of
skewness. While the zskewness value was acceptable, the K-S test remained significant.
Results from the one-sample t-test conducted with 28 PCPs (outliers removed) were not
significant. The 28 PCPs reported an average of 3.04 patients whom they had diagnosed
as having CLD/PTLDS within the past 3 years, which was remarkably similar to the
mean of 3.10 patients diagnosed with CLD/PTLDS in the previous study. The null
hypothesis for the fourth research question was retained (failed to be rejected).
The fifth and final research question for this study assessed if the median course
of antibiotic treatment (in weeks) range of response for patients diagnosed as having
CLD/PTLDS significantly differed between 23 PCPs in this study and the PCPs in
Johnson and Feder’s study. Statistical testing for skewness (i.e., computation of zskewness
values and K-S tests) revealed that the course of antibiotic treatment (in weeks) variable
was skewed. However, after the removal of one outlier, the zskewness value was acceptable,
and the K-S tests was no longer significant. A one-sample t-test conducted for the fifth
research question was significant. The approximately 10 week course of antibiotic
treatment reported by PCPs in this study was significantly lower than the 20-week course.
Is this consistent with your previous description of the answer to RQ5 reported by the
PCPs in Johnson and Feder’s (2010) study. Due to significant findings, the null
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hypothesis for the fifth research question was rejected (failed to be retained). The
following chapter ends the dissertation study. It provides discussions in relation to the
guiding theories of this and previous research studies as well as the study’s le limitations
and recommendations for application or practice and future research.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
Due to the absence of a case definition, known biological agent, and lack of
reliable laboratory testing, CLD/PTLDS remains a controversial diagnosis (Johnson &
Feder, 2010; Lantos, 2015a; Maloney, 2016, Stricker & Fesler, 2018). The controversy
and lack of clarity surrounding CLD/PTLDS have impeded understanding of health care
providers’ diagnosis, treatment, and management of patients (Lantos, 2015a; Maloney,
2016). Further research is necessary to understand and improve the health practices and
methods for PCPs when addressing a diagnosis of CLD/PTLDS (Johnson & Feder, 2010;
Lantos, et al., 2010; Lantos, 2015a; Stricker & Johnson, 2008).
The purpose of this nonexperimental, cross-sectional, comparative study was to
compare CLD/PTLDS knowledge, attitudes, and treatment/practice differences on the
how frequently they diagnosed and treated (antibiotics used) patients for LD and
CLD/PTLDS in the last 3 years. This study was a replication of Johnson and Feder’s
(2010) seminal study, with the same sampling and methodological practices and survey
instrument. The sampling frames for the two studies was the CT DPH database of
MD/DOs, with Johnson and Feder (2010) using 2006 data and this study using 2015 data.
As Johnson and Feder’s whole dataset could not be obtained, comparisons were made
between the data in this study and the available data reported in their study, with their
sample treated as the population. Additional data used to complement those in Johnson
and Feder’s (2010) study were retrieved from https://portal.ct.gov and
http://www.publichealth.uconn.edu.
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The initial data analyses was focused on assessing whether the survey
dissemination and aspects of the two samples were similar. The response rate of 11.7%
was significantly lower than the response rate of 39.1% reported by Johnson and Feder
(2010). The survey dissemination factors were largely similar. Moreover, it was found
that the two Connecticut PCPs were similar with regard to PCP specialty.
This study had five research questions. Results for the first question were not
significant, indicating that both studies had similar numbers of PCPs across specialty
areas (i.e., family medicine, internal medicine, pediatricians, and other). The similarities
between the two study samples allowed for an increased accuracy in statistical
comparisons and enhanced the internal validity of the study. Results for the second and
third research questions showed a smaller percentage of PCPs reported feeling
comfortable diagnosing LD compared to the percentage of the 2006 sample of PCPs. In
contrast, there was a much larger percentage of PCPs who reported feeling comfortable
diagnosing CLD in this study compared to the percentage of the 2006 sample of PCPs.
This finding shows the need for social change in the ways PCPs may be dealing with
such patients versus the PCPs who do not believe in the diagnosis for CLD/PTLDS.
The fourth research question required the use of a one-sample t test, using the
adjusted sample mean value of 3.04. The population sample mean was 3.10 patients. The
t test was not significant, indicating that the number of patients diagnosed and treated for
CLD/PTLDS did not significantly differ across the two groups of PCPs. The fifth
research question also involved a one-sample t test to determine if the adjusted mean of
10.61 weeks found in this study was significantly different from the mean of 20 weeks
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reported by Johnson and Feder. Results from the t test indicated that PCPs in this study
reported a significantly lower course of antibiotic treatment (in weeks) compared to the
2006 sample of PCPs.
This chapter provides a comprehensive overview of the study findings. The
chapter opens with an interpretation of findings section, which includes a review and
discussion of findings concerning prior literature, especially Johnson and Feder’s (2010)
study, and the guiding theories of the study. The chapter continues with a Study
Limitations section, where recommendations for future health care practices and
suggestions for future empirical study are denoted. The topics under discussion in the
penultimate section of the chapter, Implications, pertain to the study’s potential for
positive social change. Recommendations and a Conclusion section end the chapter.
Interpretation of Findings
The intent of this study was to validate Johnson and Feder’s (2010) seminal study
to examine the differences between two groups of Connecticut PCPs regarding their
diagnosis, treatment, and management of LD and CLD/PTLDS (health professionals tend
to prefer to use PTLDS instead of CLD, and PTLDS is a term accepted by the CDC). This
study emphasized the potential differences in the responses provided by the PCPs
regarding their knowledge and attitudes about LD and CLD/PTLDS when Johnson and
Feder conducted their study using PCPs distributions in 2006 and PCP distributions in
2015 (the data in this study). In alignment with Johnson and Feder, I focused on PCPs
who work in the state of Connecticut, as this type of physician is most likely to engage
with patients who demonstrate symptoms of LD and CLD/PTLDS (Ali et al., 2014;
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Johnson et al., 2014). The emphasis on differences required a guiding theory that
suggests why a medical idea or concept is adopted by the medical community. The
diffusion of innovations theory provided the lens to examine potential differences
between the two groups of PCPs in this study, which aligned with the KAP approach of
this study. In the following sections of the chapter, I present and discuss the findings in
relation to prior research, especially Johnson and Feder’s study and the diffusion of
innovation theory.
This study was a replication of Johnson and Feder’s (2010) study conducted with
285 PCPs working in the state of Connecticut. The first research question acted as a
validity check to determine if the PCP specialty area frequency distributions were similar
in this study and Johnson and Feder’s study. The lack of significant findings indicated
that both studies had similar numbers of PCPs across specialty areas (i.e., family
medicine, internal medicine, pediatricians, and other). The similarities between the two
study samples allowed for an increased accuracy in statistical comparisons and enhanced
the internal validity of the study.
The second and third research questions helped examine whether there were
significant differences in the frequency distributions of PCPs who felt comfortable
diagnosing LD or CLD in this study as compared to Johnson and Feder’s (2010) study. In
this study, a smaller percentage of PCPs reported feeling comfortable diagnosing LD
(79.3%) compared to the percentage of PCPs who reported feeling comfortable
diagnosing LD (98.9%) in Johnson and Feder’s study and the percentage (99%) in a
previous study by Ferrouillet et al. (2015). In contrast, there was a much larger
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percentage of PCPs who reported feeling comfortable diagnosing CLD (12.6%) in this
study compared to the percentage of PCPs who reported that feeling comfortable
diagnosing CLD (2.1%) in Johnson and Feder’s study. The significant findings for the
second and third research question suggest that PCPs in Connecticut may feel
increasingly comfortable diagnosing and treating CLD. However, there are still many
gaps in implementing a common case definition for CLD using evidence-based research,
something that is limited at this time.
The diffusion of innovation theory provided the framework to understand these
findings. In this study, the innovative health care practice was the diagnosis and treatment
of CLD/PTLDS. The diffusion process pertained to changes in PCP knowledge, attitudes,
and practices regarding CLD/PTLDS over a 10-year period (i.e., between 2008 and
2018). Study findings support diffusion of innovation’s theoretical intent regarding the
diagnosis and treatment of CLD/PTLDS. The six (2.1%) PCPs in Johnson and Feder’s
(2010) study can be considered innovators, rare physicians who felt that CLD/PTLDS
was a meaningful, real, and diagnosable disorder. The increase from 2.1% to 21.4% of
PCPs who felt comfortable diagnosing CLD in the past 10 years suggests that
CLD/PTLDS diagnosis and treatment has gone from the innovation stage to the early
adoption stage.
The diffusion of innovation theory also has implications for the findings regarding
the average course of antibiotic treatment. The average course of treatment reported by
the 17 PCPs who felt comfortable diagnosing and treating CLD in this study was
significantly lower than the course of treatment reported by the six PCPs in Johnson and
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Feder’s (2010) study. However, when considering this finding within the context of
diffusion of innovation, it could be that the change from the innovation to adoption stage
of CLD diagnosis and treatment has resulted in an improved treatment procedure. That is,
being wary of the problems associated with antibiotic treatment (e.g., over-prescribing.
Increasing resistance, side effects), the PCPs in this study may have learned that a shorter
effective antibiotic treatment course was as effective as a longer one.
The diffusion of innovation theory has less clear implications for the findings
regarding the number of patients diagnosed and treated for CLD/PTLDS in the past 3
years. The mean of 3.10 patients reported by Johnson and Feder (2010) and used in
analyses is an adjusted value. Johnson and Feder removed one outlier to obtain this value.
The number of patients diagnosed as having CLD/PTLDS was twice as high in this study
as compared to Johnson and Feder’s study when the two outliers were retained in the data
set (i.e., 6 to 3). In contrast, the adjusted mean value of 3.04 patients—obtained by
removing two outliers—was similar to the 3.10 patients reported by the six PCPs in
Johnson and Feder’s study. However, the course of antibiotic treatment (in weeks) was
significantly lower in this study compared to Johnson and Feder’s study. These differing
findings suggest that, despite an increase in the number of PCPs who report feeling
comfortable diagnosing and treating CLD in the past 10 years, PCPs are hesitant to
diagnose and treat their patients for CLD and are cautious about prescribing a long course
of antibiotic treatment for CLD. Although the acceptance of CLD diagnosis and
treatment has gone from the innovation to the adoption stage, the actual diagnosis and
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treatment of CLD remains in the innovation stage. There were limitations in this study
that likely influenced the findings in this study, which are discussed in the next section.
Limitations of the Study
This study had some limitations. One weakness was the small response rate of
11.9 %, especially when comparing it to the response rate of 33.9% reported by Johnson
and Feder (2010). Although 179 surveys were returned by the PCPs, 34 surveys had to be
discarded for a variety of reasons, most notably that the physician who completed the
survey was not a PCP or that the physician was a PCP but no longer practiced or did not
provide informed consent. When comparing both distributions with and without the 34
omitted surveys untabulated in this study, the loss of data did not seem to affect the
frequency distributions of the PCP specialty areas, as they were similar across this study
and Johnson and Feder’s study. Related problems were the small sample size of 31 PCPs
who reported feeling comfortable diagnosing and treating CLD/PTLDS. In addition, there
were missing data or outliers in the responses related to the number of patients diagnosed
and treated for CLD/PTLDS in the past 3 years and the average course of antibiotic
treatment for them. Therefore, the results from the one-sample t test regarding the
number of patients diagnosed and treated for CLD/PTLDS should be interpreted with
caution.
Other limitations concerned the PCPs’ survey answers and the survey itself.
Despite being asked to provide a numerical value when answering the questions
regarding the number of patients diagnosed and treated for LD or CLD/PTLDS, a small
number of PCPs provided answers such as “many, many” or “a few.” These responses
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made it difficult to interpret the exact number of diagnosed and treated patients.
Moreover, when answering the question regarding the average course of antibiotic
treatment for patients with CLD/PTLDS, some PCPs provided answers in months or days
instead of weeks, and a small number of PCPS provided a range of values (i.e., 3 to 6
months). These types of responses resulted in having to estimate values. Additionally,
there was limitation with the survey because of a small inconsistency in the language
used with the term CLD, which should have been consistently stated as CLD/PTLDS.
Nonetheless, the questions used in the survey were the same Questions 1-9 used by the
previous researchers, so it should not affect much the construct validity of the study.
Another limitation of this study concerned methodological biases that may have
influenced study findings. The percentage (or proportion) of PCPs who were comfortable
diagnosing CLD/PTLDS (21.4%) in this study was significantly higher than the 2.1% of
the PCPs reported in Johnson and Feder’s (2010) study. The participation bias may play a
role in this finding. PCPs who believe that CLD/PTLDS exists may have been more
likely to participate in this study, so the 21.4% value may not reflect the actual population
percentage (or proportion), which is an issue when considering the low response rate.
Alternatively, the 21.4% value may be a result of the social desirability bias. That is,
some PCPs may not have reported their actual belief—that CLD/PTLDS exists—as this
belief contradicts the current mainstream medical opinion.
Another potential concern in this study was recall bias. PCPs were asked to recall
the number of patients they diagnosed and treated for LD and CLD/PTLDS in the past
three years. A 3-year span is quite long, especially considering the number of patients
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that PCPs see daily. As such, the PCPs may have under- or over-reported the number of
patients they diagnosed as having LD or CLD/PTLDS.
Another limitation of the study pertained to the study recruitment period as it
relates to the mailing of the survey packets. Recruitment and the mailing of survey
packets occurred during summer. The summer is a difficult season to recruit study
participants, especially physicians, as professionals often take extended time off for
vacations and traveling (Johnston et al., 2010). Physician recruitment seems to improve
during the spring and winters (Johnston et al., 2010; PRA, n.d). Moreover, the survey
packets were mailed on Mondays or Saturdays, with physicians receiving the packets
early or late in the workweek. Study survey completion rates contribute to be higher on
Tuesdays or Wednesdays (Bowling, 2014; PRA, n.d.). These two-timing factors may
have contributed to the poor return rate response. It is possible that an electronic survey
would be better, as other researchers have suggested that they are faster and cheaper to
reach to PCPs through their medical societies or in conferences that they will be attending
(Dobrow et al., 2008). However, due to the increase of cyberattacks, PCPs may be
reluctant to take part in electronic surveys because they care about keeping their patient
records safe. For example, out of 10 medical doctors, eight had experienced a cyberattack
in practice (American Medical Association, 2017).
Lastly, the study database used in this study have limited information about the
participants in this study. This kind of database only keeps the license number, first
name, last name, address (most of the time is work), city, state, zip code, issue date,
expiration date, degree type, and specialty. This type of MD/DO database does not have
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information about gender, age, or race, meaning certain data descriptive data from the
participants to describe the populations under the study were unavailable. Thus, it was
challenging to provide evidence that the samples of the two surveys (2006 vs. 2015) were
comparable, and it is not possible to make inferences about the gender, age, and race
presented in this study from the PCPs who responded to the surveys.
Recommendations
There is a 10-year gap between this and Johnson and Feder’s (2010) seminal
study. There remains a relative absence of contemporary studies—quantitative or
qualitative—on physicians’ knowledge, attitudes, and treatment of CLD/PTLDS.
Moreover, both this and Johnson and Feder’s study were conducted with Connecticut
PCPs, with contact information gathered from the CT DPH MD/DO databases for 2006
and 2015. Thus, the findings can only be generalized to the PCPs who responded and
whose contact information is listed in the CT DPH MD/DO databases. These two factors
emphasize the need to conduct more epidemiological/public health empirical work to
refine knowledge and understanding of the CLD/PTLDS diagnosis rates among PCPs and
physicians in general.
As findings in this study can only be generalized to PCPs in Connecticut, a need
exists for replication studies that extend beyond the Connecticut PCP population to
include state and preferably national samples of PCPs. There is a need for cross-state
studies on whether KAP differences regarding PTLDS/CLD occur across PCPs practicing
in different geographical regions, states, or even countries. Studies that compare
PTLDS/CLD KAPs among PCPs who practice in states with low versus high rates of
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PTLDS/CLD would be especially beneficial. Other types of needed studies are (a) causal
comparative studies that examine PTLDS/CLD KAP differences between PCPs that
differ with regard to demographics (gender, age), education, and training experience; (b)
correlational studies that examine if significant relationships exist between PCPs’
attitudes toward PTLDS/CLD diagnosis, primary symptomatology, and perceived
severity/health impact and the number of patients diagnosed with and treated for
PTLDS/CLD; and (c) longitudinal studies that follow one set of physicians/PCPs over
time and measure changes in PTLDS/CLD (and LD) diagnostic and treatment practices.
Qualitative empirical work, such as phenomenological studies that capture PCPs’
experiences diagnosing and treating PTLDS/CLD and case studies on PTLDS/CLD
diagnostic and treatment modalities, would complement the quantitative research on the
study topic.
As this was a validation study of Johnson and Feder’s (2010) work, it utilized
these authors’ survey. There exists a need for validation studies that assess the
psychometric quality of Johnson and Feder’s (2010) study. Do to the controversy
surrounding the term CLD and the lack of a case definition for this disease (Borcher et
al., 2015), it would be interesting to see if differences emerge if different groups of PCPs
answer questionnaires that have the same questions but use the terms CLD, PTLDS, or
PTLDS/CLD. There is also a need to develop and psychometrically test more
comprehensive questionnaires that inquire not only about PCPs’ demographics (e.g., age,
gender) and education and training, but also delve into PCPs knowledge about
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PTLDS/CLD, its diagnostic criteria, and recommended treatment protocols, as well their
actual treatment protocols for their own patients diagnosed with PTLDS/CLD.
Specific aspects of this study and study findings provide a guide for future
studies. Findings in this study indicated that a lower percentage (or proportions) of PCPs
reported feeling comfortable diagnosing LD as compared to the PCPs in Johnson and
Feder’s (2010) study. This finding is intriguing and suggests that studies examining
changes in LD diagnostic rates among PCPs and physicians would be beneficial. The
estimated course of antibiotic treatment (in weeks) for patients with CLD/PTLDS was
similar in this and Johnson and Feder’s (2010) study. It is unknown whether the course
of treatment reported by the PCPs in this and Johnson and Feder’s (2010) study is typical
among Connecticut PCPs and PCPs in general. Additional work is needed to obtain a
better understanding of PCPs’ reported average course of antibiotic treatment for
CLD/PTLDS as well as the type and dosage of antibiotic prescribed for CLD/PTLDS, as
this type of information is currently unknown. Finally, CLD/PTLDS antibiotic treatment
efficacy studies are warranted, especially experimental studies that examine the effects of
different antibiotic types, dosages, and course lengths on CLD/PTLDS symptomatology.
However, it would unethical to conduct clinical trials when there is not a known
etiological agent to understand its susceptibility to antibiotics. Conducting epidemiology
research would be an appropriate starting point.
The uncertainty regarding the cause, origin, and specific diagnostic criteria of
CLD/PTLDS is concern among physicians (Greenberg, 2017; Halperin, 2015). Olson,
Graber, and Singh (2018) stated the difficulty that medical doctors may have when
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coming across “undesirable diagnostic events (UdesF)” due in significant part to the lack
of standardization making impossible to have health professionals to make an accurate
and timely diagnosis. The majority of the PCPs in Connecticut, as well as the CDC, and
the National Institute of Allergy and Infectious Diseases may want to adopt a
reconciliation position that will eventually help CLD/PTLDS patients indirectly since
they may feel the same way as Olson et al. (2018). One way to adopt a reconciliation
position is by utilizing a new practice diagnosis as PTLDS.
By adopting a new practice diagnosis as PTLDS, the CDC, the National Institute
of Allergy and Infectious Diseases, and the PCPs in Connecticut can do and document
PTLDS diagnosis. At the same time, it will be a good thing for the patients because they
can get most of their medical bills accepted by their health insurance, which is not a
perfect solution to alleviate the tensions between PCPs and presumed CLD/PTLDS
patients. However, it is a position in the middle that may unite PCPs from that belongs to
the Infectious Diseases Society of America and ILADS.
It would also be beneficial if CT DPH, the Connecticut Medical School,
Connecticut Convergence Institute for Translation in Regenerative Engineering would
initiate “blood serum clinics” from those people or patients who are feeling afflicted with
PLTDS/CLD. In the past, serological surveys and clinics have generated new insights for
the discovery and cure of infectious agents that became new diseases in the United States
(e.g., AIDS, syphilis) and nowadays, there are a standardized diagnosis and acceptable
treatment protocols (Metcalf et al., 2016). Additionally, parallel applications should be
dedicated to finding more about CLD/PTLDS. Without a CLD/PTLDS’s case definition,
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it would be unfair to assess what are the best PCP practices to diagnose and treat patients
for CLD/PTLDS. There should be resources to find more important issues pending and
presently unsolved pertinent to the uncertainty of CLD/PTLDS as new disease (if this is
the case) as: (a) aids in the identification, if applicable, of a known biological agent
involved in CLD/PTLDS; (b) reconcile concerns regarding Borrelia burgdorferi
exposure studies that refine the laboratory testing of LD and CLD/PTLDS agents; and (c)
move toward a medically-informed consensus of CL/PTLDS symptomatology and
diagnostic indicators (Greenberg, 2017).
Implications
Epidemiological studies that will assess CLD/PTLDS prevalence/incidence rates
and LD-CLD/PTLDS correspondence rate (i.e., how many patients diagnosed with LD go
on to develop CLD/PTLDS) would be especially worthwhile. Epidemiological studies
that will assess CL/PTLDS prevalence/incidence rates and LD-CLD/PTLDS
correspondence rate will help to minimize the current polarized understanding regarding
CLD/PTLDS that has created a dispute among many medical professionals, including
mainstream community PCPs (Marzec et al., 2017). Since there is not a case definition
for CLD/PTLDS, PCPs in Connecticut should compromise to accept PTLDS and start
collecting information about PTLDS.
The comparative findings found between this study and Johnson and Feder’s
(2010) study presented in this cross-sectional investigation contradict and complement
one another within the same alignment of the literature review presented in chapter 2.
This study and Johnson and Feder’s (2010) study have similar findings to affirm the need
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for more studies to find (a) the identification (if any) of a biological agent involved in
CLD/PTLDS; (b) associations between LD and CLD/PTLDS (d) CLD/PTLDS diagnostic
criteria; and (e) CLD/PTLDS treatment ‘best practices. It would be improper for PCPs to
have an effective standardized treatment if they do not know if the agent causing
CLD/PTLDS is infectious or not. Moreover, there is the pressing need for more studies to
find if there are any relationships between LD biofilms and late antibiotic treatment,
associated the prevalence of CLD/PTLDS, that at this time is unknown.
Moreover, without any doubts, the study findings affirm the need for new
conversations between PCPs, government officials (local, state, and federal), and patients
to allocate financial resources for further medical and epidemiological investigations
regarding CLD/PTLDS. In addition, the study findings will help to create universal
guidelines for the best optimal treatment for patients affected by CLD. Additionally,
results from this study suggest that medical doctors may find it challenging to treat
patients potentially suffering from CLD/PTLDS.
It is hoped that the knowledge generated in this study can be applied by
physicians to understand their pursuit of eliminating and minimizing morbidity and
mortality among their patients. Facing the need to force better practices for the
CLD/PTLDS diagnostic and treatment acumen will promote their sensitivity and
understanding when dealing with patients who report CLD/PTLDS symptoms. The
increasing rate of PCPs who diagnose and treat CLD/PTLDS, as evidenced in this study,
denotes a need for change in medical policies to make the CLD/PTLDS diagnosis more
cost-effective, and legitimate to be documented in a new electronic surveillance system.
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Additionally, the results of the study may help federal and state government health care
organizations (e.g., CT DPH, CDC) to urgently fund more studies to find the etiological
agents of CLD/PTLDS, to consequently develop and implement educational programs,
new policies and services that equip PCPs to have a standardized diagnosis and treatment
system across all medical doctors’ categories.
It is the intent of the researcher to develop, complete, and publish empirical
manuscripts from this study. Attention will be given to publishing in peer-reviewed
epidemiology and public health journals, in partnership with the previous researchers
(i.e., Johnson & Feder, 2000) and Walden University mentors. The study data set is
robust enough to publish results noted in this study as well as findings on additional
information gleaned from the data set. The dissertation manuscript will be published
through ProQuest and made available to Walden University professors and students.
Conclusion, Future Research, and the Need for Social Change
As posited by Johnson and Feder (2010), the diagnosis and subsequent treatment
of CLD/PTLDS remain challenging and controversial issues for PCPs in Connecticut.
PCPs, such as internists, pediatricians, family, and emergency medicine physicians, are
often the first to diagnose and treat LD. Nonetheless, in this study it was found that LD is
not as straightforward diagnosed and treated as in the previous study done 10 years ago
or maybe not as many physicians feel comfortable diagnosing regular LD anymore. This
is an interesting point to move the message in this research to create social change and it
is interesting since it looks like especially LD has strong scientific evidence to back it up.
Nonetheless I think physicians may prefer evidence-based medicine, but when a disease
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emerges that they do not know how to treat or have treated unsuccessfully using the
standard of care, they resort to case based reports or expert opinions, lower levels of
evidence. Thus, the data from this study process show how PCPs diagnose and treat
CLD/PLTSDS as an emerging disease that still requires a scientific explanation and more
research is needed. PCPs must remain attentive to the possibility that 3 to 28% of these
patients may develop CLD/PTLDS. Often, PCPs do not have the means or the time to
explore and investigate the causes of CLD/PTLDS symptoms, nor are they able to
provide a holistic and ongoing evaluation and treatment protocol for CLD/PTLDS
patients. Patients with CLD/PTLDS, both self-diagnosed or diagnosed by a PCP,
frequently suffer in silence. Ultimately, CLD/PTLDS patients’ health-related quality of
life and daily functioning may be impaired due to these controversies.
Despite the substantially higher number of 285 PCPs in the previous study, the
proportional distributions of internists, pediatricians, and family and emergency medicine
physicians were similar to those in this study (Figure 20). It can be accounted that in
Connecticut, the numbers of PCPs grow or diminish not more than 20% of any previous
year. The mean number of patients diagnosed for CLD/PTLDS by PCPs and the
estimated average course of antibiotic treatment (in weeks) did not significantly differ
between this study and Johnson and Feder’s (2010) study. However, significantly fewer
PCPs were comfortable diagnosing and treating LD in this study. This study and Johnson
and Feder’s (2010) study may collectively provide insight regarding PCPs’ KAP on
CLD/PTLDS based on their survey responses.
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Certfied PCPs from the list of MD/DO in CT in 2006 and
2015 expressed in percentages
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Figure 20. Percentages (or proportions) of the total numbers of primary care physicians
in the categories used in this study. Total numbers did not change more than 20%. This
type of information is very limited to be share. Thus, it would be more meaningful to be
able to show how the how the PCPs increase or decrease in such specialty, but such
information is well protected by at the CT DPH.
Moreover, this manuscript points out how the substantial majority of PCPs voice
discomfort and concern when diagnosing and treating LD and CLD/PTLDS. Some
patients diagnosed with LD, much less CLD/PTLDS, may never have reported a tick bite
or show the EM rash (Allen et al., 2016; Gasmi et al., 2017). There are existing PCP
customary practices (meaning PCPs want to diagnose their patients adopting an evidencebased approach); PCPs and other health care providers want to diagnose and treat all
patients without any bias, which means they want to conduct a proper medical health
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assessment on their patients to find why they are sick (Ebell, Sokol, Lee, Simons, &
Early, 2017). There may be some limitations when requesting an exact diagnostic test for
CLD/PTLDS patients because there is no known biological agent, which prevents
potential medical tests for CLD/PTLDS (Lantos, 2015c). Therefore, PCPs may not be
comfortable with CLD/PTLDS diagnosis because there is no cost-effective clinical
testing to back it up and recommended treatment (Ebell et al., 2017; Lantos, 2015a).
Consequently, the lack of a consensus on a CLD/PTLDS case definition among
leading medical organizations will continue until there are further discoveries related to
this condition (Stanek et al., 2010; Stricker & Fesler, 2018). The lack of a case definition
has important implications. The World Health Organization (2016) who developed ICD
classification codes (see Table 2) to identify a patient’s specific health condition, as well
as the respective billing code to health insurance companies, has not assigned an ICD
classification code for either CLD/PTLDS (CDC, 2017; World Health Organization,
2016). PCPs may be highly reticent in diagnosing a patient with CLD/PTLDS if they
cannot follow standardized protocols to have their patients be reimbursed by their
insurance companies or non-coverage policies.
This study may instigate a consciousness of how difficult it may be for a PCP to
better assist patients with CLD/PTLDS; this may be because the existing guidelines for
infectious diseases do not consider CLD a disease that affects people in Connecticut
(where LD was discovered) or in the United States. For example, the American Academy
of Pediatrics presently (as 2017) stated that they do not consider CLD/PTLDS a medical
diagnosis (Korioth, 2017). It is necessary for organizations (i.e., World Health
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Organization, CDC, National Institute of Health, and the CT DPH) to hold conversations
that contribute to future innovations and practices. However, to accomplish this, they
need a consensus on the most recent data collected from the care given to patients with
CLD/PTLDS.
In the study, the survey was random and anonymous, so there was limited
opportunity for the participants to exchange an active dialogue with the researcher of this
study. Nonetheless, there was at the end of the survey space for PCPs to write comments
(see Appendix A). This chapter ends with a list of specific gaps in knowledge as well as
applied practice recommendations:
•

The current treatment data lack specificity since the previous data on
standardized “treatments” (including alternative treatments) can be applied to
persons under specific CLD/PTLDS clinical conditions.

•

The present CLD/PTLDS data published up to 2019 cannot be well
characterized and it will be not useful for surveillance, prevention, or control
of disease to eliminate mortality and morbidity.

•

In the future, it helps to determinate the geographical locations of patients
afflicted by CLD/PTLDS, but the reporting of cases will need to meet the
specific case definitions (possible, probable, confirmed) – without this,
geographical mapping can be misleading so that future researchers can
determine the incidence and prevalence of CLD/PTLDS.

•

There is still lack of knowledge to find or corroborate if environmental factors
play a role in the symptomatology and developmental pathophysiology of
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such patients with CLD/PTLDS, because it is meaningless without beginning
with well pedigreed data – that is, data developed with careful forethought and
scientific objectivity, including the development and use of standardized
definitions and establishment of a representative surveillance and monitoring
system.
•

There is the need for more studies to find their effects of climate change on
tick-borne diseases (Connecticut Agricultural Experimental Station,2017;
Dumic & Severnini, 2018), notably when the CDC reports that the ticks
population keeps increasing in the last decades (CDC, 2015b)

•

There is no confirmation of the etiological agent of CLD/PTLDS thus, clinical
testing is limited, and the use of the term “CLD/PTLDS” implies the present
LD diagnostic tests have very low sensitivity and can produce many false
negatives.

•

There is a need for new innovative technologies that can help identify vectorborne diseases from non-vector bone disease since most scientists think that
CLD/PTLDS is a vector borne disease related with B. Burgdorferi (the
spirochete that causes LD).

•

There is a need for organizations such as the CDC, World Health
Organization and the Infectious Diseases Society of America to investigate if
patients with CLD/PTLDS are related to LD because LD has a standardized
case definition, and clinical care guidelines exist to develop an ICD code for
CLD/PTLDS and better medical guidelines that PCPs can follow (see Table 2)
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•

If CLD/PTLDS becomes established as an infectious disease, the Institute of
Medicine and National Center for Complementary and Integrative Health may
wish to review the applications of the Koch’s Postulates in the 21st Century
through a rigorous scientific approach and to decide what would be the best
for patients with it.

•

According to Ali at al. (2014), and Johnson et al. (2014), patients that
presumed to have CLD/PTLDS is a problem at the national level since, in
their studies, patients were recruited at large. Thus, it is necessary for some
legislation to benefit both presumed patients with CLD/PTLDS and PCPs. To
develop such legislation (local and Federal), the health organizations such as
the World Health Organization, CDC, Council of State and Territorial
Epidemiologists, International Society for Disease Surveillance, and state and
local health departments need to identify what will be the next step towards
such legislative changes. If this legislative process will be met, patients can
get their health insurance to pay for the treatments needed, and PCPs do not
need to be afraid about the care given to such presumed CLD/PTLDS patients.

•

From the biotechnological point of view, there is a need to conduct more
studies in the fields of molecular biology, immunology, and genetics to
determine the role of Borrelia burgdorferi and other Borrelia species, as well
as other bacteriological agents found in deer ticks to find potential
relationships with patients afflicted by CLD/PTLDS.
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Medical education for PCPs will continue to be a challenge and will be limited
until scientists, health professionals, organizations like the World Health Organization,
CDC, Council of State and Territorial Epidemiologists, and Infectious Diseases Society
of America resolve present existing disagreements for a standardized case definition and
ICD code for CLD/PTLDS (Id one day will have the merit to be identified as disease
alone). Once a case definition and an ICD code will be established, PCPs can follow the
same protocols and guidelines to diagnose and treat patients with CLD/PTLDS (or in
some cases with PTLDS). The main limitation for PCPs for not having a standardized
case definition for surveillance is because patients with CLD/PTLDS do not exhibit
specific symptoms for their illness like with other infectious or not infectious diseases.
While the global disease burden has been shifting towards chronic conditions,
health systems, and moreover, including primary health systems, it is crucial to have the
system that evoked the concept of CLD/PTLDS. In addition, new opportunities for
research, as well for CLD/PTLDS and LD studies, should further continue to be funded
in the United States to benefit both PCPs and their patients (World Health Organization,
2003). Finally, for CLD/PLTDS or just CLD or PTLDS, definitions usually have to come
from the medical literature and evolve over time. In this study, it is expected that the
information presented here most likely will help PCPs to come together to help that
happen by building on others and clearly defining the terms presented in this study.
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Appendix A: CT-KAP Johnson and Feder’s (2010) questions 1-9, update CT KAP 2018
(questions 10 and 11)
1. Are you in clinical practice seeing patients?
Yes

No

2. What is your specialty?
Family Physician
Internist

Pediatrician

Other (please indicate) _____

3. How would you describe your knowledge of Lyme disease?
I know the symptoms and feel comfortable diagnosing it.
I know the symptoms, but I don’t feel comfortable diagnosing it.
I don’t know the symptoms and I don’t diagnose it.
4. How would you describe your knowledge of Chronic Lyme disease?
I know the symptoms and feel comfortable diagnosing it.
I know the symptoms, but I don’t feel comfortable diagnosing it.
I don’t know the symptoms and I don’t feel comfortable diagnosing it.
I don’t believe it exists. (Go to question #6.)
5. In your experience Chronic Lyme disease includes which of the following? Check
all that apply; you may check none, or more than one.
Following the treatment for Lyme disease, a patient has persistent symptoms like
headache, trouble concentrating, fatigue, myalgias, and/or arthralgias. Some of these
patients have Chronic Lyme disease and require prolonged antibiotic therapy.
A patient has never previously been diagnosed with Lyme Disease but has
persistent headache, trouble concentrating, fatigue, myalgias, and /or is seropositive
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for Borrelia burgdorferi antibodies. Some of these patients have Chronic Lyme
disease and require prolonged antibiotic therapy.
A patient has never been diagnosed with Lyme Disease but has persistent
headache, trouble concentrating, fatigue, myalgias, and/or arthralgias is seronegative
for Borrelia burgdorferi antibodies. Some of these patients have Chronic Lyme
disease and require prolonged antibiotic therapy.
Other-please describe _____________________________________________
6. Over the past 3 years approximately how many patients have you diagnosed and
treated with Lyme disease? __________
7. Over the past 3 years approximately how many patients have you diagnosed and
treated with Chronic Lyme disease? _________________________ (if “0”, please go
to question 8.)
a. What has been the average total course of antibiotics therapy for these patients
with Chronic Lyme disease? __________________________
b. In your opinion, have these patients diagnosed with patients with
Chronic Lyme disease been helped by the antibiotics?
Yes

No

I don’t know

8. Over the past 3 years approximately how many patients have you diagnosed and
treated with Chronic Lyme disease (or PTLDS) by other physicians?
____________________________
8a. In your opinion have these patients diagnosed with Chronic Lyme disease
been helped by antibiotics?
Yes

No

I don’t know

9. In your opinion, how frequently does Chronic Lyme disease occur in
Connecticut?
Commonly
Uncommonly
Never
I don’t know
10. Did you participate in the same previous same mailed survey done in 2006 by
Johnson& Feder (2010).
Yes

No
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11. I should understand that the fact that you mailed the survey back to me is the
corroboration that you have given me consent to use your anonymous data in this
study?
Yes

No

Extra: Comments (optional): write below.
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Appendix B: The Reportable Disease Confidential Case Report Form PD-23

Retrieved from https://portal.ct.gov/-/media/Departments-andAgencies/DPH/dph/infectious_diseases/CTEPINEWS/Vol38No1.pdf?la=en
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Appendix C: Laboratory Finding Report- Form OL-15C

CT Epidemiologist, 2018. Retrieved from https://portal.ct.gov/-/media/Departments-and
Agencies/DPH/dph/infectious_diseases/CTEPINEWS/Vol38No1.pdf?la=en
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Appendix D: Frequencies of Primary Care Physicians in Connecticut from 2005 to 2016
Table D1
Frequency of Primary Care Physicians
Year

Number total MD/DO in CT from 1998 to 2018

2005
15047
2006
15424
2007
15831
2008
16238
2009
16604
2010
17904
2011
16692
2012
17130
2013
17294
2014
17428
2015
17464
2016
17664
Note. Adapted from the Connecticut Department of Health (2019). The year before 2006
and after 2015 have minimal changes in the total frequencies of PCPs. The PCP
population in Connecticut shows stable growth.

Figure D1. Histogram for frequency of primary care physicians.
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Appendix E: Original Data About Connecticut Primary Care Physicians of 2006 and
2015
Table E1
Data on Primary Care Physicians Based on Category
PCP Category or
Specialty
Total number of MD/DO
from original data
Family physicians
Internal Medecine
Pediatricians
Other
Total
Total number of PCPs
selected to participate in
this study taking a 33%

CT DPH of total
CT DPH of total
data of PCPS of
data of PCPS of
2006 (original)
2006 proportions.
in %.

CT DPH of
CT DPH of total data
total data of
of PCPS of
PCPs 2015
2017proportions.
(original) in %.

15,424

17,464

*69%
*20%
*10%

10643
3085
1542
1155
1524

65.4
19.1%
10.4%

1034 (33 % of
3091)

11422
3336
1816
890
17464

1726 (33% of
5231).

Table E2
Frequency Results Based on Category
Results
Family MD

Internal Medicine

Pediatricians

Other

Row Totals

Frequencies
of 2006 PCPs
3085 (3011.36) [1.80] 10643 (10348.17) [8.40] 1542 (1574.85) [0.69] 154 (489.62) [230.06] 15424
before
randomization
Frequencies
of PCPs of
3336 (3409.64) [1.59] 11422 (11716.83) [7.42] 1816 (1783.15) [0.61] 890 (554.38) [203.18] 17464
2015 before
randomization
Column
Totals

6421

22065

3358

1044

32888 (Grand
Total)

Note.* Adapted from three sources (a)
http://www.publichealth.uconn.edu/assets/primarycarereport_02_09.pdf, (b)
https://portal.ct.gov/DPH/Practitioner-Licensing--Investigations/PLIS/LicensingStatistics and (c) the data from the Johnson and Feder (2010).
The chi-square statistic is 453.7446. The p-value is < 0.00001. The result is significant
at p < .05.
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Appendix F: Distribution of the Population Used in this Study (2006 vs. 2015)
Population

2006 Population
from Johnson &
Feder (2010)

2015
Population
from This
Study

Total number of the original
population of PCPs from the
databases from CT Public Health
Department years (2006 vs.
2015)

15424

17464

Population (proportion) after the
selection of PCP in the
categories (F,IM, P) needed for
the study from Original
population of PCPs from the CT
DPH MD/DO list.

3091

Population (proportion) within
the pre-selection of the 33 %
from the population of PCPs
from the CT DPH MD/DO list
randomized to receive the
survey.
Population (proportion) of the
Number of PCPs that responses
were received successfully from
the survey and were mailed
back to the researchers.
Population(proportion) of the
number of PCP that responses
were received before exclusions
were applied in the studies.
Final Population (proportion) of
the number of PCPs that
responses were received used for
data analysis in the studies.

z Score

p value

5231

20.6351

p < .0001
p < .05
Significant
Dissimilar

1034

1726

0.4273

p < .0001
p <. 05
Not Significant
Similar

843

1507

4.1353

p < .0001
p < .05
Significant
Dissimilar

330

179

-15.3912

p < .0001
p < .05
Significant
Dissimilar

285

145

1.594

p = 0.1184
(no significant).
*Proportions
are Similar

Note. The population proportions for this study were similar (2006 vs. 2015).
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Appendix G: The Margin of Error Calculated for this Study
The margin of error (with finite population expected of 300, but I only got 145 (2015P) is
±5.86%
Where: z = 1.96 for a confidence level (α) of 95%, p = proportion (expressed as a
decimal), N = population size, n = sample size.
z = 1.96, p = 0.5, N = 300, n = 145
margin of error = 1.96 * √0.5 * (1 - 0.5) / √ (300 - 1) * 145 / (300 - 145); margin of error
= 0.98 / 16.725 * 100 = 5.86%
The margin of error (with finite population correction) is ±5.86%
The margin of error 145 (2015) PCP survey responses received is ±8.138%
Where: z = 1.96 for a confidence level (α) of 95%, p = proportion (expressed as a
decimal), n = sample size.
z = 1.96, p = 0.5, n = 145
margin of error = 1.96 * √0.5 * (1 - 0.5) / √145= margin of error = 0.98 / 12.042 * 100 =
8.138%
The margin of error is ±8.138%
The margin of error (145 PCP survey responses only) is ±5.805%
Where: z = 1.96 for a confidence level (α) of 95%, p = proportion (expressed as a
decimal), n = sample size.
z = 1.96, p = 0.5, n = 285
margin of error = 1.96 * √0.5 * (1 - 0.5) / √285; margin of error = 0.98 / 16.882 * 100 =
5.805%
The margin of error is ±5.805%
The margin of error for the whole population of 2006(285 & 145 PCP survey) 430 PCP
survey responses is ±4.726%
The margin of error is calculated according to the formula: margin of error = z * √p * (1 p) / √n
Where: z = 1.96 for a confidence level (α) of 95%, p = proportion (expressed as a
decimal), n = sample size.
z = 1.96, p = 0.5, n = 430
margin of error = 1.96 * √0.5 * (1 - 0.5) / √430 = margin of error = 0.98 / 20.736 * 100 =
4.726%
The margin of error is ±4.726%
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Appendix H: Representation of the Two Population Proportions After Adjustment

Results
Family MD

Internal Medicine
MD

Pediatrician MD

Other (i.e.
Emergency MD)

Row Totals

Frequencies of PCPs of
2006 in the study of J&F

57 (56.00) [0.02] 113 (118.50) [0.26] 107 (100.50) [0.42] 8 (10.00) [0.40]

285

Frequencies of 2015
adjusted in this study

55 (56.00) [0.02] 124 (118.50) [0.26] 94 (100.50) [0.42] 12 (10.00) [0.40]

285

Column Totals

112

570 (Grand
Total)

237

201

20

The Chi-square statistic is 2.1871. The p-value is .534502. The result is not significant at p <
.05. (dependent variable).
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Appendix I: G*Power Analysis Findings
t-tests :Means: Difference from constant (one sample
case)
Analysis: a priori: Compute required sample size
Input: Tail(s) = two
Effect size (d)= 0.1625
α err prob = 0.05
Power (1-β err prob)= 0.80
Output: Noncentrality parameter δ = 2.8145826
Critical t= 1.9679297
df=299
Total sample size = 300
Actual power = 0.8011039

Note. Source from Erdfelder et al. (2007). Retrieved from
https://link.springer.com/article/10.3758/BRM.41.4.1149

